
<html lang="en"     class="pb-page"  data-request-id="379a81ef-15a4-4fb0-b45a-0a1c2de2c7df"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-13;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c00233;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors" /></meta><meta name="dc.Creator" content="Yongfu  Liu" /></meta><meta name="dc.Creator" content="Jun  Wu" /></meta><meta name="dc.Creator" content="Mingwei  Zhou" /></meta><meta name="dc.Creator" content="Wenming  Chen" /></meta><meta name="dc.Creator" content="Dongbo  Li" /></meta><meta name="dc.Creator" content="Zhanguo  Wang" /></meta><meta name="dc.Creator" content="Benoit  Hornsperger" /></meta><meta name="dc.Creator" content="Johannes D.  Aebi" /></meta><meta name="dc.Creator" content="Hans-Peter  Märki" /></meta><meta name="dc.Creator" content="Bernd  Kuhn" /></meta><meta name="dc.Creator" content="Lisha  Wang" /></meta><meta name="dc.Creator" content="Andreas  Kuglstatter" /></meta><meta name="dc.Creator" content="Jörg  Benz" /></meta><meta name="dc.Creator" content="Stephan  Müller" /></meta><meta name="dc.Creator" content="Remo  Hochstrasser" /></meta><meta name="dc.Creator" content="Giorgio  Ottaviani" /></meta><meta name="dc.Creator" content="Jian  Xin" /></meta><meta name="dc.Creator" content="Stephan  Kirchner" /></meta><meta name="dc.Creator" content="Susanne  Mohr" /></meta><meta name="dc.Creator" content="Philippe  Verry" /></meta><meta name="dc.Creator" content="William  Riboulet" /></meta><meta name="dc.Creator" content="Hong C.  Shen" /></meta><meta name="dc.Creator" content="Alexander V.  Mayweg" /></meta><meta name="dc.Creator" content="Kurt  Amrein" /></meta><meta name="dc.Creator" content="Xuefei  Tan" /></meta><meta name="dc.Description" content="Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone level..." /></meta><meta name="Description" content="Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone level..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 12, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00233" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00233" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00233" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00233" /></link>
        
    
    

<title>Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00233" /></meta><meta property="og:title" content="Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0025.jpeg" /></meta><meta property="og:description" content="Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure–activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold in vivo selectivity against CYP11B1." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00233"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00233">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00233&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00233&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00233&amp;href=/doi/10.1021/acs.jmedchem.0c00233" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6876-6897</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00111" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00123" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yongfu Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongfu Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongfu++Liu">Yongfu Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Wu">Jun Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingwei Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingwei Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingwei++Zhou">Mingwei Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenming Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenming Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenming++Chen">Wenming Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongbo Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongbo Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongbo++Li">Dongbo Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhanguo Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhanguo Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhanguo++Wang">Zhanguo Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benoit Hornsperger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benoit Hornsperger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benoit++Hornsperger">Benoit Hornsperger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johannes D. Aebi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johannes D. Aebi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johannes+D.++Aebi">Johannes D. Aebi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hans-Peter Märki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hans-Peter Märki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hans-Peter++M%C3%A4rki">Hans-Peter Märki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernd Kuhn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernd Kuhn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CADD, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernd++Kuhn">Bernd Kuhn</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4301-562X" title="Orcid link">http://orcid.org/0000-0002-4301-562X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisha Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisha Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CADD, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisha++Wang">Lisha Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Kuglstatter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Kuglstatter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lead Discovery, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Kuglstatter">Andreas Kuglstatter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jörg Benz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jörg Benz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lead Discovery, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%B6rg++Benz">Jörg Benz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephan Müller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephan Müller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lead Discovery, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephan++M%C3%BCller">Stephan Müller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Remo Hochstrasser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Remo Hochstrasser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lead Discovery, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Remo++Hochstrasser">Remo Hochstrasser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giorgio Ottaviani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giorgio Ottaviani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giorgio++Ottaviani">Giorgio Ottaviani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Xin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Xin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Shanghai, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Xin">Jian Xin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephan Kirchner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephan Kirchner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephan++Kirchner">Stephan Kirchner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susanne Mohr</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susanne Mohr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susanne++Mohr">Susanne Mohr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philippe Verry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philippe Verry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Cardiovascular and Metabolic Diseases, Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Verry">Philippe Verry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William Riboulet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William Riboulet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Cardiovascular and Metabolic Diseases, Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William++Riboulet">William Riboulet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong C. Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong C. Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong+C.++Shen">Hong C. Shen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3477-8932" title="Orcid link">http://orcid.org/0000-0002-3477-8932</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexander V. Mayweg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexander V. Mayweg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+V.++Mayweg">Alexander V. Mayweg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kurt Amrein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kurt Amrein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Cardiovascular and Metabolic Diseases, Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kurt++Amrein">Kurt Amrein</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Xuefei Tan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuefei Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2f575a4a494a46015b4e416f5d404c474a014c4042"><span class="__cf_email__" data-cfemail="bcc4c9d9dad9d592c8ddd2fcced3dfd4d992dfd3d1">[email protected]</span></a>. Phone: +86 21 28946746.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuefei++Tan">Xuefei Tan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7629-2255" title="Orcid link">http://orcid.org/0000-0001-7629-2255</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00233&amp;href=/doi/10.1021%2Facs.jmedchem.0c00233" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6876–6897</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 12, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 February 2020</li><li><span class="item_label"><b>Published</b> online</span>12 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00233" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00233</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6876%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYongfu%2BLiu%252C%2BJun%2BWu%252C%2BMingwei%2BZhou%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D13%26contentID%3Dacs.jmedchem.0c00233%26title%3DDiscovery%2Bof%2B3-Pyridyl%2BIsoindolin-1-one%2BDerivatives%2Bas%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BActive%2BAldosterone%2BSynthase%2B%2528CYP11B2%2529%2BInhibitors%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6897%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00233"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1258</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00233" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yongfu&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Mingwei&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Wenming&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Dongbo&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhanguo&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Benoit&quot;,&quot;last_name&quot;:&quot;Hornsperger&quot;},{&quot;first_name&quot;:&quot;Johannes&quot;,&quot;last_name&quot;:&quot;D. Aebi&quot;},{&quot;first_name&quot;:&quot;Hans-Peter&quot;,&quot;last_name&quot;:&quot;Märki&quot;},{&quot;first_name&quot;:&quot;Bernd&quot;,&quot;last_name&quot;:&quot;Kuhn&quot;},{&quot;first_name&quot;:&quot;Lisha&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Kuglstatter&quot;},{&quot;first_name&quot;:&quot;Jörg&quot;,&quot;last_name&quot;:&quot;Benz&quot;},{&quot;first_name&quot;:&quot;Stephan&quot;,&quot;last_name&quot;:&quot;Müller&quot;},{&quot;first_name&quot;:&quot;Remo&quot;,&quot;last_name&quot;:&quot;Hochstrasser&quot;},{&quot;first_name&quot;:&quot;Giorgio&quot;,&quot;last_name&quot;:&quot;Ottaviani&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Xin&quot;},{&quot;first_name&quot;:&quot;Stephan&quot;,&quot;last_name&quot;:&quot;Kirchner&quot;},{&quot;first_name&quot;:&quot;Susanne&quot;,&quot;last_name&quot;:&quot;Mohr&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Verry&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Riboulet&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;C. Shen&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;V. Mayweg&quot;},{&quot;first_name&quot;:&quot;Kurt&quot;,&quot;last_name&quot;:&quot;Amrein&quot;},{&quot;first_name&quot;:&quot;Xuefei&quot;,&quot;last_name&quot;:&quot;Tan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6876-6897&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00233&quot;},&quot;abstract&quot;:&quot;Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure–activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold in vivo selectivity against CYP11B1.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00233&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00233" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00233&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00233" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00233&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00233" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00233&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00233&amp;href=/doi/10.1021/acs.jmedchem.0c00233" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00233" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00233" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00233%26sid%3Dliteratum%253Aachs%26pmid%3D32530624%26genre%3Darticle%26aulast%3DLiu%26date%3D2020%26atitle%3DDiscovery%2Bof%2B3-Pyridyl%2BIsoindolin-1-one%2BDerivatives%2Bas%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BActive%2BAldosterone%2BSynthase%2B%2528CYP11B2%2529%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D13%26spage%3D6876%26epage%3D6897%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290865" title="Nitrogen">Nitrogen</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/jmcmar.2020.63.issue-13/20200709/jmcmar.2020.63.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure–activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound <b>52</b>, in an <i>in vivo</i> cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold <i>in vivo</i> selectivity against CYP11B1.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The renin angiotensin aldosterone system (RAAS) is an endocrine system that regulates the body’s blood pressure and fluid balance. Its dysregulation contributes to the pathogenesis of a number of cardiovascular, renal, and metabolic diseases. Therefore, it is a pathway that has been successfully targeted by many RAAS inhibitors, including angiotensin AT1 receptor blockers (ARBs), angiotensin-converting-enzyme inhibitors (ACEIs), renin inhibitors, and mineralocorticoid receptor antagonists (MRAs).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Aldosterone, as one component of RAAS, besides its well-known function in regulating fluid and electrolyte homeostasis, has recently been recognized as one important contributor to end-organ damage in various cardiovascular and renal diseases.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2−5)</a> An elevated aldosterone level, especially in conjunction with high sodium/oxidative stress, is associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In addition, in hypertensive patients who are treated with either ACEIs or ARBs for a longer duration, an “aldosterone breakthrough” phenomenon leading to rebound aldosterone levels after an initial decline is associated with end-organ damage.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Antagonizing the aldosterone effect by an MR antagonist has been shown to reduce the risk of death in congestive heart failure (CHF) patients when used in conjunction with ACEI (RALES trial) and to improve survival and reduce hospitalization in patients with postmyocardial infarction heart failure when added to the standard treatment regimen (EPHESUS trial).<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> However, a suppression of the plasma aldosterone level by an MR antagonist, after a prolonged usage, would induce an increased aldosterone level by a compensatory mechanism and therefore limit its efficacy. Therefore, blocking the biosynthesis of aldosterone by an aldosterone synthase inhibitor (ASI) has been explored as an alternative approach in recent years.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> Additionally, an ASI is expected to block MR-independent genomic and nongenomic effects, and it may provide even better protection against the aforementioned diseases.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Aldosterone is a steroid hormone synthesized from cholesterol via a cascade of enzymatic reactions by a number of cytochrome P450s. Located mainly in the adrenal gland zona glomerulosa, aldosterone synthase (encoded by the CYP11B2 gene) is the enzyme responsible for the last three steps of reactions by converting 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxy-corticosterone intermediates (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Since in humans, the aldosterone synthase shows a high sequence identity (∼93%) to cortisol synthase (encoded by the CYP11B1 gene, mainly present in the zona fasciculate/reticularis),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> the development of a highly selective aldosterone synthase inhibitor has been challenging over the past several years.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0001.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Terminal steroidogenesis pathways leading to aldosterone and cortisol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The proof-of-concept efficacy study was first demonstrated by Novartis ASI LCI699 in patients with primary hyperaldosteronism. The oral administration of LCI699 first at 0.5 mg <i>b.i.d</i>. for 2 weeks, followed by 1.0 mg <i>b.i.d</i>. for another 2 weeks, significantly reduced levels of aldosterone in both plasma and urine, leading to a rapid correction of hypokalemia, and a modest decrease in blood pressure. However, due to the low selectivity of LCI699 (CYP11B1 IC<sub>50</sub>/CYP11B2 IC<sub>50</sub> = 3.6-fold), a blunted cortisol response to adrenocorticotropic hormone (ACTH) was observed at dose 1 mg/day or greater in the safety evaluation.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Good selectivity against CYP11B1 is critical to prevent undesired side effects related to the hypothalamic–pituitary–adrenal (HPA) axis. We recently reported our own clinical study of a highly selective ASI RO6836191 (CYP11B1 IC<sub>50</sub>/CYP11B2 IC<sub>50</sub> = 100-fold). In a phase I SAD study (0–360 mg/day), RO6836191 achieved high CYP11B1/CYP11B2 selectivity with maximum suppression of aldosterone production at 10 mg/day and no change of the cortisol level up to 360 mg/day. Such good selectivity was also reflected by an increase of precursors 11-deoxycorticosterone and 11-deoxycortisol only at ≥90 mg.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">Herein, we report a new type of ASIs with even superior CYP11B1/CYP11B2 selectivity both <i>in vitro</i> and <i>in vivo</i>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> SAR and Lead Optimization Strategy</h3><div class="NLM_p">To identify novel ASIs, we performed a focused screen of a subset of the Roche library. The first selection criterion for this library was the presence of a nitrogen lone pair in a heteroaromatic ring without substitution α to the nitrogen atom to enable potential heme-iron binding in CYP11B2. This initial list was further reduced to a final set of 2000 compounds by 2D fingerprint and 3D shape similarity to several selected reference inhibitors (Supporting Information (SI), <a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">Figure S1</a>),<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a> molecular property filtering, and structure clustering. Screening of this library against human CYP11B2 yielded a significant number of hits, several of them with very high ligand efficiencies. However, only few compounds of the hit list showed initial selectivity against human CYP11B1. This is not surprising as the active site residues are fully conserved between the two isoforms.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Interestingly, despite the presence of unshielded nitrogen lone pairs in our hit structures, which are privileged motifs for iron–heme binding, we did not find strong cross-reactivities against the drug-metabolizing CYP isoforms 3A4, 2C9, 2D6, 2C19, and 1A2.</div><div class="NLM_p">Among the promising hits, a class of <i>N</i>-(3-pyridyl)benzamides (<b>1–6</b>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> was selected as our chemistry starting point. These initial hits showed submicromolar CYP11B2 IC<sub>50</sub> values and some selectivity against human CYP11B1 in in-house-developed cellular assays (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Initial structure–activity relationships (SARs) indicated that a chlorine (<b>1</b>) or nitrile (<b>2</b>) substitution at the para-position of the benzamide was favored for better potency. In addition, in the ortho-position, small substituents like fluorine (<b>5</b>) or methyl (<b>6</b>) slightly improved the potency. Methylation at the benzamide nitrogen led to almost inactive compounds (<b>7–9</b>), presumably because of the drastic conformational change compared to the unsubstituted analogues.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Preliminary SAR for Initial <i>N</i>-(3-Pyridyl)benzamide Hits, <b>1–9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0018.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">structure</th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">CYP11B2</th><th class="colsep0 rowsep0" align="center" char=".">CYP11B1</th><th class="colsep0 rowsep0" align="center">SF<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.42</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">>7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">0.454</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">>7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">n.a.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.967</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">>3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.297</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.277</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">>11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">n.a.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">n.a.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">n.a.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>: concentration of compound that inhibited 50% enzyme activity.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SF: selective factor defined as the ratio between the IC<sub>50</sub> values of human CYP11B1 and CYP11B2.</p></div></div></div><div class="NLM_p">Subsequent conformational restriction of 4-chloro-<i>N</i>-(3-pyridyl)benzamide <b>1</b> via cyclization gave either the 6-membered lactam, 3,4-dihydroisoquinolin-1-one derivative <b>10</b> (IC<sub>50</sub> = 61 nM), or the 5-membered lactam, isoindolin-1-one derivative <b>13</b> (IC<sub>50</sub> = 179 nM), which showed 7- and 2-fold CYP11B2 potency improvements, respectively. Additional substitution on the phenyl ring, such as <b>11</b>, did not gain further potency. The CN substituted isoindolin-1-one analogue <b>14</b> (IC<sub>50</sub> = 232 nM), despite a twofold potency improvement (vs <b>2</b>), was still inferior to a chlorine substitution. Apart from their better potencies, the cyclized lactams also showed encouraging double-digit selectivity factors against CYP11B1 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency, Selectivity, and Microsomal Stability of 3,4-Dihydroisoquinolin-1-one and Isoindolin-1-one Derivatives, <b>10–14</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0019.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">structure</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">LM<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> (mL/(min kg))</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">CYP11B2</th><th class="colsep0 rowsep0" align="center">CYP11B1</th><th class="colsep0 rowsep0" align="center">SF<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.061</td><td class="colsep0 rowsep0" align="left">5.002</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left"><3.5</td><td class="colsep0 rowsep0" align="left"><20.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.104</td><td class="colsep0 rowsep0" align="left">3.541</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left"><3.5</td><td class="colsep0 rowsep0" align="left">30.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.12</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.179</td><td class="colsep0 rowsep0" align="left">10.74</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">12.8</td><td class="colsep0 rowsep0" align="left">76.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.232</td><td class="colsep0 rowsep0" align="left">15.544</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">45.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>: concentration of compound that inhibited 50% enzyme activity.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">SF: selective factor defined as the ratio between the IC<sub>50</sub> values of human CYP11B1 and CYP11B2.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">LM: scaled intrinsic clearance of compound in liver microsomes.</p></div></div></div><div class="NLM_p">Compared to the 3,4-dihydroisoquinolin-1-one analogue <b>10</b> (log <i>D</i> = 2.25), the slightly more lipophilic isoindolin-1-one analogue <b>13</b> (log <i>D</i> = 2.52) was much less stable in liver microsomes, likely due to oxidative metabolism at the benzylic C–H position. Although metabolic stability could be improved by lowering the lipophilicity, as demonstrated by analogue <b>14</b> (log <i>D</i> = 1.35), we also envisioned that increasing the steric hindrance at the benzylic carbon could reduce metabolic oxidation. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, a number of such analogues were prepared as either a racemic mixture or an achiral compound. Indeed, benzylic substitutions (Me, Et, and cyclopropyl) did improve the metabolic stability (<b>15</b>, <b>16</b>, and <b>19</b>), and gem-dimethyl (<b>17</b>) as well as spirocyclopropyl (<b>18</b>) analogues showed the most significant improvement in liver microsomal stability. Except for the benzyl substituted <b>20</b>, all analogues (<b>15–19</b>) substituted at the benzylic position retained comparable CYP11B2 potency and selectivity against CYP11B1. Encouraging, but difficult to rationalize, a surprising 202-fold CYP11B1 selectivity was observed for analogue <b>19</b> (IC<sub>50</sub> = 161 nM). On the other hand, analogues derived from derivatization at the 3- or 4- position of the 3,4-dihydroisoquinolin-1-one core such as <b>21–22</b> (Me) and <b>23</b> (gem-dimethyl) either had decreased potency or selectivity or had reduced microsomal stability (vs <b>10</b>). These new types of compounds also showed excellent selectivity against a common cytochrome P450 screening panel (3A4, 2D6, and 2C9) with IC<sub>50</sub> values generally greater than 50 μM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potency, Selectivity, and Microsomal Stability of 3,4-Dihydroisoquinolin-1-one and Isoindolin-1-one Derivatives, <b>15–23</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0020.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">structure</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">LM<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> (mL/(min kg))</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>3</sup>/R<sup>4</sup></th><th class="colsep0 rowsep0" align="center" char=".">CYP11B2</th><th class="colsep0 rowsep0" align="center">CYP11B1</th><th class="colsep0 rowsep0" align="center">SF<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.123</td><td class="colsep0 rowsep0" align="left">1.248</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">12.2</td><td class="colsep0 rowsep0" align="left">66.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">0.121</td><td class="colsep0 rowsep0" align="left">3.341</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">65.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">gem-dimethyl</td><td class="colsep0 rowsep0" align="char" char=".">0.108</td><td class="colsep0 rowsep0" align="left">4.276</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left"><3.5</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">spirocyclopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.120</td><td class="colsep0 rowsep0" align="left">4.450</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">cyclopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.161</td><td class="colsep0 rowsep0" align="left">32.522</td><td class="colsep0 rowsep0" align="left">202</td><td class="colsep0 rowsep0" align="left">9.4</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">Bn</td><td class="colsep0 rowsep0" align="char" char=".">1.07</td><td class="colsep0 rowsep0" align="left">0.214</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Me/-</td><td class="colsep0 rowsep0" align="char" char=".">0.761</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>13</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">-/Me</td><td class="colsep0 rowsep0" align="char" char=".">0.164</td><td class="colsep0 rowsep0" align="left">2.588</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">-/gem-dimethyl</td><td class="colsep0 rowsep0" align="char" char=".">1.538</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>7</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>: concentration of compound that inhibited 50% enzyme activity.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">SF: selective factor defined as the ratio between the IC<sub>50</sub> values of human CYP11B1 and CYP11B2.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">LM: scaled intrinsic clearance of compound in liver microsomes.</p></div></div></div><div class="NLM_p">Having optimized the pyridine left-hand-side moiety, in particular the isoindolin-1-one core for potency, selectivity, and liver microsomal stability, the lead optimization effort then focused onto the central pyridine. An overlay between the modeled binding mode of compound <b>13</b> in the X-ray complex structure of deoxycorticosterone with CYP11B2 indicated room for extension at the steroid D ring and its polar substituent (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We first tried to mimic this motif with a bicyclic tetrahydroisoquinoline core. Thus, a number of 5,6,7,8-tetrahydroisoquinolin-8-amine-derived analogues were prepared with a small set of amide or sulfonamide modifications to both mimic the deoxycorticosterone hydroxymethyl ketone and as a way to modulate physicochemical properties (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Similar to previously reported examples,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> the chirality of C-8 was found to be critical for CYP11B2 potency, with the (<i>R</i>)-configuration enantiomer being the preferred one (<b>25</b>, IC<sub>50</sub> = 44 nM vs <b>24</b>, IC<sub>50</sub> = 5.14 μM). In general, amide substitutions were more potent than sulfonamide (<b>25</b> vs <b>27</b>, and <b>26</b> vs <b>28</b>), and bigger substitutions were better tolerated than smaller ones (e.g., propyl amide <b>26</b> vs acetyl amide <b>25</b>, and ethyl sulfonamide <b>28</b> vs methyl sulfonamide <b>27</b>). Interestingly, for this new series of compounds, even without benzylic substitution at the isoindolin-1-one core, all analogues were quite stable in liver microsomes. The most potent propyl amide analogue <b>26</b> showed a CYP11B2 IC<sub>50</sub> of 28 nM and a 186-fold selectivity vs CYP11B1, together with a very good physicochemical profile (lipophilicity, log <i>D</i> = 2.14, permeability, Pampa Pe = 3.63 × 10<sup>–6</sup> cm/s, and solubility, LYSA > 460 μg/mL). Subsequent hybrids with isoindolin-1-one derivatives having small alkyl substitutions at the benzylic position did result in further potency improvements and single-digit nanomolar IC<sub>50</sub> values. Unfortunately, several of the most potent analogues (<b>30</b>, IC<sub>50</sub> = 4 nM; <b>31</b>, IC<sub>50</sub> = 7 nM; and <b>34</b>, IC<sub>50</sub> = 6 nM) did not pass the 100-fold CYP11B1 selectivity threshold that we had set to achieve. The combination with the 3,4-dihydroisoquinolin-1-one core (<b>39–41</b>) also did not yield better candidates for further development.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0002.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of the modeled binding mode of compound <b>13</b> (magenta) with the X-ray cocrystal structure of human CYP11B2 with deoxycorticosterone (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVQ">4DVQ</a>; protein in green, and heme and steroid ligand in cyan). In the model, the pyridine nitrogen atom engages in a short contact with the heme iron atom (dashed line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Potency, Selectivity, and Microsomal Stability of 5,6,7,8-Tetrahydroisoquinolin-8-amine-Derived Analogues, <b>24–41</b><a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0021.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0022.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>: concentration of compound that inhibited 50% enzyme activity.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">SF: selective factor defined as the ratio between the IC<sub>50</sub> values of human CYP11B1 and CYP11B2.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">LM: scaled intrinsic clearance of compound in liver microsomes using a well-stirred liver model.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">LM measured in rat.</p></div></div><div></div></div><div class="NLM_p">The relative configurations of compounds <b>29–38</b> were tentatively assigned based on optical rotation and the log <i>D</i> value correlation between each pair of diasteromers, in which (3<i>R</i>,8<i>R</i>) vs (3<i>S</i>,8<i>R</i>) had a consistent trend (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">Table S6</a>). Corresponding gem-dimethyl and spirocyclopropyl hybrid analogues could not be synthesized via the Ullman coupling reaction with the 5,6,7,8-tetrahydroisoquinolin-8-amine building block due to significant steric hindrance at the α position of the lactam nitrogen.</div><div class="NLM_p">The structural model in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> suggests that extension in the meta-position on the right-hand-side of the central pyridyl ring could be a good direction to further grow into the CYP11B2 binding site. Consequently, a number of 5-pyridyl substituted analogues with different sizes and polarities were synthesized while keeping the 5-chloro-3,3-dimethyl-2-(3-pyridyl)isoindolin-1-one constant on the left-hand side (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Based on the assumption that electron-donating substitution might help improve potency via enhancing the pyridine-nitrogen-binding affinity to the heme-iron, we decided to limit substitutions to carbon-, oxygen-, and nitrogen-linked attachments. Various types of linkers with variable lengths were explored, and a terminal amine group was specifically chosen for further derivatization with either amides or sulfonamides. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, the majority of analogues showed improved CYP11B2 potencies compared to the unsubstituted analogue <b>17</b> (IC<sub>50</sub> = 108 nM). For a few methylene amine-linked compounds (<b>42–47</b>), either the installation of an (<i>R</i>)-methyl at the methylene carbon (<b>45</b>, IC<sub>50</sub> = 8 nM) or a 3-methylpyridyl amide substitution (<b>47</b>, IC<sub>50</sub> = 9 nM) resulted in single-digit nanomolar potencies. While the binding affinity toward CYP11B2 could be improved >10-fold in this way, it is worth mentioning that the ligand efficiency (LE) is significantly reduced (<b>17</b>: LE = 0.50; <b>45</b>: LE = 0.43; <b>47</b>: LE = 0.37). This indicates that protein interactions made on the right-hand side of the scaffold contribute less binding energy per atom compared to the rest of the molecule.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Potency and Selectivity of 5-Chloro-3,3-dimethyl-2(3-pyridyl)isoindolin-1-one Derivatives, <b>42–62</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0023.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0024.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>: concentration of compound that inhibited 50% enzyme activity.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last"><i>h</i>SF: selective factor defined as the ratio between the IC<sub>50</sub> values of human CYP11B1 and CYP11B2.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last"><i>cy</i>SF: selective factor defined as the ratio between the IC<sub>50</sub> values of cynomolgus monkey CYP11B1 and CYP11B2.</p></div></div><div></div></div><div class="NLM_p">To further guide our inhibitor design efforts, we determined the X-ray structure of human CYP11B2 in complex with compound <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Despite the limited resolution of 3.0 Å, the structure clearly confirmed our proposed binding mode with the central pyridine nitrogen in close contact with the heme-iron atom (<i>d</i> = 2.2 Å) and the isoindolin-1-one core positioned on the left-hand side of the binding pocket. Pyridine and isoindolin-1-one ring systems are rotated against each other by ∼60°, and the gem-dimethyl group is engaged in a number of van der Waals interactions with Phe 130 and Trp 116, respectively. Several additional protein interactions are made around the isoindolin-1-one moiety. In contrast, only a few short protein contacts are visible around the ethylmethanesulfonamide substituent, which fills the right-hand side of the binding pocket only partly. This is in line with the generally reduced ligand efficiency when substituting at the 5-pyridyl position.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0003.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of human CYP11B2 in complex with compound <b>45</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8">6XZ8</a>). The protein is displayed in green, and the heme cofactor and compound <b>45</b> are shown as cyan sticks. Protein residues with short contacts to the ligand (<i>d</i> < 4.0 Å) are highlighted as green sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several factors likely contribute to the enhanced potency of the substitutions displayed in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. First, electron-donating substituents might increase the interaction strength of the central pyridine nitrogen atom with the heme iron. Second, additional favorable protein interactions can be formed in some cases, as in the matched pair of compound <b>44</b> (IC<sub>50</sub> = 33 nM) with the methylated analogue <b>45</b> (IC<sub>50</sub> = 8 nM). In this example, the extra methyl group in <b>45</b> engages in a short dispersion interaction with the side chain of Ile 488 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which likely contributes to its 4-fold potency improvement. On the other hand, suboptimal interactions for some substitutions, as exemplified by the amide and sulfonamide pairs <b>42</b> vs <b>43</b> and <b>44</b> vs <b>46</b>, respectively, can lead to reduced CYP11B2 binding. In <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the terminal methyl group of compound <b>46</b> would point to a rather polar region of the binding site, and the resulting desolvation penalty might explain the loss of binding affinity.</div><div class="NLM_p">Unfortunately, none of the methylene amine-linked analogues showed a selectivity against CYP11B1 greater than 100-fold. Therefore, linkers with different shapes and lengths including piperidine (<b>48–49</b>), piperazine (<b>50–51</b>), 2,6-diazaspiro[3.3]heptane (<b>59–62</b>), oxygen-linked azetidine (<b>52</b> and <b>56–58</b>), pyrrolidine (<b>53–54</b>), and piperidine (<b>55</b>) were prepared. Notably, now we found analogues for each of these types of linkers (<b>48–62</b>), which had superior CYP11B2 activities (<10 nM), revealing that quite diverse substituents are well tolerated in this region of the binding site. It suggests that this part of the binding site is quite flexible, to be able to accommodate such a variety of substitutions. One would expect an entropic penalty for binding to such a region, which is supported by the generally reduced ligand efficiency for 5-pyridyl substituents. For some substitutions at the terminal nitrogen, we finally achieved very good CYP11B1 selectivities (>100-fold). In particular, analogues containing the unique heteroaryl amide substitution patterns in <b>57</b>, <b>58</b>, and <b>62</b> gave superior CYP11B1 selectivity even over 500-fold while maintaining excellent CYP11B2 potency.</div><div class="NLM_p">We were able to determine the X-ray cocrystal structure of the highly selective compound <b>58</b>, revealing particular protein interactions of the terminal heterocycle (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Apart from a hydrogen bond of the pyrazole nitrogen atom with the side chain of Tyr 485, we observed significant protein-induced fit around Phe 381 and Phe 406. Interestingly, there is one amino acid difference between CYP11B2 and B1 in a 5 Å environment around the 5-pyridyl substituent, which is at position 404 (B2: Gln vs B1: Arg). We hypothesize that the increased selectivity for <b>58</b> and related compounds might be a consequence of (a) different free energy costs for CYP11B2 and B1 to accommodate the terminal heterocycle in the induced fit pocket, and (b) potentially different positions of the side chain of Tyr 485 leading to different hydrogen-bond interactions. Cocrystal structures of these compounds with CYP11B1 would be highly valuable to shed further light on the reasons for selectivity.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0004.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overlay of X-ray structures of human CYP11B2 with compounds <b>45</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8">6XZ8</a>; protein in green, and heme and ligand in cyan) and <b>58</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ9">6XZ9</a>; protein in orange, and heme and ligand in magenta) illustrating protein-induced fit around the pyrazole tail. The heme iron–pyridine nitrogen contact and the hydrogen bond between the ligand pyrazole and Tyr 485 are shown as dashed lines. At position 404, the Gln residue CYP11B2 is mutated to Arg in CYP11B1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">One of the challenges in identifying selective ASIs and validating them in <i>in vivo</i> studies is the fact that the primary structures between human and rodent CYP11B2 and CYP11B1 enzymes are relatively poorly conserved (68% for human and rodent CYP11B2, and 63% for human and rodent CYP11B1). Moreover, rodents produce corticosterone as their major glucocorticoid rather than cortisol observed in man and monkeys.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> As such, pharmacodynamic characterization of a selective ASI in a rodent animal model cannot be easily translated into a human situation. Therefore, in recent years, due to higher species homology between humans and monkeys (93% for both CYP11B2 and CYP11B1), functional animal models in nonhuman primates were developed to support the discovery and development of selective ASIs.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28">(24−28)</a> To validate candidate molecules in cynomolgus monkeys, good <i>in vitro</i> potency and selectivity toward the cynomolgus-monkey-derived enzymes were assessed. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> summarizes the potency and selectivity results of compounds <b>42–62</b> using cell line G401 expressing the corresponding monkey enzymes. In general, this series of analogues showed more potent cyCYP11B2 activities (1–16-fold increase) and a higher cyCYP11B1 selectivity. For analogues that already achieved >100-fold CYP11B1/CYP11B2 selectivity in human enzymes, their selectivity values for the monkey enzymes were even higher (<b>49</b>, <b>51</b>, <b>52</b>, <b>56</b>, and <b>57</b>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vivo</i> Rat and Cynomolgus Monkey Pharmacokinetics Studies</h3><div class="NLM_p">Compounds with subnanomolar human CYP11B2 potency (<10 nM) and >100-fold human CYP11B1 selectivity were evaluated in a rat single-dose pharmacokinetics (SDPK) study first (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). A good <i>in vitro</i> and <i>in vivo</i> clearance correlation was observed for this series of compounds, as the <i>in vivo</i> clearance could be well predicted from rat liver microsomal clearance. Meanwhile, due to acceptable solubility and permeability, these analogues also showed good to excellent oral bioavailability. Among three sulfonamides (<b>49</b>, <b>51</b>, and <b>52</b>), the oxygen-linked azetidine analogue <b>52</b> showed a better metabolic stability than those of piperidine (<b>49</b>) and piperazine (<b>51</b>) analogues. Therefore, it achieved a higher oral exposure with a bioavailability of 45%. A similar or better PK profile was also maintained for the two heteroaryl amides that were derived from the same linker (<b>56</b> and <b>58</b>). A spiro analogue <b>62</b>, which was designed to address the metabolic liability of the piperazine linker, also gave good oral exposure due to the decreased metabolism of the 2,6-diazaspiro[3.3]heptane ring (e.g., rat LMs for compounds <b>50</b>, <b>51</b>, <b>59</b>, and <b>60</b> are 17.7 and 16.8 vs 3.71 and 0.87 mL/(min kg), respectively).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Property and Single-Dose Pharmacokinetic Evaluation of Representative Compounds in Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">LYSA<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">PAMPA<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center" char=".">RLM<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (mL/(min kg))</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>iv</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (mL/(min kg))</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–∞)</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> po (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">4.01</td><td class="colsep0 rowsep0" align="char" char=".">35.1</td><td class="colsep0 rowsep0" align="char" char=".">29.7</td><td class="colsep0 rowsep0" align="char" char=".">1465</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">6.03</td><td class="colsep0 rowsep0" align="char" char=".">16.8</td><td class="colsep0 rowsep0" align="char" char=".">16.6</td><td class="colsep0 rowsep0" align="char" char=".">1640</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="char" char=".">4.17</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">6370</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">3.32</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">10818</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="char" char=".">290</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">10.4</td><td class="colsep0 rowsep0" align="char" char=".">15.8</td><td class="colsep0 rowsep0" align="char" char=".">1020</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">310</td><td class="colsep0 rowsep0" align="char" char=".">3.45</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">7880</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">3.63</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">5660</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">LYSA: lyophilization solubility assay.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">PAMPA: parallel artificial membrane permeability assay.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">RLM: scaled intrinsic clearance of compound in rat liver microsomes.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Cl<sub>iv</sub>: plasma clearance.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">AUC: area under the curve.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">F: oral bioavailability; intravenous dosing (i.v.) at 1 mg/kg, oral dosing (po) at 3 mg/kg.</p></div></div></div><div class="NLM_p">Compounds with a good oral exposure in rats were subsequently evaluated in the cynomolgus monkey SDPK study. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, although low <i>in vivo</i> clearances were maintained, lower oral bioavailabilities were observed for both compounds <b>52</b> and <b>62</b>. The portal vein cannulated cynomolgus monkey PK study later suggested that for these analogues high intestinal CYP3A4 metabolism could be the cause for the lower bioavailability observed in cynomolgus monkey PK studies.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Single-Dose Pharmacokinetic Parameter Comparison between Rats and Cynomolgus Monkeys for Compounds <b>52</b> and <b>62</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">fu<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char=".">Hepa Cl<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (mL/(min kg))</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>iv</sub><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a> (mL/(min kg))</th><th class="colsep0 rowsep0" align="center" char=".">AUC_dose<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a> (h·kg·ng/mL/mg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t7fn5" aria-label="e">e</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">26.7</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">2123</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey</td><td class="colsep0 rowsep0" align="char" char=".">13.8</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">1085</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char="."><4.4</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">1889</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char="."><3.0</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">3111</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">fu: percentage of compound free fraction in a plasma protein binding assay.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Hepa Cl: scaled intrinsic clearance of compound in liver hepatocytes.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Cl<sub>iv</sub>: plasma clearance.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">AUC_Dose: dose normalized area under the curve.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">F: oral bioavailability.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vivo</i> Evaluation of ASI in a Cynomolgus Monkey ACTH Model</h3><div class="NLM_p">In clinical studies, the adrenocorticotropic hormone (ACTH, Synacthen) stimulation test is used as a diagnostic tool to assess adrenocortical function. Plasma aldosterone and cortisol both increase in response to an ACTH stimulation. This test can be used to measure quantitatively the aldosterone (potency)/cortisol (selectivity) production change as a consequence of CYP11B2/B1 inhibition.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> As previously described, we chose to adapt this test to cynomolgus monkeys and developed an acute Synacthen challenge animal model for PKPD profiling of ASI in-house.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Measuring steroid levels reliably in monkeys requires a lot of skill and the right cooperative animals together with well-trained animal keepers. Indeed, in the cohort that we were using, only those animals that displayed robust ACTH-induced steroid responses and that were cooperative and voluntarily donated blood samples were selected. For animal welfare reasons, we had to limit the number of primates used in this study to <i>n</i> = 2 and the number of compounds tested to an absolute minimum.</div><div class="NLM_p">Using compound <b>52</b> as an example, both plasma exposure and several steroid profile changes in cynomolgus monkeys (<i>n</i> = 2) were recorded over a period of 24 h following the oral doses of isoindolin-one compound <b>52</b> at 0.01, 0.1, 1, and 10 mg/kg (<i>t</i> = 0 min) and an ACTH challenge (<i>t</i> = 1 h, time point close to the <i>C</i><sub>max</sub> of <b>52</b>). Highly sensitive LC/MS-MS analysis was applied to guarantee each hormone level’s accurate measurement. A time of 60 min post ACTH stimulation was selected in agreement with the human protocol for the Synacthen test and our experience of achieving stable and maximal steroid induction. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> shows the levels of five steroids 1 h after the ACTH challenge. Compound <b>52</b> reduced the stimulated aldosterone level below basal levels with three of the four tested doses (0.1, 1, and 10 mg/kg). The corresponding CYP11B2-dependent steroid precursors, corticosterone, and 11-deoxycorticosterone remained comparable to vehicle-treated animals displaying a natural variability. Concomitantly, selectivity against CYP11B1 was investigated independently by assessing both the precursor level (11-deoxycortisol) and the product level (cortisol) of the CYP11B1 enzyme. There were no or minimum cortisol changes at doses 0.01, 0.1, and 1 mg/kg. At the highest dose of 10 mg/kg, cortisol levels were observed below average pretreatment levels (vehicle <i>t</i> = 0 min); importantly, the precursor 11-deoxycortisol changed minimally or not at all. This in marked contrast to LCI699 that led to a dramatic increase in the precursors of deoxycorticosterone and deoxycortisol. This phenomenon has been reported in clinical studies as well when another type of ASI was tested at high, nonselective doses.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Selectivity in enzyme inhibition at the 10 mg/kg dose is also suggested based on simple PK/PD modeling (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Four different doses were applied to cynomolgus monkeys. For each dose, the average free exposure was calculated from AUC<sub>0–7h</sub> and corrected for plasma protein binding. There is a good linear correlation between applied doses and average free drug concentrations. When comparing exposure data with measured cellular IC<sub>50</sub> values, we predict that compound <b>52</b> is efficacious and selective at doses between ∼0.1 and 72 mg/kg; this modeling data is in agreement with data shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. For a definitive answer, doses of up to 100 mg/kg would have to be tested, which are expected to result in free exposures clearly above the IC<sub>50</sub> of CYP11B1.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0005.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Steroid levels in cynomolgus monkeys 60 min post ACTH challenge and treatment with compound <b>52</b> are compared to the changes of steroid levels induced by LCI699, a less selective ASI. Note that the three highest doses of compound <b>52</b> lowered the aldosterone clearly below basal levels (vehicle <i>t</i> = 0 min). <b>LCI699</b> treatment led to a dramatic increase in deoxycorticosterone and deoxycortisol levels. Enzymatic steps mediated by CYP11B1 or CYP11B2 are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0006.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK/PD prediction in cynomolgus monkeys. Different doses of compound <b>52</b> were applied, and the PK profile was determined (see also the SI, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">Table S8</a>). For each dose, the average free exposure was calculated from AUC<sub>0–7h</sub> and corrected for plasma protein binding. Overall, a good linear correlation between applied doses and achieved free plasma exposures was observed. Horizontal crosslines mark the IC<sub>50</sub> values for CYP11B2 and CYP11B1. This predicts that the doses of 0.1, 1, and 10 mg/kg display significant and selective inhibition of aldosterone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additionally, selectivity against CYP11B1 is not the only concern. For example, an early ASI FAD286 was derived from a known aromatase (CYP19A1) inhibitor Fadrozole. To exclude such un-selectivity, we studied steroid production in the human adrenocarcinoma cell line H295R. A similar assay was recently published as part of the ToxCast program that includes measurement of steroid hormones, including progestagens, corticosteroids, androgens, and estrogens.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Specifically, we induced steroidogenesis with 16 mM potassium chloride for 48 h in the presence of various amounts of inhibitors (0.001–20 μM) and analyzed nine different steroids (deoxycorticosterone, corticosterone, 18-hyroxycorticosterone, aldosterone, deoxycortisol, cortisol, 17-hydroxyprogesterone, testosterone, and estrone). Using nonlinear four-parameter fitting (GraphPad Prism 7.04), the concentration that led to a 50% reduction of steroid levels was calculated. In this analysis, aldosterone and 18-hydroxycorticosterone were the only two steroids inhibited by compound <b>52</b> at less than 1 nM drug concentrations (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">Table S8</a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of compounds <b>10–23</b> are depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. These analogues were generally prepared through copper(I)-catalyzed Ullman coupling reactions of substituted 3,4-dihydroisoquinolin-1-ones or isoindolin-ones intermediates with 3-bromo or 3-iodopyridine.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For commercially unavailable intermediates, their syntheses are described in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>. For example, the 3,4-dihydroisoquinolin-1-one <b>63</b> was obtained via polyphosphoric acid (PPA) catalyzed ring cyclization of methyl phenethylcarbamate <b>63b</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Similar syntheses were also applied for the preparation of 3,4-dihydroisoquinolin-1-ones <b>74–76</b>. In another route, the 3,4-dihydroisoquinolin-1-one <b>64</b> was prepared by first cyclization of <i>N</i>-trifluoroacylated phenethylamine <b>64e</b> in the presence of paraformaldehyde and acetic-sulfuric acid to provide tetrahydroisoquinoline <b>64f</b>, followed by protecting group removal and iodosylbenzene oxidation (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). For the isoindolin-one intermediate <b>67</b>, it started from the ester formation of 4-bromo-2-methyl-benzoic acid to yield <b>67b</b>, followed by nucleophilic aromatic substitution with CuCN to give <b>67c</b>. Bromination of <b>67c</b> with NBS/BPO furnished <b>67d</b>, which further reacted with PMBNH<sub>2</sub> to give an in situ cyclized product, isoindolin-one <b>67e</b>. Removal of the <i>para</i>-methoxylbenzyl (PMB) protecting group by treatment with cerium ammonium nitrate (CAN) then afforded intermediate <b>67</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Syntheses of Aldosterone Synthase Inhibitors, <b>10–23</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-bromopyridine, CuI, K<sub>2</sub>CO<sub>3</sub> (or Cs<sub>2</sub>CO<sub>3</sub>), <i>N</i>,<i>N</i>′-dimethylethylenediamine (or (+)-(<i>S,S</i>)-1,2-diaminocyclohexane), 1,4-dioxane, 110–150 °C.</p></p></figure><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of 3,4-Dihydroisoquinolin-1-one Intermediates, <b>63</b> and <b>64</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl chloroformate, Et<sub>3</sub>N, dichloromethane (DCM), room temperature (rt); (b) neat PPA, 120 °C; (c) PBr<sub>3</sub>, DCM, 0 °C; (d) trimethylsilyl cyanide, tetrabutylammonium fluoride (TBAF), CH<sub>3</sub>CN, reflux; (e) BH<sub>3</sub>-THF, reflux; (f) trifluoroacetic anhydride, Et<sub>3</sub>N, DCM, rt; (g) paraformaldehyde, AcOH, H<sub>2</sub>SO<sub>4</sub>, rt; (h) K<sub>2</sub>CO<sub>3</sub>, MeOH-H<sub>2</sub>O, rt; (i) KBr, iodosylbenzene, H<sub>2</sub>O, rt.</p></p></figure><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Isoindolin-one Intermediate, <b>67</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCl<sub>2</sub>, MeOH, 70 °C; (b) CuCN, 1-methyl-pyrrolidin-2-one, 180 °C; (c) NBS, BPO, CCl<sub>4</sub>, reflux; (d) PMBNH<sub>2</sub>, THF, rt; (e) CAN, CH<sub>3</sub>CN, 0 °C.</p></p></figure><div class="NLM_p">For the several 3-substituted 5-chloro-isoindolin-1-one intermediates <b>68–72</b>, an efficient two-step synthesis was developed as outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The first step involved the reaction of 2-bromo-5-chloro-benzonitrile with corresponding Grignard reagents under the conditions of (a) sodium borohydride reduction, (b) Ti(Oi-Pr)<sub>4</sub>-mediated addition, and (c) Lewis acid BF<sub>3</sub>·OEt<sub>2</sub> catalyzed addition to give benzylic substituted phenylmethanamine intermediates <b>68a–72a</b>, respectively. These intermediates then underwent palladium-catalyzed carbonylation and in situ cyclization to give 3-substituted 5-chloro-isoindolin-1-ones <b>68–72</b>. Alternatively, a 3-substituted 5-chloro-isoindolin-one intermediate, such as <b>73</b>, could also be synthesized via reacting 5-chloro-isoindole-1,3-diones with benzylmagnesium chloride followed by Et<sub>3</sub>SiH reduction; however, under this route, a mixture of two regioisomeric products was produced, with only the desired one shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Additionally, when there is a chiral center involved, chiral column separation was applied to obtain each individual enantiomeric intermediate. Based on the optical rotation measurement, the relative configuration of an enantiomer was assigned as either <i>R</i> (negative sign) or <i>S</i> (positive sign) accordingly.</div><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Isoindolin-one Intermediates, <b>68–72</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeMgBr (or EtMgBr, or cyclopropyl MgBr), THF, 0 °C, and then NaBH<sub>4</sub>, rt; (b) MeMgBr, THF, 0 °C, and then Ti(Oi-Pr)<sub>4</sub>, rt; (c) Ti(Oi-Pr)<sub>4</sub>, EtMgBr, −78 °C to rt, and then BF<sub>3</sub>-Et<sub>2</sub>O; (d) Pd(dppf)Cl<sub>2</sub>, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), CO, 130 °C.</p></p></figure><figure id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Isoindolin-one Intermediate, <b>73</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzylmagnesium chloride, DCM, 0 °C; (b) Et<sub>3</sub>SiH, trifluoroacetic acid (TFA), rt.</p></p></figure><div class="NLM_p">The syntheses of bicyclic tetrahydroisoquinoline series of isoindolin-one compounds <b>24–41</b> are depicted in <a class="ref internalNav" href="#sch6" aria-label="Schemes 6">Schemes 6</a> and <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. The key intermediate <b>83</b> was prepared as previously disclosed.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Esterification of commercially available 5-bromo-4-methyl nicotinic acid with ethanol under 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/4-dimethylaminopyridine (EDCI/DMAP) activation provided ethyl ester <b>80</b>. Deprotonation of the methyl group with freshly prepared lithium diisopropylamide (LDA) followed by addition of methyl acrylate gave access to intermediate <b>80</b> via a two-step cascade reaction. The crude keto ester <b>81</b> was then engaged in a Krapcho decarboxylation using 6 M aq. HCl to provide ketone <b>82</b>. A reductive amination of ketone <b>82</b> with ammonia in methanol in the presence of titanium(IV) isopropoxide and treatment with sodium borohydride furnished the key building block <b>83</b>. After chiral column separation, the obtained individual enantiomers <b>(−)-(</b><i><b>S</b></i><b>)-83</b> and <b>(+)-(</b><i><b>R</b></i><b>)-83</b> were applied in the subsequent Ullman coupling reactions with 5-chloroisoindolin-1-one to give intermediates <b>(−)-(</b><i><b>S</b></i><b>)-84</b> and <b>(+)-(</b><i><b>R</b></i><b>)-85</b>, which were further reacted with either acid chlorides or sulfonyl chlorides to give compounds <b>24–28</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Similarly, compounds <b>29–41</b> were prepared by first reacting <b>(+)-(</b><i><b>R</b></i><b>)-83</b> with acetyl chloride, propanoyl propanoate, and methanesulfonyl chloride to give intermediates <b>(+)-(</b><i><b>R</b></i><b>)-86</b>, <b>(+)-(</b><i><b>R</b></i><b>)-87</b>, and <b>(+)-(R)-88</b>, respectively. Subsequent Ullman coupling reaction with appropriate 3-substituted isoindolin-ones or 3,4-dihydroisoquinolin-1-one then afforded compounds <b>29–41</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).</div><figure id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Syntheses of Bicyclic Tetrahydroisoquinoline Series of Isoindolin-one Aldosterone Synthase Inhibitors, <b>24–28</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, EDCI, DMAP, DCM, rt; (b) LDA, methyl acrylate, THF and then 10% AcOH; (c) 6 M HCl, reflux; (d) Ti(Oi-Pr)<sub>4</sub>, NH<sub>3</sub>-MeOH, 0 °C, and then NaBH<sub>4</sub>; (e) CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, Cs<sub>2</sub>CO<sub>3</sub>, <b>(−)-(</b><i><b>S</b></i><b>)-83</b> (or <b>(+)-(</b><i><b>R</b></i><b>)-83</b>), 1,4-dioxane, microwave 150 °C; (f) acetyl chloride (or propanoyl propanoate, methanesulfonyl chloride, ethanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C.</p></p></figure><figure id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Syntheses of Bicyclic Tetrahydroisoquinoline Series of Isoindolin-one Aldosterone Synthase Inhibitors, <b>29–41</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) acetyl chloride (or propanoyl propanoate, methanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C; (b) <b>68</b> (or <b>69</b>, <b>72</b>), CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave 150 °C; (c) chiral column separation; (d) <b>63</b>, CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave 150 °C.</p></p></figure><div class="NLM_p">The syntheses of 5-chloro-3,3-dimethyl-isoindolin-1-one derivatized compounds <b>42–47</b> are described in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Starting from (5-bromo-3-pyridyl)methanol, treatment with thionyl chloride followed by quenching with ammonia in methanol afforded 3-pyridylmethanamine <b>90</b>. Subsequent Ullman coupling reaction with 5-chloro-3,3-dimethyl-isoindolin-1-one then provided compound <b>91</b>, which further reacted with various acid chlorides and sulfonyl chlorides to give compounds <b>42–47</b>. Compound <b>45</b> was obtained in a similar manner when 1-(5-bromo-3-pyridyl)ethanamine <b>92</b> was used as the corresponding starting material.</div><figure id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>42–47</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCl<sub>2</sub>, DCM, rt; (b) NH<sub>3</sub>-MeOH, 60 °C; (c) intermediate <b>62</b>, CuI, Cs<sub>2</sub>CO<sub>3</sub>, (+)-(<i>S,S</i>)-1,2-diaminocyclohexane, 1,4-dioxane, 150 °C; (d) acetyl chloride (or propanoyl propanoate, methanesulfonyl chloride, ethanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C; (e) 3-methylpyridine-2-carboxylic acid, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU), DIPEA, DCM, rt.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a> outlines the syntheses of compounds <b>48</b> and <b>49</b>, which contain a piperdinyl linker. Commercial available 1,2,3,6-tetrahydropyridine was first protected with acetyl chloride or ethyl sulfonyl chloride. Arylation with 3-bromo-5-iodopyridine under the reductive Heck coupling condition gave compounds <b>97</b> and <b>98</b>. The subsequent Ullman coupling reaction with 5-chloro-3,3-dimethyl-isoindolin-1-one then afforded compounds <b>48</b> and <b>49</b>. Compounds <b>50</b> and <b>51</b> that utilized piperazine as the linker were prepared as depicted in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>. The Buchwald coupling reaction between 3,5-dibromopyridine and piperazine-1-carboxylic acid <i>tert</i>-butyl ester gave compound <b>100</b>, which was further reacted with 5-chloro-3,3-dimethyl-isoindolin-1-one under the Ullman coupling condition to afford compound <b>101</b>. After removal of the <i>N</i>-Boc-protecting group, the resulting intermediate was reacted with acetyl chloride and methyl sulfonyl chloride to give compounds <b>50</b> and <b>51</b>, respectively.</div><figure id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0017.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>48–49</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>3</sub>N, ethanesulfonyl chloride (or acetyl chloride), DCM, 0 °C; (b) 3-bromo-5-iodo-pyrdine, palladium(II)bis(triphenylphosphine) dichloride, Et<sub>3</sub>N, formic acid, DMF, 90 °C; (c) intermediate 62, CuI, Cs<sub>2</sub>CO<sub>3</sub>, <i>trans</i>-cyclohexane-1,2-diamine, 1,4-dioxane, 150 °C.</p></p></figure><figure id="sch10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>50–51</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) piperazine-1-carboxylic acid <i>tert-</i>butyl ester, palladium(II) acetate, XPhos, sodium <i>tert</i>-butoxide, 1,4-dioxane, microwave, 130 °C; (c) TFA, DCM, rt; (d) acetyl chloride (or methanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C.</p></p></figure><div class="NLM_p">Finally, for the syntheses of compounds <b>52–58</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>), the key intermediate <b>103</b> was first prepared by reacting 5-chloro-3,3-dimethyl-isoindolin-1-one with 3,5-diiodo-pyridine under the Ullman coupling condition. The oxygen-linked compounds <b>52–58</b> were prepared via CuI-mediated nucleophilic aromatic displacement of iodine with various alcohols. The resulting amino intermediates were then capped with various acylating reagents to give compounds <b>52–58</b>. Compounds <b>59–62</b> that contained a 2,6-diazaspiro[3.3]heptane as the linker were prepared in a similar manner when the corresponding starting materials were applied.</div><figure id="sch11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>52–62</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3,5-diiodo-pyridine, CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C; (b) CuI, 1,10-phenanthroline, Cs<sub>2</sub>CO<sub>3</sub>, <i>tert</i>-butyl 3-hydroxyazetidine-1-carboxylate (or (<i>R</i>)-3-hydroxy-pyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester, (<i>S</i>)-3-hydroxy-pyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester, <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate), toluene, 110 °C; then, TFA, DCM, rt; (c) Et<sub>3</sub>N, DCM, ethanesulfonyl chloride (or acetyl chloride); (d) 3-chloropyridine-2-carboxylic acid (or 4-methylpyridine-3-carboxylic acid, 1-methylpyrazole-4-carboxylic acid), HATU, DIPEA, DCM, 0 °C; (e) <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate, Pd<sub>2</sub>dba<sub>3</sub>, BINAP, <i><sup>t</sup></i>BuONa, Et<sub>3</sub>N, toluene, 85 °C; (f) TFA, DCM, rt.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Achieving high selectivity against the highly homologous CYP11B1 enzyme is necessary for the development of an effective and safe aldosterone synthase (CYP11B2) inhibitor but challenging due to the high sequence conservation in the substrate binding site. Starting from a focused screening benzamide pyrimidine hit, we identified a series of isoindoline-1-one derivatives as potent and selective CYP11B2 inhibitors. The right-hand-side modification on the central pyridine core not only provided a way for potency and selectivity improvements but was also effective in modulating the physical and chemical property profiles for good PK oral exposure. Through the systematic exploration of a pocket identified from biostructure analysis, we found unique structural features for achieving high CYP11B1 selectivity. We speculate that this is due to differences in protein flexibility and hydrogen-bonding geometry between both proteins. Representative selective compounds were evaluated in an acute ACTH-challenged animal model and demonstrated both excellent <i>in vivo</i> efficacy of aldosterone-lowering effect and superior selectivity impact of minimum cortisol change. We hope that our findings will be useful in designing the next generation of potent and highly selective aldosterone synthase inhibitors to enter into clinical testing.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Methods for Chemistry</h3><div class="NLM_p">Reactions involving air-sensitive reagents were carried out under an atmosphere of nitrogen or argon. The microwave-assisted reactions were carried out in a Biotage Initiator Sixty. Solvents and reagents were obtained from commercial sources and were used without further purification unless otherwise noted. All reactions were monitored by thin-layer chromatography (TLC) on Merck silica gel 60 F254 TLC glass plates (visualized by UV fluorescence at λ = 254 nm) or analytical liquid chromatography–mass spectrometry (LC-MS). All intermediates and final compounds were purified by either silica gel flash chromatography or preparative high-performance liquid chromatography (prep-HPLC) using one of the following instruments: (i) Biotage SP1 system and the Quad 12/25 cartridge module or (ii) ISCO Combi-flash chromatography instrument. Silica gel brand and pore size were as follows: (a) KP-SIL 60 Å, particle size 40–60 μm; (b) CAS registry no., silica gel, 63231-67-4, particle size 47–60 μm silica gel; (c) ZCX from Qingdao Haiyang Chemical Co., Ltd., pore 200–300 or 300–400; and (iii) prep-HPLC on a reverse-phase column using a Waters XBridge OBD Phenyl (30 mm × 100 mm, 5 μm) or OBD RP18 (30 mm × 100 mm, 5 μm) column under acidic conditions (A, 0.1% formic acid in H<sub>2</sub>O; B, 0.1% formic acid in acetonitrile) or basic conditions (A, 0.01% ammonia in H<sub>2</sub>O; B, acetonitrile). For SFC chiral separation, either intermediates or final compounds were separated using a chiral column (Daicel Chiralpak IC, 30 mm × 250 mm, 5 μm) on a Mettler Teledo SFC-Multigram system (solvent system of 95% CO<sub>2</sub> and 5% IPA (0.5% Et<sub>3</sub>N in IPA), backpressure of 100 bar, UV detection at 254 nm). Optical rotation was measured using a Rudolph Autopol V automatic polarimeter at a wavelength of 589 nm. The purity of the final compounds as measured by LC-MS was ≥95%. LC-MS spectra were obtained using ultraperformance liquid chromatography (UPLC) coupled with a single quadrupole mass detector (Waters Acquity UPLC-3100 Mass Detector, Waters Acquity UPLC-SQ Detector, Waters Acquity UPLC-SQ Detector 2). Standard LC-MS conditions were as follows. Columns: Waters Acquity BEH C18, 2.1 mm × 50 mm × 1.7 μm and Waters Acquity CSH C18 column, 2.1 mm × 50 mm × 1.7 μm. Flow rate: 0.8 mL/min. Gradient: 5–95% eluent B over 3 min under mobile phase conditions: (1) acidic condition: A, 0.1% formic acid in H<sub>2</sub>O; B, 0.1% formic acid in acetonitrile; or (2) basic condition: A, 0.05% NH<sub>3</sub>·H<sub>2</sub>O in H<sub>2</sub>O; B, acetonitrile. Mass spectra (MS): Generally only ions that indicate the parent mass are reported, and unless otherwise stated, the mass ion quoted is the positive mass ion (M + H)<sup>+</sup>. NMR spectra were obtained using a Bruker Avance 400 MHz spectrometer, operating at 400.13 MHz (<sup>1</sup>H) and 100.62 MHz (<sup>13</sup>C). High-resolution mass spectra were obtained on a Xevo G2-XS-QTOF mass spectrometer equipped with an electrospray ionization source. All of the reported yields are for isolated products and not optimized.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Synthetic Procedure for the Synthesis of 6-Chloro-2-(3-pyridyl)-3,4-dihydroisoquinolin-1-one (<b>10</b>)</h4><div class="NLM_p">In a sealed tube, 3-bromopyridine (0.1 g, 0.633 mmol) was combined with 6-chloro-3,4-dihydro-2<i>H</i>-isoquinolin-1-one (intermediate <b>63</b>, 0.115 g, 633 mmol), copper(I) iodide (0.012 g, 0.063 mmol), potassium carbonate (0.175 g, 1.27 mmol), and <i>N</i>,<i>N</i>′-dimethylethylenediamine (0.013 g, 0.127 mmol) in 1,4-dioxane (2 mL). The reaction mixture was heated at 110 °C overnight. The mixture was cooled to room temperature, filtered through dicalite, and washed with DCM. The residue was purified by silica gel flash chromatography eluting with a 5–100% EtOAc-heptane gradient to give the title compound (0.107 g, 65% yield) as a white solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 259.1. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.64–8.70 (m, 1H), 8.47–8.54 (m, 1H), 8.09 (d, <i>J</i> = 8.31 Hz, 1H), 7.75–7.82 (m, 1H), 7.33–7.41 (m, 2H), 7.27–7.29 (m, 1H), 4.00–4.08 (m, 2H), 3.11–3.22 (m, 2H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 163.5, 147.2, 146.1, 139.9, 139.3, 138.6, 132.7, 130.5, 127.8, 127.5, 127.1, 123.3, 49.0, 28.3.</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>10</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 6-Chloro-7-fluoro-2-(3-pyridyl)-3,4-dihydroisoquinolin-1-one (<b>11</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.19 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 277.1. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.66–8.74 (m, 1H), 8.40–8.53 (m, 1H), 7.90–8.00 (m, 1H), 7.78–7.89 (m, 1H), 7.50–7.61 (m, 2H), 4.01–4.14 (m, 2H), 3.16–3.27 (m, 2H).</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 2-(3-Pyridyl)isoindolin-1-one (<b>12</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 211.1. HRMS calcd [(M + H)<sup>+</sup>] 211.0871, measured [(M + H)<sup>+</sup>] 211.0874. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.89–9.09 (m, 1H), 8.52–8.58 (m, 1H), 8.40–8.51 (m, 1H), 7.91–7.96 (m, 1H), 7.60–7.68 (m, 1H), 7.50–7.59 (m, 2H), 7.33–7.45 (m, 1H), 4.91 (s, 2H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 167.9, 145.4, 140.0, 140.0, 132.6, 132.4, 128.7, 126.5, 124.3, 122.8, 50.0.</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 5-Chloro-2-(3-pyridyl)isoindolin-1-one (<b>13</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 245.1. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.85–8.96 (m, 1H), 8.40–8.54 (m, 2H), 7.82–7.91 (m, 1H), 7.47–7.59 (m, 2H), 7.33–7.42 (m, 1H), 4.81–4.94 (m, 2H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.8, 145.7, 141.5, 140.0, 139.1, 131.0, 129.4, 126.6, 125.6, 123.8, 123.3, 49.6.</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 1-Oxo-2-(3-pyridyl)isoindoline-5-carbonitrile (<b>14</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 236.1. HRMS calcd [(M + H)<sup>+</sup>] 236.0824, measured [(M + H)<sup>+</sup>] 236.0816. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.92–8.98 (m, 1H), 8.44–8.54 (m, 2H), 8.03–8.11 (m, 1H), 7.77–7.92 (m, 2H), 7.37–7.44 (m, 1H), 4.97–5.00 (m, 2H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 165.9, 146.3, 140.4, 140.3, 136.2, 135.5, 132.6, 126.9, 125.2, 123.9, 117.9, 116.1, 49.8.</div></div><div id="sec5_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 5-Chloro-3-methyl-2-(3-pyridyl)isoindolin-1-one (<b>15</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.14 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 259.1. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.93 (d, <i>J</i> = 2.53 Hz, 1H), 8.46 (dd, <i>J</i> = 1.52, 4.80 Hz, 1H), 8.15 (ddd, <i>J</i> = 1.39, 2.65, 8.34 Hz, 1H), 7.86 (d, <i>J</i> = 8.08Hz,1H), 7.77 (s, 1H), 7.55–7.64 (m, 2H), 5.47–5.55 (m, 1H), 1.49 (d, <i>J</i> = 6.57 Hz, 3H).</div></div><div id="sec5_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 5-Chloro-3-ethyl-2-(3-pyridyl)isoindolin-1-one (<b>16</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.45 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 273.2. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.89 (d, <i>J</i> = 2.02 Hz, 1H), 8.43 (dd, <i>J</i> = 1.52,4.80 Hz, 1H), 8.13 (d, <i>J</i> = 8.54 Hz, 1H), 7.84 (d, <i>J</i> = 8.34 Hz, 1H), 7.72 (s, 1H), 7.53–7.61 (m, 2H), 5.59 (dd, <i>J</i> = 2.78, 5.05 Hz, 1H), 2.05–2.15 (m, 1H), 1.92–2.04 (m, 1H), 0.45 (t, <i>J</i> = 7.33 Hz, 3H).</div></div><div id="sec5_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 5-Chloro-3,3-dimethyl-2-(3-pyridyl)isoindolin-1-one (<b>17</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.36 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 273.1. HRMS calcd [(M + H)<sup>+</sup>] 273.0795, measured [(M + H)<sup>+</sup>] 273.0794. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.67 (dd, <i>J</i> = 1.52, 4.80 Hz, 1H), 8.56 (dd, <i>J</i> = 0.76, 2.53 Hz, 1H), 7.81–7.91 (m, 3H), 7.59–7.67 (m, 2H), 1.59 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.9, 153.1, 150.4, 149.4, 138.9, 137.2, 132.5, 129.1, 128.4, 125.7, 124.1, 121.7, 64.4, 26.8.</div></div><div id="sec5_1_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 5′-Chloro-2′-(3-pyridyl)spiro[cyclopropane-1,3′-isoindoline]-1′-one (<b>18</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.30 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 271.2. HRMS calcd [(M + H)<sup>+</sup>] 271.0638, measured [(M + H)<sup>+</sup>] 271.0638. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.68 (dd, <i>J</i> = 1.52, 5.05 Hz,1H), 8.53 (d, <i>J</i> = 2.53 Hz, 1H), 7.88 (d, <i>J</i> = 7.99 Hz, 1H), 7.85 (d, <i>J</i> = 7.78 Hz, 1H), 7.54–7.69 (m, 2H), 7.47 (d, <i>J</i> = 1.77 Hz, 1H), 1.52–1.67 (m, 2H), 1.34–1.48 (m, 2H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 167.3, 150.6, 149.9, 149.0, 138.8, 137.4, 130.8, 129.3, 128.3, 125.5, 124.2, 118.5, 46.5, 11.6.</div></div><div id="sec5_1_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 5-Chloro-3-cyclopropyl-2-(3-pyridyl)isoindolin-1-one (<b>19</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 285.1. HRMS calcd [(M + H)<sup>+</sup>] 285.0794, measured [(M + H)<sup>+</sup>] 285.0790. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.79 (d, <i>J</i> = 2.51 Hz, 1H), 8.52 (dd, <i>J</i> = 1.38, 4.89 Hz, 1H), 8.06 (d, <i>J</i> = 8.31 Hz, 1H), 7.85 (d, <i>J</i> = 8.20 Hz, 1H), 7.81 (s, 1H), 7.63 (d, <i>J</i> = 7.78 Hz, 1H), 7.57–7.61 (m, 1H), 4.78 (d, <i>J</i> = 9.54 Hz, 1H), 0.85–0.95 (m, 1H), 0.62–0.73 (m, 2H), 0.43–0.52 (m, 1H), 0.34 (td, <i>J</i> = 4.77, 6.02 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 165.5, 146.5, 145.8, 137.8, 133.2, 132.3, 128.8, 128.5, 124.5, 122.8, 122.4, 64.7, 13.7, 3.7.</div></div><div id="sec5_1_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-Benzyl-5-chloro-2-(3-pyridyl)isoindolin-1-one (<b>20</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.66 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 335.1. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.93 (d, <i>J</i> = 2.53 Hz, 1H), 8.46 (dd, <i>J</i> = 1.52, 4.80 Hz, 1H), 8.16 (d, <i>J</i> = 7.99 Hz, 1H), 7.72 (d, <i>J</i> = 7.62 Hz, 1H), 7.52–7.61 (m, 3H), 7.05–7.17 (m, 3H), 6.75 (d, <i>J</i> = 6.58 Hz, 2H), 5.88 (dd, <i>J</i> = 4.17, 6.19 Hz, 1H), 3.39 (dd, <i>J</i> = 4.04, 14.15 Hz, 1H), 3.17 (dd, <i>J</i> = 6.19, 14.27 Hz, 1H).</div></div><div id="sec5_1_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 6-Chloro-3-methyl-2-(3-pyridyl)-3,4-dihydroisoquinolin-1-one (<b>21</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.38 min, 98% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 273.1. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.64 (s, 1H), 8.54 (dd, 1H), 8.04–7.90 (m, 2H), 7.63–7.54 (m, 1H), 7.48–7.42 (m, 2H), 4.39–4.28 (m, 1H), 3.63 (dd, 1H), 3.01 (dd, 1H), 1.24 (d, 3H).</div></div><div id="sec5_1_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 6-Chloro-4-methyl-2-(3-pyridyl)-3,4-dihydroisoquinolin-1-one (<b>22</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.44 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 273.1. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.69 (d, 1H), 8.48 (dd, 1H), 8.03 (d, 1H), 7.97–7.90 (m, 1H), 7.60–7.51 (m, 1H), 7.47 (d, 1H), 7.44 (dd, 1H), 4.21 (dd, 1H), 3.81 (dd, 1H), 3.41–3.35 (m, 1H), 1.46 (d, 3H).</div></div><div id="sec5_1_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 6-Chloro-4,4-dimethyl-2-(3-pyridyl)-3<u class="uu"><i>H</i></u>-isoquinolin-1-one (<b>23</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.56 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 287.2. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.70 (dd, 1H), 8.49 (dd, 1H), 8.05 (d, 1H), 7.95 (ddd, 1H), 7.58–7.53 (m, 2H), 7.44 (dd, 1H), 3.89 (s, 2H), 1.48 (s, 6H).</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthetic Procedure for the Synthesis of (−)-<i>N</i>-[(8<i>S</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>24</b>)</h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (−)-2-[(8<i>S</i>)-8-Amino-5,6,7,8-tetrahydroisoquinolin-4-yl]-5-chloro-isoindolin-1-one (<b>(−)-(</b><i><b>S</b></i><b>)-84</b>)</h5><div class="NLM_p last">5-Chloroisoindolin-1-one (501 mg, 3 mmol), (−)-(<i>S</i>)-4-bromo-5,6,7,8-tetrahydroisoquinolin-8-amine (intermediate <b>(−)-(</b><i><b>S</b></i><b>)-83</b>, 703 mg, 3.1 mmol), CuI (171 mg, 0.9 mmol), (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine (69 mg, 0.6 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (1.95 g, 6 mmol) were dissolved in 1,4-dioxane (45 mL). The reaction mixture was subjected to microwave reaction at 150 °C for 2.5 h before it was poured into H<sub>2</sub>O (50 mL) and extracted with EtOAc (25 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the title compound (800 mg, 85.2% yield) as a yellow solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 314.1.</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (−)-<i>N</i>-[(8<i>S</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>24</b>)</h5><div class="NLM_p last">To a stirred solution of (−)-2-[(8<i>S</i>)-8-amino-5,6,7,8-tetrahydroisoquinolin-4-yl]-5-chloro-isoindolin-1-one (intermediate <b>(−)-(</b><i><b>S</b></i><b>)-84</b>, 438 mg, 1.4 mmol) and Et<sub>3</sub>N (3.0 mL) in DCM (10 mL) was added acetyl chloride (0.106 mL, 1.4 mmol) at 0 °C, and stirring was continued at 0 °C for 1 h. The resulting mixture was extracted with EtOAc (100 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford a crude product, which was purified by prep-HPLC to yield the title compound (99.4 mg, 20% yield) as a white solid. LC-MS: <i>t</i><sub>R</sub> 1.06 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 356.1. HRMS calcd [(M + H)<sup>+</sup>] 356.1166, measured [(M + H)<sup>+</sup>] 356.1166. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −47.6 (1.8 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.43–8.51 (m, 2H), 7.83–7.90 (m, 1H), 7.71–7.77 (m, 1H), 7.59–7.67 (m, 1H), 5.22–5.28 (m, 1H), 4.93 (s, 2H), 2.60–2.81 (m, 2H), 2.05 (s, 3H), 1.79–2.01 (m, 4H).</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthetic Procedure for the Synthesis of (+)-<i>N</i>-[(8<i>R</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>25</b>)</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (+)-2-[(8<i>R</i>)-8-Amino-5,6,7,8-tetrahydroisoquinolin-4-yl]-5-chloro-isoindolin-1-one (<b>(+)-(</b><i><b>R</b></i><b>)-85</b>)</h5><div class="NLM_p last">5-Chloroisoindolin-1-one (1.02 g, 6 mmol), (+)-(<i>R</i>)-4-bromo-5,6,7,8-tetrahydroisoquinolin-8-amine (intermediate <b>(+)-(</b><i><b>R</b></i><b>)-83</b>, 1.4 g, 6.2 mmol), CuI (342 mg, 1.8 mmol), (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine (140 mg, 1.2 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (3.9 g, 12 mmol) were dissolved in 1,4-dioxane (100 mL). The reaction mixture was subjected to microwave reaction at 150 °C for 2.5 h before it was poured into H<sub>2</sub>O (50 mL) and extracted with EtOAc (25 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the title compound (1.5 g, 80% yield) as a yellow solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 314.1.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (+)-<i>N</i>-[(8<i>R</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>25</b>)</h5><div class="NLM_p">To a stirred solution of (+)-2-[(8<i>R</i>)-8-amino-5,6,7,8-tetrahydroisoquinolin-4-yl]-5-chloro-isoindolin-1-one (intermediate <b>(+)-(</b><i><b>R</b></i><b>)-85</b>, 438 mg, 1.4 mmol) and Et<sub>3</sub>N (3 mL) in DCM (10 mL) was added acetyl chloride (0.106 mL, 1.4 mmol) at 0 °C, and stirring was continued at 0 °C for 1 h. The resulting mixture was extracted with EtOAc (100 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford a crude product, which was purified by prep-HPLC to yield the title compound (64.6 mg, 13% yield) as a white solid. LC-MS: <i>t</i><sub>R</sub> 1.06 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 356.1. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +37.8 (1.8 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.40–8.52 (m, 2H), 7.81–7.91 (m, 1H), 7.71–7.78 (m, 1H), 7.59–7.66 (m, 1H), 5.20–5.31 (m, 1H), 4.92 (s, 2H), 2.61–2.81 (m, 2H), 2.01 (s, 3H), 1.77–1.98 (m, 4H).</div><div class="NLM_p last">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>25</b> from either commercially available reagents or in-house-prepared intermediates.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (+)-<i>N</i>-[(8<i>R</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide (<b>26</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.14 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 370.1. HRMS calcd [(M + H)<sup>+</sup>] 370.1322, measured [(M + H)<sup>+</sup>] 370.1317. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +54.3 (1.6 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.43–8.47 (m, 2H), 7.83–7.89 (m, 1H), 7.72–7.75 (m, 1H), 7.59–7.67 (m, 1H), 5.21–5.30 (m, 1H), 4.97 (s, 2H), 2.68–2.80 (m, 2H), 2.24–2.39 (m, 2H), 1.94–2.09 (m, 2H), 1.84–1.93 (m, 2H), 1.17–1.27 (m, 3H).</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (+)-<i>N</i>-[(8<i>R</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]methanesulfonamide (<b>27</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.23 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 392.1. HRMS calcd [(M + H)<sup>+</sup>] 392.0836, measured [(M + H)<sup>+</sup>] 392.0847. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +7.7 (1 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.72–8.77 (m, 1H), 8.43–8.49 (m, 1H), 7.82–7.90 (m, 1H), 7.71–7.76 (m, 1H), 7.60–7.66 (m, 1H), 5.20–5.30 (m, 1H), 4.97 (s, 2H), 3.18 (s, 3H), 2.60–2.79 (m, 2H), 2.11–2.30 (m, 2H), 1.91–2.06 (m, 2H).</div></div><div id="sec5_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (+)-<i>N</i>-[(8<i>R</i>)-4-(5-Chloro-1-oxo-isoindolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]ethanesulfonamide (<b>28</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.23 min, 98% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 406.1. HRMS calcd [(M + H)<sup>+</sup>] 406.0992, measured [(M + H)<sup>+</sup>] 406.0993. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +28.7 (1.4 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.73–8.78 (m, 1H), 8.43–8.48 (m, 1H), 7.83–7.89 (m, 1H), 7.70–7.77 (m, 1H), 7.59–7.66 (m, 1H), 4.96 (s, 2H), 4.72–4.81 (m, 1H), 3.13–3.20 (m, 2H), 2.61–2.75 (m, 2H), 2.08–2.26 (m, 2H), 1.92–2.08 (m, 2H), 1.38–1.46 (m, 3H).</div></div><div id="sec5_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (+)-<i>N</i>-[(8<i>R</i>)-4-(6-Chloro-1-oxo-3,4-dihydroisoquinolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>39</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 370.0. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.42 (d, 1H), 8.37 (d, 1H), 7.99 (d, 1H), 7.41–7.47 (m, 2H), 5.19–5.27 (m, 1H), 3.95–4.13 (m, 1H), 3.76–3.88 (m, 1H), 3.20–3.38 (m, 3H), 2.64–2.85 (m, 2H), 1.82–2.09 (m, 5H), 1.78–2.18 (m, 1H), 1.78–2.22 (m, 1H).</div></div><div id="sec5_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (+)-<i>N</i>-[(8R)-4-(6-Chloro-1-oxo-3,4-dihydroisoquinolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide (<b>40</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.50–8.31 (m, 2H), 8.01 (d, 1H), 7.46 (s, 1H), 7.45 (d, 2H), 5.23 (br t,1H), 4.18–3.95 (m, 1H), 3.92–3.73 (m, 1H), 3.57–3.35 (m, 1H), 3.30–3.08 (m, 2H), 2.75 (br t, 2H), 2.39–2.21 (m, 2H), 2.08–1.81 (m, 4H), 1.31–1.14 (m, 3H).</div></div><div id="sec5_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (+)-<i>N</i>-[(8R)-4-(6-Chloro-1-oxo-3,4-dihydroisoquinolin-2-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]methanesulfonamide (<b>41</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.19 min, 98% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 406.0. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.74–8.65 (m, 1H), 8.38 (s, 1H), 8.00 (d, 1H), 7.46 (s, 1H), 7.45 (d, 2H), 4.84–4.70 (m, 1H), 4.15–3.94 (m, 1H), 3.90–3.70 (m, 1H), 3.56–3.35 (m, 1H), 3.31–3.18 (m, 2H), 3.13 (d, 3H), 2.91–2.63 (m, 2H), 2.29–2.09 (m, 1H), 2.08–1.82 (m, 3H).</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthetic Procedure for the Syntheses of (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>R</i>)-5-Chloro-3-ethyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>31</b>) and (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>S</i>)-5-Chloro-3-ethyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>32</b>)</h4><div class="NLM_p">5-Chloro-3-ethyl-isoindolin-1-one (intermediate <b>69</b>, 900 mg, 4.62 mmol), (+)-<i>N</i>-[(8<i>R</i>)-4-bromo-5,6,7,8-tetrahydro-isoquinolin-8-yl]-acetamide (intermediate <b>(+)-(</b><i><b>R</b></i><b>)-86</b>, 1.2 g, 4.62 mmol), CuI (263 mg, 1.38 mmol), (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine (333 mg, 2.7 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (3 g, 9.24 mmol) were dissolved in 1,4-dioxane (45 mL). The reaction mixture was subjected to microwave reaction at 150 °C for 2.5 h before it was poured into H<sub>2</sub>O (50 mL) and extracted with EtOAc (25 mL × 2). The combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a crude product, which was purified by silica gel flash chromatography eluting with a 0–30% MeOH-EtOAc gradient to give the racemic title compound (707.8 mg, 40% yield) as a white solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 384.1.</div><div class="NLM_p">This racemic mixture was then separated by chiral HPLC to afford the enantiomeric compound <b>31</b> (45 mg), LC-MS: <i>t</i><sub>R</sub> 1.27 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 384.1. HRMS calcd [(M + H)<sup>+</sup>] 384.1478, measured [(M + H)<sup>+</sup>] 384.1476. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +147.6 (3.2 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.26–8.58 (m, 2H), 7.80–7.96 (m, 1H), 7.70–7.80 (m, 1H), 7.56–7.70 (m, 1H), 5.06–5.49 (m, 2H), 2.48–2.75 (m, 2H), 1.90–2.17 (m, 7H), 1.72–1.91 (m, 2H), 0.66–0.84 (m, 3H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 169.4, 150.8, 148.9, 146.7, 144.4, 138.8, 134.1, 129.2, 125.6, 122.9, 62.2, 44.6, 28.9, 24.7, 24.1, 23.3, 18.3, 7.0 and enantiomeric compound <b>32</b> (53 mg), LC-MS: <i>t</i><sub>R</sub> 1.27 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 384.1. HRMS calcd [(M + H)<sup>+</sup>] 384.1478, measured [(M + H)<sup>+</sup>] 384.1474. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +37.8 (2.3 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.27–8.56 (m, 2H), 7.79–7.98 (m, 1H), 7.71–7.81 (m, 1H), 7.56–7.70 (m, 1H), 5.06–5.51 (m, 2H), 2.51–2.78 (m, 2H), 1.71–2.21 (m, 9H), 0.62–0.92 (m, 3H).</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compounds <b>31</b> and <b>32</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>R</i>)-5-Chloro-3-methyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>29</b>) and (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>S</i>)-5-Chloro-3-methyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>30</b>)</h5><div class="NLM_p last">Enantiomeric compound <b>29</b>, LC-MS: <i>t</i><sub>R</sub> 1.29 min, 95% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 370.1. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +90.0 (1 mg/mL, MeOH). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.26–8.54 (m, 2H), 7.85 (br d, <i>J</i> = 7.78 Hz, 1H), 7.70–7.80 (m, 1H), 7.63 (dd, <i>J</i> = 1.76, 8.28 Hz, 1H), 5.22–5.43 (m, 2H), 2.54–2.69 (m, 2 H), 1.80–2.07 (m, 6 H), 1.50 (br d, <i>J</i> = 6.27 Hz, 2H), 1.41 (br d, <i>J</i> = 6.27 Hz, 1H), 1.23–1.37 (m, 1H). Enantiomeric compound <b>30</b>, LC-MS: <i>t</i><sub>R</sub> 1.27 min, 95% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 370.1. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +16.0 (1 mg/mL, MeOH). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.41–8.62 (m, 2H), 7.85 (br d, <i>J</i> = 8.28 Hz, 1H), 7.77 (s, 1H), 7.63 (dd, <i>J</i> = 1.76, 8.28 Hz, 1H), 5.25–5.36 (m, 2H), 2.91 (br d, <i>J</i> = 1.51 Hz, 1H), 2.52–2.76 (m, 1H), 1.83–2.14 (m,6H), 1.66–1.94 (m, 2H), 1.41–1.48 (m, 2H), 1.23–1.35 (m, 1H).</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>R</i>)-5-Chloro-3-methyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide (<b>33</b>) and (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>S</i>)-5-Chloro-3-methyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide (<b>34</b>)</h5><div class="NLM_p last">Enantiomeric compound <b>33</b>, LC-MS: <i>t</i><sub>R</sub> 1.36 min, 98% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 374.1. HRMS calcd [(M + H)<sup>+</sup>] 384.1478, measured [(M + H)<sup>+</sup>] 384.1476. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +100.0 (1 mg/mL, MeOH). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.38–8.50 (m, 2H), 7.84–7.86 (m, 1H), 7.76–7.78 (m, 1H), 7.62–7.65 (m, 1H), 5.27–5.36 (m, 2H), 2.55–2.70 (m, 1H), 2.15–2.38 (m, 2H), 1.70–1.96 (m, 3H), 1.50 (m, 1H), 1.42 (m, 1H), 1.26–1.36 (m, 2H), 1.06–1.25 (m, 3H), 0.82–1.05 (m, 1H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 173.3, 150.9, 149.2, 148.6, 146.1, 145.8, 138.8, 129.3, 125.5, 122.9, 59.3, 57.3, 44.5, 32.0, 29.9, 29.7, 29.1, 24.4, 19.1, 18.4, 9.8. Enantiomeric compound <b>34</b>, LC-MS: <i>t</i><sub>R</sub> 1.36 min, 98% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 384.1. HRMS calcd [(M + H)<sup>+</sup>] 384.1479, measured [(M + H)<sup>+</sup>] 384.1480. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +20.0 (1 mg/mL, MeOH). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.31–8.50 (m, 2H), 7.84 (br d, <i>J</i> = 8.28 Hz, 1H), 7.77 (s, 1H), 7.58–7.66 (m, 1H), 5.32–5.47 (m, 1H), 5.26 (m, 1H), 2.94 (m, 1H), 2.58 (m, 1H), 2.32 (q, <i>J</i> = 7.19 Hz, 2H), 2.08 (br s, 1H), 1.93–2.04 (m, 1H), 1.84 (br d, <i>J</i> = 8.03 Hz, 1H), 1.48 (br d, <i>J</i> = 6.53 Hz, 1H), 1.41 (br d, <i>J</i> = 6.78 Hz, 2H), 1.28–1.35 (m, 2H), 1.15–1.26 (m, 3H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 173.4, 165.8, 149.8, 148.6, 146.1, 138.8, 134.3, 131.7, 129.3, 125.4, 122.7, 59.5, 45.3, 29.9, 29.7, 29.5, 24.9, 24.9, 19.5, 18.0, 9.9.</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>R</i>)-5-Chloro-3-ethyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide (<b>35</b>) and (+)-<i>N</i>-[(8<i>R</i>)-4-[(3<i>S</i>)-5-Chloro-3-ethyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide (<b>36</b>)</h5><div class="NLM_p last">Enantiomeric compound <b>35</b>, LC-MS: <i>t</i><sub>R</sub> 1.45 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 398.1. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +110.6 (1.2 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.24–8.54 (m, 2H), 7.78–7.94 (m, 1H), 7.71–7.82 (m, 1H), 7.56–7.66 (m, 1H), 5.05–5.52 (m, 2H), 2.53–2.76 (m, 2H), 2.22–2.38 (m, 2H), 1.73–2.18 (m, 6H), 1.12–1.29 (m, 3H), 0.62–0.89 (m, 3H). Enantiomeric compound <b>36</b>, LC-MS: <i>t</i><sub>R</sub> 1.45 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 398.1. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +25.1 (1.3 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.29–8.53 (m, 2H), 7.80–7.96 (m, 1H), 7.71–7.81 (m, 1H), 7.56–7.68 (m, 1H), 5.02–5.47 (m, 2H), 2.49–2.70 (m, 1H), 2.23–2.40 (m, 2H), 1.71–2.18 (m, 7H), 1.13–1.28 (m, 3H), 0.65–0.87 (m, 3H).</div></div><div id="sec5_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>N</i>-[(8<i>R</i>)-4-[(3<i>R</i>)-5-Chloro-3-cyclopropyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>37</b>) and <i>N</i>-[(8<i>R</i>)-4-[(3<i>S</i>)-5-Chloro-3-cyclopropyl-1-oxo-isoindolin-2-yl]-5,6,7,8-tetrahydroisoquinolin-8-yl]acetamide (<b>38</b>)</h5><div class="NLM_p last">Enantiomeric compound <b>37</b>, LC-MS: <i>t</i><sub>R</sub> 1.37 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 396.7. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +370.0 (1 mg/mL, MeOH). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i>6) δ ppm 8.48 (br d, 0.5H), 8.30–8.42 (m, 1.5H), 7.72–7.92 (m, 2H), 7.66 (d, 1H), 4.99–5.19 (m, 1H), 4.57 (d, 0.5H), 4.17 (d, 0.5H), 2.40–2.80 (m, 4H), 1.80–1.95 (m, 5H), 1.66 (bs s, 2H), 1.25 (b, 1H), 0.77–1.03 (m, 1H), 0.49–0.74 (m, 1H), 0.24 (br s, 1H), −0.15 (dt, 1H). Enantiomeric compound <b>38</b>, LC-MS: <i>t</i><sub>R</sub> 1.37 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 396.7. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −24.0 (1 mg/mL, MeOH). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i>6) δ ppm 8.31–8.47 (m, 2H). 7.78–7.83 (m, 2H), 7.66 (dd, 1H), 5.05–5.14 (m, 1H), 4.57 (d, 0.6H), 4.17 (d, 0.4H), 2.37–2.80 (m, 4H), 1.80–1.96 (m, 5H), 1.65 (br d, 2H), 0.81–1.04 (m, 1H), 0.47–0.75 (m, 2H), 0.20–0.36 (m, 1H), −0.14 (dq, 1H).</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Synthetic Procedure for the Synthesis of <i>N</i>-[[5-(6-Chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]methyl]acetamide (<b>42</b>)</h4><div class="NLM_p">To a stirred solution of 2-[5-(aminomethyl)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (intermediate <b>91</b>, 210 mg, 0.7 mmol) and Et<sub>3</sub>N (2.0 mL) in DCM (10 mL) was added acetyl chloride (0.051 mL, 0.7 mmol) at 0 °C, and stirring was continued at 0 °C for 1 h. The resulting mixture was extracted with EtOAc (100 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a crude product, which was purified by prep-HPLC to afford the title compound (36 mg, 15% yield) as a white foam. LC-MS: <i>t</i><sub>R</sub> 1.15 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 344.2. HRMS calcd [(M + H)<sup>+</sup>] 344.1165, measured [(M + H)<sup>+</sup>] 344.1164. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.28–8.75 (m, 2H), 7.75–7.89 (m, 3H), 7.54–7.63 (m, 1H), 4.38–4.56 (m, 2H), 1.91–2.11 (m, 3H), 1.47–1.67 (m, 6H).</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>42</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>-[[5-(6-Chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]methyl]propanamide (<b>43</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.22 min, 95% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 358.1. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.60 (d, <i>J</i> = 2.01 Hz, 1H), 8.44–8.47 (m, 1H), 7.82–7.86 (m, 2H), 7.80–7.82 (m, 1H), 7.58–7.63 (m, 1H), 4.46 (s, 2H), 2.64–2.72 (m, 2H), 1.55–1.61 (m, 6H), 1.10–1.22 (m, 3H).</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>N</i>-[[5-(6-Chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]methyl]methanesulfonamide (<b>44</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.26 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 380.1. HRMS calcd [(M + H)<sup>+</sup>] 380.0836, measured [(M + H)<sup>+</sup>] 380.0835. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.61–8.76 (m, 1H), 8.44–8.54 (m, 1H), 7.87–7.97 (m, 1H), 7.79–7.86 (m, 2H), 7.57–7.63 (m, 1H), 4.32–4.51 (m, 2H), 3.00 (s, 3H), 1.60 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 167.1, 153.2, 149.5, 148.7, 139.1, 136.7, 133.9, 132.6, 129.2, 128.1, 125.6, 121.8, 64.7, 44.1, 41.2, 26.8.</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>-[[5-(6-Chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]methyl]ethanesulfonamide (<b>46</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.33 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 394.1. HRMS calcd [(M + H)<sup>+</sup>] 394.0992, measured [(M + H)<sup>+</sup>] 394.0988. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.65–8.69 (m, 1H), 8.47–8.51 (m, 1H), 7.89–7.93 (m, 1H), 7.79–7.86 (m, 2H), 7.58–7.64 (m, 1H), 4.43 (s, 2H), 3.06–3.15 (m, 2H), 1.63 (s, 6H), 1.30–1.40 (m, 3H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.9, 153.2, 149.5, 148.7, 139.1, 136.7, 134.1, 132.5, 129.1, 125.7, 121.7, 64.6, 47.8, 44.2, 27.7, 26.8, 8.3.</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Synthetic Procedure for the Synthesis of (+)-<i>N</i>-[(1R)-1-[5-(6-Chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]ethyl]methanesulfonamide (<b>45</b>)</h4><div class="NLM_p">To a stirred solution of 2-[5-(1-aminoethyl)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (intermediate <b>92</b>, 360 mg, 1.14 mmol) and Et<sub>3</sub>N (477 μL, 3.42 mmol) in DCM (15 mL) was added methanesulfonyl chloride (89.4 μL, 1.14 mmol) at 0 °C and stirred continuously at 0 °C for 1 h. The resulting mixture was extracted with EtOAc (100 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The residue was purified by silica gel flash chromatography eluting with a 0–10% MeOH-EtOAc gradient to give a racemic mixture of the title compound (160 mg, 34%) as a light-yellow solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 394.1.</div><div class="NLM_p last">This racemic mixture was then subject to chiral HPLC separation to afford the enantiomeric compound <b>45</b> (36 mg) as a light-yellow solid, optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +6.1 (1 mg/mL, DCM). LC-MS: <i>t</i><sub>R</sub> 1.30 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 394.1. HRMS calcd [(M + H)<sup>+</sup>] 394.0992, measured [(M + H)<sup>+</sup>] 394.0993. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.67–8.73 (m, 1H), 8.45–8.50 (m, 1H), 7.89–7.93 (m, 1H), 7.80–7.86 (m, 2H), 7.58–7.64 (m, 1H), 4.77–4.84 (m, 1H), 2.93 (s, 3H), 1.60 (d, <i>J</i> = 6.90 Hz, 9H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 167.0, 153.1, 149.2, 147.6, 139.1, 135.2, 132.6, 129.2, 128.2, 125.6, 121.7, 64.7, 51.0, 42.1, 26.9, 26.8, 23.5.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Synthetic Procedure for the Synthesis of <i>N</i>-[[5-(6-Chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]methyl]-3-methyl-pyridine-2-carboxamide (<b>47</b>)</h4><div class="NLM_p last">To a solution of 2-[5-(aminomethyl)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (intermediate <b>91</b>, 210 mg, 0.7 mmol) and 3-methylpyridine-2-carboxylic acid (120 mg, 0.87 mmol) in DCM were added HATU (400 mg, 1.05 mmol) and DIPEA (2 mL) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred overnight. Brine was added to quench the reaction, and the mixture was extracted with DCM twice. The organic layers were combined, washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a yellowish oil, which was purified by prep-HPLC to give the title compound (29.4 mg, 10% yield) as a white foam. LC-MS: <i>t</i><sub>R</sub> 1.49 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 421.1. HRMS calcd [(M + H)<sup>+</sup>] 421.1431, measured [(M + H)<sup>+</sup>] 421.1429. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.64–8.74 (m, 1H), 8.41–8.52 (m, 2H), 7.88–7.98 (m, 1H), 7.81–7.85 (m, 1H), 7.79–7.81 (m, 1H), 7.73–7.77 (m, 1H), 7.56–7.62 (m, 1H), 7.41–7.46 (m, 1H), 4.72 (s, 2H), 2.61 (s, 3H), 1.58 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.8, 166.2, 153.2, 149.2, 148.9, 146.6, 145.6, 140.9, 138.9, 136.5, 135.7, 135.3, 132.4, 129.0, 128.4, 126.0, 125.7, 121.7, 64.5, 40.4, 26.8, 20.5.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Synthetic Procedure for the Synthesis of 5-Chloro-2-[5-(1-ethylsulfonyl-4-piperidyl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one (<b>49</b>)</h4><div class="NLM_p">A mixture of 3-bromo-5-(1-ethylsulfonyl-4-piperidyl)pyridine (intermediate <b>98</b>, 200 mg, 0.6 mmol), 5-chloro-3,3-dimethyl-isoindolin-1-one (intermediate <b>70</b>, 130 mg, 0.67 mmol), copper(I) iodide (34 mg, 0.18 mmol), <i>trans</i>-cyclohexane-1,2-diamine (41 mg, 0.36 mmol), and cesium carbonate (422 mg, 1.3 mmol) in 1,4-dioxane (5 mL) was heated at 150 °C for 2 h. After the reaction mixture was cooled back to room temperature, it was filtered and the filtrate was concentrated <i>in vacuo</i> to give a crude product, which was purified by prep-HPLC to give the title compound (10 mg, 4% yield) as a white solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 448.1. HRMS calcd [(M + H)<sup>+</sup>] 448.1462, measured [(M + H)<sup>+</sup>] 448.1463. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.61 (s, 1H), 8.42 (s, 1H), 7.75–7.88 (m, 3H), 7.60 (dd, <i>J</i> = 1.88, 8.16 Hz, 1H), 3.89–3.96 (m, 2H), 3.10 (q, <i>J</i> = 7.28 Hz, 2H), 3.02 (dt, <i>J</i> = 2.51, 12.30 Hz, 2H), 2.93 (tt, <i>J</i> = 3.51, 12.17 Hz, 1H), 2.03 (br d, <i>J</i> = 11.04 Hz, 2H), 1.85 (dq, <i>J</i> = 4.02, 12.55 Hz, 2H), 1.59 (s, 6H), 1.36 (t, <i>J</i> = 7.40 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.9, 153.1, 148.5, 148.3, 140.9, 139.0, 135.2, 132.5, 129.1, 128.4, 125.7, 121.7, 64.4, 46.3, 44.4, 39.4, 32.9, 26.8, 7.9.</div><div class="NLM_p">For the following compounds, except those described specifically, all of the analogues were prepared in analogy to compound <b>49</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 2-[5-(1-Acetyl-4-piperidyl)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (<b>48</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.34 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 398.1. HRMS calcd [(M + H)<sup>+</sup>] 398.1635, measured [(M + H)<sup>+</sup>] 398.1628. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.61 (d, <i>J</i> = 2.01 Hz, 1H), 8.41 (d, <i>J</i> = 2.26 Hz, 1H), 7.76–7.85 (m, 3H), 7.60 (dd, <i>J</i> = 1.76, 8.03 Hz, 1H), 4.65–4.83 (m, 1H), 4.09 (td, <i>J</i> = 1.95, 13.68 Hz, 1H), 3.25–3.31 (m, 1H), 2.95–3.16 (m, 1H), 2.77 (dt, <i>J</i> = 2.64, 12.99 Hz, 1H), 2.16 (s, 3H), 1.91–2.06 (m, 2H), 1.80 (dd, <i>J</i> = 4.27, 12.55 Hz, 1H),1.68 (dd, <i>J</i> = 4.27, 12.80 Hz, 1H), 1.58 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 168.9, 166.7, 153.1, 148.4, 141.2, 139.0, 135.3, 132.3, 129.0, 128.4, 125.7, 121.7, 64.4, 46.8, 41.9, 39.9, 33.4, 32.5, 26.8, 21.5.</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Synthetic Procedure for the Synthesis of 2-[5-(4-Acetylpiperazin-1-yl)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (<b>50</b>)</h4><div class="NLM_p">To a solution of 5-chloro-3,3-dimethyl-2-(5-piperazin-1-yl-pyridin-3-yl)-2,3-dihydro-isoindol-1-one (intermediate <b>102</b>, 52 mg, 0.146 mmol) and Et<sub>3</sub>N (29.5 mg, 0.292 mmol) in DCM (5 mL) was added acetyl chloride (17.2 mg, 0.219 mmol) dropwise at 0 °C. After stirring at room temperature for 1 h, the mixture was treated with water and extracted with DCM. The organic layer was dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a crude product, which was purified by prep-HPLC to afford the title compound (23 mg, 40% yield) as a white solid. LC-MS: <i>t</i><sub>R</sub> 1.30 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 399.1. HRMS calcd [(M + H)<sup>+</sup>] 399.1588, measured [(M + H)<sup>+</sup>] 399.1591. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.39 (d, <i>J</i> = 2.51 Hz, 1H), 7.98 (d, <i>J</i> = 1.76 Hz,1H), 7.80 (s, 1H), 7.81 (d, <i>J</i> = 9.51 Hz, 1H), 7.59 (dd, <i>J</i> = 1.76,8.03 Hz,1H), 7.40 (t, <i>J</i> = 2.38 Hz,1H), 3.70–3.82 (m, 4H), 3.35–3.50 (m, 4H), 2.17 (s, 3H), 1.59 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 169.0, 166.9, 153.2, 140.8, 138.9, 138.1, 129.1, 128.3, 125.6, 123.7, 121.7, 64.5, 48.6, 48.3, 45.8, 40.9, 26.9, 21.2.</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>50</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 5-Chloro-3,3-dimethyl-2-[5-(4-methylsulfonylpiperazin-1-yl)-3-pyridyl]isoindolin-1-one (<b>51</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.43 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 435.1. HRMS calcd [(M + H)<sup>+</sup>] 435.1258, measured [(M + H)<sup>+</sup>] 435.1259. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.41 (d, <i>J</i> = 2.76 Hz, 1H), 8.00 (d, <i>J</i> = 1.76 Hz, 1H), 7.82 (d, <i>J</i> = 10.01 Hz, 1H), 7.80 (s, 1H), 7.59 (dd, <i>J</i> = 1.63, 8.16 Hz, 1H), 7.42 (t, <i>J</i> = 2.38 Hz, 1H), 3.35–3.52 (m, 8H), 2.91 (s, 3H), 1.59 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.8, 152.9, 146.9, 141.1, 139.0, 138.5, 132.7, 129.1, 128.4, 125.6, 124.0, 121.7, 64.5, 48.4, 45.5, 34.8, 26.9.</div></div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Synthetic Procedure for the Synthesis of 5-Chloro-2-[5-(1-ethylsulfonylazetidin-3-yl)oxy-3-pyridyl]-3,3-dimethyl-isoindolin-1-one (<b>52</b>)</h4><div class="NLM_p">To a mixture of 2-[5-(azetidin-3-yloxy)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (intermediate <b>104</b>, 35 mg, 0.1 mmol) and Et<sub>3</sub>N (200 mg, 2.0 mmol) in DCM (5 mL) was added ethanesulfonyl chloride (50 mg, 0.4 mmol) at 0 °C, and the resulting mixture was stirred at room temperature for 3 h. The mixture was then washed with water, and the separated organic layer was concentrated <i>in vacuo</i> to give a crude product, which was purified by prep-HPLC to afford the title compound (11 mg, 25.2% yield) as a white solid. LC-MS: <i>t</i><sub>R</sub> 1.52 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 436.1. HRMS calcd [(M + H)<sup>+</sup>] 436.1097, measured [(M + H)<sup>+</sup>] 436.1092. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.35 (br d, <i>J</i> = 2.26 Hz, 1H), 8.23 (s, 1H), 7.80–7.85 (m, 2H), 7.61 (d, <i>J</i> = 1.76 Hz, 1H), 7.37–7.41 (m, 1H), 5.15–5.25 (m, 1H), 4.37 (dd, <i>J</i> = 6.40, 9.66 Hz, 2H), 4.10 (dd, <i>J</i> = 4.52, 9.54 Hz, 2H), 3.10–3.18 (m, 2H), 1.50–1.66 (s, 6H), 1.36 (t, <i>J</i> = 7.40 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.9, 153.1, 152.9, 143.2, 139.1, 136.7, 133.3, 129.2, 128.2, 125.7, 123.1, 121.7, 65.5, 64.6, 56.8, 46.4, 26.9, 7.9.</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>52</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (−)-2-[5-[(3<i>R</i>)-1-Acetylpyrrolidin-3-yl]oxy-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (<b>53</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 400.2. HRMS calcd [(M + H)<sup>+</sup>] 400.1427, measured [(M + H)<sup>+</sup>] 400.1422. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −23.01 (3 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.37–8.44 (m, 1H), 8.16–8.21 (m, 1H), 7.77–7.88 (m, 2H), 7.57–7.63 (m, 1H), 7.50–7.54 (m, 1H), 5.18–5.29 (m, 1H), 3.48–3.84 (m, 4H), 2.22–2.39 (m, 2H), 2.15 (s, 3H), 1.61 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 169.5, 166.9, 153.2, 142.6, 142.4, 139.0, 137.8, 129.1, 125.6, 123.7, 123.4, 121.7, 64.6, 52.8, 51.2, 45.2, 43.5, 31.7, 30.1, 22.3.</div></div><div id="sec5_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (+)-2-[5-[(3<i>S</i>)-1-Acetylpyrrolidin-3-yl]oxy-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (<b>54</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.30 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 400.2. HRMS calcd [(M + H)<sup>+</sup>] 400.1428, measured [(M + H)<sup>+</sup>] 400.1433. Optical rotation: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +19.42 (3.5 mg/mL, DCM). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.36–8.43 (m, 1H), 8.17–8.23 (m, 1H), 7.79–7.86 (m, 2H), 7.58–7.63 (m, 1H), 7.49–7.54 (m, 1H), 5.18–5.31 (m, 1H), 3.47–3.85 (m, 4H), 2.22–2.40 (m, 2H), 2.16 (s, 3H), 1.64 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 169.5, 166.9, 153.5, 153.2, 142.5, 139.0, 137.8, 137.6, 133.1, 129.1, 128.3, 125.7, 121.7, 64.7, 52.7, 51.2, 45.2, 43.5, 31.7, 29.9, 22.3.</div></div><div id="sec5_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 2-[5-[(1-Acetyl-4-piperidyl)oxy]-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (<b>55</b>)</h5><div class="NLM_p last">LC-MS: <i>t</i><sub>R</sub> 1.39 min, 100% (254 nm). MS obsd (ESI+) [(M + H)<sup>+</sup>] 414.2. HRMS calcd [(M + H)<sup>+</sup>] 414.1584, measured [(M + H)<sup>+</sup>] 414.1583. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.60–8.63 (m, 1H), 8.46–8.52 (m, 1H), 7.81 (s, 3H), 7.57–7.63 (m, 1H), 3.35–3.44 (m, 4H), 3.30–3.35 (m, 5H), 2.82 (s, 3H), 1.59 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 169.0, 166.9, 153.1, 142.2, 139.0, 138.6, 129.1, 128.3, 125.7, 123.8, 121.7, 72.7, 64.6, 42.9, 38.0, 30.8, 30.0, 26.9, 26.8, 21.4.</div></div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Synthetic Procedure for the Synthesis of 5-Chloro-2-[5-[1-(3-chloropyridine-2-carbonyl)azetidin-3-yl]oxy-3-pyridyl]-3,3-dimethyl-isoindolin-1-one (<b>56</b>)</h4><div class="NLM_p">To a solution of 2-[5-(azetidin-3-yloxy)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (intermediate <b>104</b>, 35 mg, 0.1 mmol) and 3-chloropyridine-2-carboxylic acid (20 mg, 0.15 mmol) in DCM were added HATU (76 mg, 0.2 mmol) and DIPEA (2 mL) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred overnight. Brine was added to quench the reaction, and the mixture was extracted with DCM twice. Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a yellow oil, which was purified by prep-HPLC to give the title compound (6.4 mg, 13% yield) as a white solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 483.1. HRMS calcd [(M + H)<sup>+</sup>] 483.0991, measured [(M + H)<sup>+</sup>] 483.0990. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.53 (dd, <i>J</i> = 1.25, 4.52 Hz, 1H), 8.29 (s, 1H), 8.23 (d, <i>J</i> = 2.26 Hz, 1H), 7.79–7.90 (m, 2H), 7.46–7.56 (m, 2H), 7.36 (dd, <i>J</i> = 4.52, 8.28 Hz, 1H), 7.16 (br s, 1H), 5.04–5.20 (m, 1H), 4.57–4.76 (m, 2H), 4.29–4.45 (m, 2H), 1.58 (d, <i>J</i> = 5.77 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.8, 165.0, 153.1, 153.0, 149.6, 147.0, 143.2, 139.0, 138.5, 136.6, 133.3, 130.1, 129.1, 128.2, 125.7, 125.6, 123.0, 121.7, 66.8, 64.6, 58.5, 55.5, 26.9.</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>56</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 5-Chloro-3,3-dimethyl-2-[5-[1-(4-methylpyridine-3-carbonyl)azetidin-3-yl]oxy-3-pyridyl]isoindolin-1-one (<b>57</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 463.1. HRMS calcd [(M + H)<sup>+</sup>] 463.1536, measured [(M + H)<sup>+</sup>] 463.1535. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.56 (br s, 2H), 8.29 (br s, 1H), 8.23 (br s, 1H), 7.85 (br d, <i>J</i> = 8.03 Hz, 1H), 7.42–7.56 (m, 2H), 7.22–7.35 (m, 1H), 7.13 (br s, 1H), 5.11 (br s, 1H), 4.66 (br s, 1H), 4.30–4.50 (m, 2H), 4.15 (br s, 1H), 2.53 (s, 3H), 1.58 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 168.8, 166.8, 153.1, 152.9, 150.9, 147.6, 145.9, 143.1, 139.1, 136.6, 133.4, 129.4, 129.2, 128.1, 126.0, 125.7, 123.0, 121.7, 66.4, 64.6, 58.4, 55.4, 26.9, 19.2.</div></div><div id="sec5_1_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 5-Chloro-3,3-dimethyl-2-[5-[1-(1-methylpyrazole-4-carbonyl)azetidin-3-yl]oxy-3-pyridyl]isoindolin-1-one (<b>58</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 452.1. HRMS calcd [(M + H)<sup>+</sup>] 452.1489, measured [(M + H)<sup>+</sup>] 452.1487. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 8.37 (d, <i>J</i> = 2.76 Hz, 1H), 8.24 (d, <i>J</i> = 2.01 Hz, 1H), 8.09 (s, 1H), 7.79–7.89 (m, 3H), 7.60 (dd, <i>J</i> = 1.76, 8.03 Hz, 1H), 7.37–7.45 (m, 1H), 5.25–5.34 (m, 1H), 4.91 (br s, 1H), 4.57 (br dd, <i>J</i> = 8.53, 18.82 Hz, 2H), 4.19 (br d, <i>J</i> = 9.79 Hz, 1H), 3.94 (s, 3H), 1.61 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 165.9, 162.8, 152.0, 142.0, 138.1, 138.0, 135.6, 132.3, 131.4, 128.1, 127.1, 124.7, 122.1, 120.7, 115.3, 66.0, 63.7, 38.3, 25.9.</div></div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Synthetic Procedure for the Synthesis of 2-[5-(2-Acetyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-5-chloro-3,3-dimethyl-isoindolin-1-one (<b>59</b>)</h4><div class="NLM_p">To a solution of 5-chloro-2-[5-(2,6-diazaspiro[3.3]heptan-2-yl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one (intermediate <b>108</b>, 40 mg, 0.1 mmol) were added Et<sub>3</sub>N (1 mmol) and acetyl chloride (30 mg, 0.38 mmol) at 0 °C. The resulting reaction mixture was stirred at room temperature for 1 h before it was poured into H<sub>2</sub>O (1 mL) and extracted with EtOAc (15 mL × 2). Combined organics were washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a crude product, which was purified by prep-HPLC to give the title compound (8 mg, 19.5% yield) as a white solid. MS obsd (ESI+) [(M + H)<sup>+</sup>] 411.2. HRMS calcd [(M + H)<sup>+</sup>] 411.1588, measured [(M + H)<sup>+</sup>] 411.1580. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.00 (d, <i>J</i> = 2.01 Hz, 1H), 7.91–7.96 (m, 1H), 7.82–7.88 (m, 1H), 7.45–7.53 (m, 2H), 6.64–6.72 (m, 1H), 4.31–4.37 (m, 2H), 4.19–4.26 (m, 2H), 4.07–4.19 (m, 4H), 1.91 (s, 3H), 1.56 (s, 6H).</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>59</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 5-Chloro-2-[5-(2-ethylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one (<b>60</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 461.1. HRMS calcd [(M + H)<sup>+</sup>] 461.1414, measured [(M + H)<sup>+</sup>] 461.1415. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 8.00 (d, <i>J</i> = 2.01 Hz, 1H), 7.94–7.98 (m, 1H), 7.83–7.89 (m, 1H), 7.48–7.59 (m, 2H), 6.66–6.78 (m, 1H), 4.31–4.39 (m, 2H), 4.22–4.3 (m, 2H), 4.00–4.21 (m, 4H), 3.06–3.15 (m, 2H), 1.63 (s, 6H), 1.30–1.40 (m, 3H).</div></div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Synthetic Procedure for the Synthesis of 5-Chloro-3,3-dimethyl-2-[5-[2-(4-methylpyridine-3-carbonyl)-2,6-diazaspiro[3.3]heptan-6-yl]-3-pyridyl]isoindolin-1-one (<b>61</b>)</h4><div class="NLM_p">To a solution of 5-chloro-2-[5-(2,6-diazaspiro[3.3]heptan-2-yl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one (intermediate <b>108</b>, 1.6 g, 4.3 mmol) and 4-methylpyridine-3-carboxylic acid (1.2 g, 8.7 mmol) in DCM were added HATU (3.2 g, 8.4 mmol) and DIPEA (2 g, 15.5 mmol) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred overnight. Brine was added to quench the reaction, and the mixture was extracted with DCM twice. The organic layers were combined, washed with brine, dried over anhy. Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a yellow oily residue, which was purified by silica gel flash chromatography to afford the title compound (732 mg, 35% yield) as a white foam. MS obsd (ESI+) [(M + H)<sup>+</sup>] 488.1. HRMS calcd [(M + H)<sup>+</sup>] 488.1853, measured [(M + H)<sup>+</sup>] 488.1846. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.45–8.52 (m, 2H), 7.99 (d, <i>J</i> = 1.51 Hz, 1H), 7.81–7.92 (m, 2H), 7.74 (s, 1H), 7.57–7.62 (m, 1H), 7.26–7.38 (m, 1H), 6.77–6.85 (m, 1H), 4.16–4.32 (m, 4H), 4.02–4.14 (m, 4H), 2.34 (s, 3H), 1.48 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 168.5, 166.9, 153.2, 150.7, 147.5, 147.0, 146.0, 139.3, 138.9, 134.3, 132.5, 129.5, 129.0, 128.5, 126.1, 125.6, 121.7, 119.3, 64.5, 62.2, 61.7, 58.4, 34.3, 26.7, 19.2.</div><div class="NLM_p">For the following compounds, except for those described specifically, all of the analogues were prepared in analogy to compound <b>61</b> from either commercially available reagents or in-house-prepared intermediates.</div><div id="sec5_1_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 5-Chloro-3,3-dimethyl-2-[5-[2-(1-methylpyrazole-4-carbonyl)-2,6-diazaspiro[3.3]heptan-6-yl]-3-pyridyl]isoindolin-1-one (<b>62</b>)</h5><div class="NLM_p last">MS obsd (ESI+) [(M + H)<sup>+</sup>] 477.1. HRMS calcd [(M + H)<sup>+</sup>] 477.1805, measured [(M + H)<sup>+</sup>] 477.1804. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 7.98–8.03 (m, 1H), 7.92–7.96 (m, 1H), 7.82 (s, 2H), 7.71 (s, 1H), 7.44–7.53 (m, 2H), 6.65–6.71 (m, 1H), 4.31–4.67 (m, 4H), 4.16 (s, 4H), 3.95 (s, 3H), 1.56 (s, 6H). <sup>13</sup>C NMR (101 MHz, CHCl<sub>3</sub>-<i>d</i>) δ ppm 166.9, 163.6, 153.2, 147.1, 139.3, 138.9, 138.8, 134.4, 132.5, 132.4, 129.0, 128.5, 125.6, 121.7, 119.3, 116.5, 64.5, 62.3, 39.3, 34.9, 29.6, 26.8.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>In Vitro</i> Assay for the Determination of CYP11B2 and CYP11B1 Inhibition</h3><div class="NLM_p last">CYP11B1 and CYP11B2 proteins were expressed in a human renal leiomyoblastoma cell line (ATCC Number CRL-1440). Quantitative polymerase chain reaction (qPCR) revealed that these cells express FDXR and FDX, two proteins that are crucial for the enzymatic activity of CYP11B enzymes and importantly do not express detectable levels of CYP11B1 or CYP11B2 activity. The cells were grown in ATCC-formulated McCoy’s 5a medium modified (catalog no. 30-2007) containing 10% fetal bovine serum. Stable cells expressing ectopically CYP11B1 or CYP11B2 from either human, cynomolgus monkey, or mouse were developed by transfecting appropriate expression plasmids. The plasmids contain the cDNA (GeneCopoeia) for either CYP11B1 or CYP11B2 from the appropriate species (mouse, cynomolgus monkey, or man) under the control of a CMV promoter and the neomycin resistance marker. Using electroporation expression, plasmids were transfected into cells, and these cells were then selected for expressing the given resistance markers. Individual cell clones were then selected (400 μg/mL G-418; Geneticin) and assessed for displaying the desired enzymatic activity using 11-deoxycorticosterone (CYP11B2) or 11-deoxycortisol (CYP11B1) as a substrate. Cellular enzyme assays were performed in a DMEM/F12 medium containing 2.5% charcoal-treated FCS and an appropriate concentration of substrate (1 μM 11-deoxycorticosterone or 11-deoxycortisol). For assaying the enzymatic activity, cells were plated onto 96-well plates and incubated for 16 h. An aliquot of the supernatant was then transferred and analyzed for the concentration of the expected product (aldosterone for CYP11B2; cortisol for CYP11B1). The concentrations of these steroids can be determined using homogeneous time-resolved fluorescence (HTRF) assays from CisBio analyzing either aldosterone or cortisol. Inhibition of the release of produced steroids can be used as a measure of the respective enzyme inhibition by test compounds added during the cellular enzyme assay. The dose-dependent inhibition of enzymatic activity by a compound is calculated by means of plotting added inhibitor concentrations (<i>x</i>-axes) vs the measured steroid/product level (<i>y</i>-axes). The inhibition is then calculated by fitting the following four-parameter sigmoidal function [Morgan–Mercer–Flodin (MMF) model] to the raw data points using the least-squares method:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_m001.gif" alt="" id="_i82" /></img></span>where <i>A</i> is the maximum <i>y</i> value, <i>B</i> is the EC<sub>50</sub> value determined using XLfit, <i>C</i> is the minimum <i>y</i> value, and <i>D</i> is the slope value. The maximum value <i>A</i> corresponds to the amount of steroid produced in the absence of an inhibitor, and the value <i>C</i> corresponds to the amount of steroid detected when the enzyme is fully inhibited.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Microsomal Stability (LM)</h3><div class="NLM_p last">Each test compound was preincubated in an incubation mixture consisting of 0.5 mg of microsomal protein/mL liver microsomes, 1 mM NADP, 3 mM glucose 6-phosphate, 3 mM MgCl<sub>2</sub>, and 0.05 mg/mL glucose 6-phosphate dehydrogenase in a total volume of 400 μL of potassium phosphate buffer (100 mM, pH 7.4) for 10 min at 37 °C. The reactions were initiated by the addition of nicotinamide adenine dinucleotide phosphate (NADPH) regenerating system. At different time points (0, 3, 6, 9, 15, and 30 min), an aliquot (50 μL) sample was taken and quenched with 150 μL of acetonitrile containing an internal standard. Following precipitation and centrifugation, the supernatants were analyzed by LC/MS-MS.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Log <i>D</i> Determination</h3><div class="NLM_p last">Distribution coefficient of compounds was determined in a carrier-mediated distribution system (CAMDIS, EP2005102211A) assay, as previously reported.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Membrane Permeability</h3><div class="NLM_p last">The permeability of compounds was determined via a parallel artificial membrane permeation assay (PAMPA) using a “sandwich” construction. A sample stock solution (dimethyl sulfoxide, DMSO) was diluted to 150 μM (DMSO% < 2%) with a donor buffer, and after the filtration, the solution was added into a donor plate. An acceptor plate coated with phospholipids (membrane) was placed onto the donor plate containing the drug solution. Finally, the upper plate was filled with a buffer solution. The donor concentration was determined at t-start as the reference concentration. The drug concentrations in the acceptor and the donor plate were detected at the t-end (∼18 h). The donor buffer is 0.05 M MOPSO buffer at pH 6.5 with 0.5% (w/v) glycocholic acid, the acceptor buffer is 0.05 M MOPSO buffer at pH 6.5, and the membrane is 10% (w/v) egg lecithin with 0.5% (w/v) cholesterol in dodecane.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Solubility</h3><div class="NLM_p last">The solubility of compounds was determined in a lyophilization solubility assay (LYSA). The test samples were prepared in duplicate from a 10 mM DMSO stock solution. After evaporation of DMSO with a centrifugal vacuum evaporator, the compounds were redissolved in a phosphate buffer (0.05 M, pH 6.5). The mixture was stirred for 1 h, shaken for 2 h, and then allowed to stand overnight and filtered through a microtiter filter plate. The filtrate and its 1/10 dilution were analyzed by HPLC-UV. Solubility determination was determined from a four-point calibration curve. The percentage of the sample measured in solution after evaporation divided by the calculated maximum of the sample amount was higher than 80%; in addition, the solubility data were reported as higher than this value, with a unit of μg/mL.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Plasma Protein Binding</h3><div class="NLM_p last">The percentage of unbound compound was determined using a 96-well micro-equilibrium dialysis device (HTDialysis, Gales Ferry, CT) with a molecular weight cutoff membrane of 12–14 kDa (HTDialysis, Gales Ferry, CT) and using Diazepam as a positive control. Pooled rat and cynomolgus monkey plasma were purchased from Biopredic (Rennes, France). Compounds were measured in a cassette of 2–5 with an initial total concentration of 1 μM, and one of the cassette compounds is the positive control. The integrity of membranes was validated by confirming the unbound fraction values of the positive control. Equal volumes of a blank dialysis buffer (Soerensen buffer at pH 7.4) and matrix samples containing substances were loaded into the acceptor and donor compartments, respectively. The HTD dialysis block was then sealed and kept in an incubator at 37 °C for 5 h under a 5% CO<sub>2</sub> environment. At the end of dialysis, the plasma and buffer samples were retrieved and the drug concentrations were quantified by LC/MS-MS.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Rat PK</h3><div class="NLM_p last">All studies conducted were approved by the Institutional Animal Care and Use Committee (IACUC) of Roche Pharma Research and Early Development, Roche Innovation Center Shanghai. The single-dose PK in male Wister-Han rats was performed to assess their pharmacokinetic properties. Compounds were dissolved in NMP:NS (v/v, 30/70) to yield a final concentration of 0.5 mg/mL for the iv dose (1 mg/kg) and in a vehicle containing 2% Klucel and 0.1% Polysorbate 80 to yield a final concentration of 0.25 mg/mL for the oral dose (3 mg/kg). Three rats in each group were used for blood collection at each time point. Blood samples were collected at eight time points (iv) and seven time points (po) post dose into sodium heparin centrifuge tubes, and plasma samples were then isolated by centrifugation and stored at −20 °C prior to analysis. Plasma concentrations were determined by LC/MS-MS, and the data were analyzed by noncompartmental methods using WinNonlin Pro (Pharsight Corp., Mountain View, CA).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Experimental Details for Protein Crystallization and Structure Determination of CYP11B2 with Compounds <b>45</b> and <b>58</b></h3><div class="NLM_p last">CYP11B2 protein was overexpressed in <i>Escherichia coli</i> and purified with nickel affinity and ion-exchange chromatography. The ligand complex was cocrystallized by vapor diffusion in sitting drops with 10% PEG3350 in 90 mM ammonium citrate (pH 7.0). Thin plates grew after several days and were flash-frozen after addition of 20% ethylene glycol. X-ray diffraction images were collected at 100 K at the beam line X10SA (PXII) of the Swiss Light Source (SLS) using a Pilatus pixel detector.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Experimental Details for <i>In Vivo</i> Cynomolgus Monkey Experiments</h3><div class="NLM_p last">Animal work was performed according to the Swiss federal law for animal protection and was approved by the Veterinary Office Basel. Before use, animals were provided an acclimation period of >5 days under conventional hygienic conditions for housing and standard diet. To prepare for the <i>in vivo</i> experiment, non-naive grouped male cynomolgus monkeys (<i>Macaca fascicularis</i>) were kept in cages on a 12 h light–dark cycle with natural light in 50–60% humidity and at 22.5–22.8 °C. Animals received the diet 3448 EM S12 (80 g 7 kg<sup>–1</sup> day<sup>–1</sup> animal<sup>–1</sup>; Provimi-Kliba, Kaiseraugst, Switzerland) 2–3 times daily, on top of daily fruits, vegetables, and nuts. Water access was ad libitum. Animals identified as good Synacthen (Novartis, Basel, Switzerland) responders participated in the study under the following conditions: at least a 2-fold increase of plasma aldosterone, cortisol, and corticosterone production should be measured 1 h after intramuscular acute application of Synacthen. On the day of the experiment, the monkeys were moved from their group cages and individually housed in stainless steel mesh cages (<i>H</i> 1.5 m × <i>L</i> 1.2 m × <i>W</i> 0.8 m) according to the Swiss regulation on animal welfare. For oral gavage (po), all samples were analyzed using a routine protein precipitation technique followed by LC/MS-MS analysis. PK parameters were calculated using noncompartmental analysis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Oral treatment and Synacthen were given as follows: <i>T</i> = 0 min, oral dosing of 2 monkeys per group (vehicle or compound <b>52</b>) with compound administered as suspension in hydroxyethylcellulose, polysorbate 80, methyparaben, and propylparaben vehicle using 2 mL/kg administration volume; <i>T</i> = 1 h, intramuscular application of 14.5 μg/kg Synacthen. Blood samples were collected at 5 min before and 30 min, 55 min, 1.5 h, 2 h, 3 h, 5 h, 7 h, and 24 h after compound or vehicle application. The selected animals were cooperative and trained to donate blood voluntarily. At each time point, 1.2 mL of blood was collected in EDTA-coated tubes (BD Vacutainer K2 EDTA, Becton Dickinson, Franklin Lakes, NJ) for plasma mineral corticoids and compound concentration measurements. Blood was centrifuged at 10 000 rpm for 15 min at 4 °C. Subsequently, plasma was separated and stored at −20 °C for further analysis. Plasma steroids, % inhibition of CYP11B1 and CYP11B2, and exposure data for compound <b>52</b> were analyzed from all time points by the LC/MS-MS methodology (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">SI</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00233" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00233?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00233</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Structures of selected reference inhibitors; experimental procedures for the syntheses of key intermediates; <sup>1</sup>H NMR, <sup>13</sup>C NMR, and LC-MS spectra of compounds <b>52</b> and <b>62</b>; relative configuration assignment of compounds <b>29–38</b>; analytical method for the measurement of steroid concentrations in cynomolgus monkey plasma; selectivity assessment of steroid production in potassium-induced Hek293 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>1</b>–<b>62</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf">jm0c00233_si_001.pdf (767.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_002.csv">jm0c00233_si_002.csv (3.99 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB codes for <b>45</b> and <b>58</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8">6XZ8</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ9">6XZ9</a>, respectively. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00233" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47850" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47850" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuefei Tan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7629-2255" title="Orcid link">http://orcid.org/0000-0001-7629-2255</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#166e637370737f38627778566479757e733875797b"><span class="__cf_email__" data-cfemail="e49c918182818dca90858aa4968b878c81ca878b89">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongfu Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Wu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingwei Zhou</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenming Chen</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongbo Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhanguo Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoit Hornsperger</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johannes D. Aebi</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans-Peter Märki</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernd Kuhn</span> - <span class="hlFld-Affiliation affiliation">CADD, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4301-562X" title="Orcid link">http://orcid.org/0000-0002-4301-562X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisha Wang</span> - <span class="hlFld-Affiliation affiliation">CADD, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Kuglstatter</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jörg Benz</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephan Müller</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Remo Hochstrasser</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giorgio Ottaviani</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Sciences, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Xin</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Sciences, Roche Pharma Research
& Early Development, Roche Innovation Center Shanghai, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephan Kirchner</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Sciences, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susanne Mohr</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Sciences, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Verry</span> - <span class="hlFld-Affiliation affiliation">Discovery Cardiovascular
and Metabolic
Diseases, Roche Pharma Research & Early Development, Roche Innovation
Center Basel, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Riboulet</span> - <span class="hlFld-Affiliation affiliation">Discovery Cardiovascular
and Metabolic
Diseases, Roche Pharma Research & Early Development, Roche Innovation
Center Basel, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong C. Shen</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3477-8932" title="Orcid link">http://orcid.org/0000-0002-3477-8932</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander V. Mayweg</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, 
    , , , Roche R&D Center (China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, 
    , , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kurt Amrein</span> - <span class="hlFld-Affiliation affiliation">Discovery Cardiovascular
and Metabolic
Diseases, Roche Pharma Research & Early Development, Roche Innovation
Center Basel, , , , , F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5998-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86503" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86503" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge Yang Lu, Liqin Chen, Peilan Ding, Qingshan Gao, Wenzhi Chen, and Dr. Wei Li for technical assistance in the purification of final compounds and analytical analysis. We thank Yi Zhang, Hongxia Qiu, Yuxia Zhang, and Sheng Zhong for the support of DMPK profiling. We thank Henry Cabrière Angelika Schuler and Dr. Doris Roth and Dr. Remo Hochstrasser for developing and performing the CYP11B1 and CYP11B2 <i>in vitro</i> assays, Emmanuelle Hainaut, Anthony Vandjour, Anthony Retournard, Peter Schrag, and Dr. Agnès Bénardeau for <i>in vivo</i> work, and Monique Wittig for running the LC/MS-MS steroid analytics. We also thank Dr. Daniel Schlatter for protein production and Catherine Joseph for protein crystallization. This work was supported exclusively by F. Hoffmann-La Roche Ltd.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">MR</td><td class="NLM_def"><p class="first last">mineralocorticoid receptor</p></td></tr><tr><td class="NLM_term"><i>b.i.d</i>.</td><td class="NLM_def"><p class="first last">twice (two times) a day</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">single ascending dose</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450 enzymes</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">Pe</td><td class="NLM_def"><p class="first last">permeability</p></td></tr><tr><td class="NLM_term">SDPK</td><td class="NLM_def"><p class="first last">single-dose pharmacokinetics</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PKPD</td><td class="NLM_def"><p class="first last">pharmacokinetic pharmacodynamic</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">polyphosphoric acid</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">BPO</td><td class="NLM_def"><p class="first last">benzoyl peroxide</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last"><i>para</i>-methoxylbenzyl</p></td></tr><tr><td class="NLM_term">CAN</td><td class="NLM_def"><p class="first last">cerium ammonium nitrate</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">XPhos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76820" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76820" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mentz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakris, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghiade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruilope, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggioni, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piña, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiuzat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span> <span> </span><span class="NLM_article-title">The present, past, and future of renin-angiotensin aldosterone system inhibition</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1677</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.ijcard.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=23121914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADC%252BC3s7gsVKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2013&pages=1677-1687&author=R.+J.+Mentzauthor=G.+L.+Bakrisauthor=B.+Waeberauthor=J.+J.+V.+McMurrayauthor=M.+Gheorghiadeauthor=L.+M.+Ruilopeauthor=A.+P.+Maggioniauthor=K.+Swedbergauthor=I.+L.+Pi%C3%B1aauthor=M.+Fiuzatauthor=C.+M.+O%E2%80%99Connorauthor=F.+Zannadauthor=B.+Pitt&title=The+present%2C+past%2C+and+future+of+renin-angiotensin+aldosterone+system+inhibition&doi=10.1016%2Fj.ijcard.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The past, present and future of renin-angiotensin aldosterone system inhibition</span></div><div class="casAuthors">Mentz Robert J; Bakris George L; Waeber Bernard; McMurray John J V; Gheorghiade Mihai; Ruilope Luis M; Maggioni Aldo P; Swedberg Karl; Pina Ileana L; Fiuzat Mona; O'Connor Christopher M; Zannad Faiez; Pitt Bertram</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1677-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease.  RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction.  This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials.  Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies.  Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR75G_qn1L8TLjnyZkbE8yXfW6udTcc2eZVy4JH17EhO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7gsVKmtg%253D%253D&md5=07628ed63ea52e65ab86b7b79577ac20</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DMentz%26aufirst%3DR.%2BJ.%26aulast%3DBakris%26aufirst%3DG.%2BL.%26aulast%3DWaeber%26aufirst%3DB.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DGheorghiade%26aufirst%3DM.%26aulast%3DRuilope%26aufirst%3DL.%2BM.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DPi%25C3%25B1a%26aufirst%3DI.%2BL.%26aulast%3DFiuzat%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DC.%2BM.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DPitt%26aufirst%3DB.%26atitle%3DThe%2520present%252C%2520past%252C%2520and%2520future%2520of%2520renin-angiotensin%2520aldosterone%2520system%2520inhibition%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2013%26volume%3D167%26spage%3D1677%26epage%3D1687%26doi%3D10.1016%2Fj.ijcard.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Funder, J. W.</span></span> <span> </span><span class="NLM_article-title">New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">S8</span>– <span class="NLM_lpage">S11</span>, <span class="refDoi"> DOI: 10.1067/mhj.2002.129971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1067%2Fmhj.2002.129971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=12422135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVWntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2002&pages=S8-S11&author=J.+W.+Funder&title=New+biology+of+aldosterone%2C+and+experimental+studies+on+the+selective+aldosterone+blocker+eplerenone&doi=10.1067%2Fmhj.2002.129971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone</span></div><div class="casAuthors">Funder, John W.</div><div class="citationInfo"><span class="NLM_cas:title">American Heart Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5, Suppl.</span>),
    <span class="NLM_cas:pages">S8-S11</span>CODEN:
                <span class="NLM_cas:coden">AHJOA2</span>;
        ISSN:<span class="NLM_cas:issn">0002-8703</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, the effect of aldosterone/salt on a variety of cardiovascular functions has been shown to reflect direct effects through mineralocorticoid receptors in nonepithelial tissue as well as classic effects on sodium retention and potassium excretion at epithelia.  The clin. importance of aldosterone receptor blockade has been convincingly shown for heart failure by the RALES trial.  Exptl. studies in a variety of hyperaldosteronemic models of hypertension have shown that selective aldosterone blockade by eplerenone attenuates the proinflammatory effect of aldosterone/salt imbalance and confers substantial end-organ (brain. kidney, heart) protection, even in the presence of elevated angiotensin levels.  In a normoaldosteronemic model (pig angioplasty), eplerenone is similarly protective of coronary arteries.  Although the extent of end-organ protection in clin. practice awaits outcome trials, the results of preclin. studies suggest a crit. role for eplerenone in the optimal treatment of hypertension as well as heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtcMEsw-7zALVg90H21EOLACvtfcHk0lh0ZcFepDC1dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVWntL4%253D&md5=812424980d3e310255d29cae35895d8e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1067%2Fmhj.2002.129971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmhj.2002.129971%26sid%3Dliteratum%253Aachs%26aulast%3DFunder%26aufirst%3DJ.%2BW.%26atitle%3DNew%2520biology%2520of%2520aldosterone%252C%2520and%2520experimental%2520studies%2520on%2520the%2520selective%2520aldosterone%2520blocker%2520eplerenone%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2002%26volume%3D144%26spage%3DS8%26epage%3DS11%26doi%3D10.1067%2Fmhj.2002.129971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoogwerf, B. J.</span></span> <span> </span><span class="NLM_article-title">Renin-angiotensin system blockade and cardiovascular and renal protection</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">30A</span>– <span class="NLM_lpage">35A</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.amjcard.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=20102971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyitLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2010&pages=30A-35A&author=B.+J.+Hoogwerf&title=Renin-angiotensin+system+blockade+and+cardiovascular+and+renal+protection&doi=10.1016%2Fj.amjcard.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Renin-Angiotensin System Blockade and Cardiovascular and Renal Protection</span></div><div class="casAuthors">Hoogwerf, Byron J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1, Suppl.</span>),
    <span class="NLM_cas:pages">30A-35A</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of a variety of clin. conditions, including atherosclerosis, hypertension, left ventricular hypertrophy, myocardial infarction, and heart failure.  Inhibition of the RAAS with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) has been shown to be effective in lowering blood pressure and reducing cardiovascular mortality and morbidity in various at-risk patient populations.  A no. of studies have shown that these 2 classes are effective in reducing the rate of renal disease progression in patients with diabetic nephropathy, although more long-term vascular outcome studies are needed in patients with chronic kidney disease.  The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) was the first study to show comparable reno- and cardioprotective effects between an ARB (telmisartan) and ramipril in a broad section of at-risk patients, on top of usual std. care.  However, telmisartan showed better tolerability than ramipril in ONTARGET, with less cough and angioedema.  This difference was obtained despite patients having been selected for tolerability to both drugs at study entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwwUoM9Hf3NbVg90H21EOLACvtfcHk0lh0ZcFepDC1dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyitLzM&md5=597d07f5301d1ee06ae000cdf68b763d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DHoogwerf%26aufirst%3DB.%2BJ.%26atitle%3DRenin-angiotensin%2520system%2520blockade%2520and%2520cardiovascular%2520and%2520renal%2520protection%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2010%26volume%3D105%26spage%3D30A%26epage%3D35A%26doi%3D10.1016%2Fj.amjcard.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leoncini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viazzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontremoli, R.</span></span> <span> </span><span class="NLM_article-title">RAAS inhibition and renal protection</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.2174/138161212799436520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.2174%2F138161212799436520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=22283776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADC%252BC383ltFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=971-980&author=G.+Leonciniauthor=F.+Viazziauthor=R.+Pontremoli&title=RAAS+inhibition+and+renal+protection&doi=10.2174%2F138161212799436520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">RAAS inhibition and renal protection</span></div><div class="casAuthors">Leoncini Giovanna; Giovanna Leoncini; Viazzi Francesca; Francesca Viazzi; Pontremoli Roberto; Roberto Pontremoli</div><div class="citationInfo"><span class="NLM_cas:title">Current pharmaceutical design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">971-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity.  It is currently estimated that nearly 15% of the general population has some degree of renal damage, a figure that reaches 50% in at-risk subgroups.  Renin-angiotensin-aldosterone system (RAAS) inhibitors represent the agents of choice to control hypertension and reduce urinary albumin excretion, thereby delaying renal function deterioration.  Greater blockade of the RAAS either by the combined use of multiple drugs or by supramaximal doses of single agents may provide greater renal protection.  Furthermore, it has been proposed especially in the presence of proteinuria.  However, at this time there is insufficient evidence to routinely recommend this therapeutic approach in patients with chronic kidney disease.  The present article examines the currently available evidence and practical implications of pharmacological disruption of RAAS activity for renal protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRq5tMlSZ--yw8IxFYvehhofW6udTcc2eY08NvnaeLP2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ltFGnsg%253D%253D&md5=707978d75a16cc4300928ea54b0e75b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F138161212799436520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212799436520%26sid%3Dliteratum%253Aachs%26aulast%3DLeoncini%26aufirst%3DG.%26aulast%3DViazzi%26aufirst%3DF.%26aulast%3DPontremoli%26aufirst%3DR.%26atitle%3DRAAS%2520inhibition%2520and%2520renal%2520protection%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D971%26epage%3D980%26doi%3D10.2174%2F138161212799436520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span> <span> </span><span class="NLM_article-title">Eplerenone in patients with systolic heart failure and mild symptoms</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1009492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJMoa1009492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=21073363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=11-21&author=F.+Zannadauthor=J.+J.+V.+McMurrayauthor=H.+Krumauthor=D.+J.+van+Veldhuisenauthor=K.+Swedbergauthor=H.+Shiauthor=J.+Vincentauthor=S.+J.+Pocockauthor=B.+Pitt&title=Eplerenone+in+patients+with+systolic+heart+failure+and+mild+symptoms&doi=10.1056%2FNEJMoa1009492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone in patients with systolic heart failure and mild symptoms</span></div><div class="casAuthors">Zannad, Faiez; McMurray, John J. V.; Krum, Henry; van Veldhuisen, Dirk J.; Swedberg, Karl; Shi, Harry; Vincent, John; Pocock, Stuart J.; Pitt, Bertram</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction.  We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms.  In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Assocn. class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addn. to recommended therapy.  The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.  The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 mo.  The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P < 0.001).  A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P = 0.008); 10.8% and 13.5%, resp., died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P = 0.01).  Hospitalizations for heart failure and for any cause were also reduced with eplerenone.  A serum potassium level exceeding 5.5 mmol per L occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P < 0.001).  Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRI60N9G6VWrVg90H21EOLACvtfcHk0li2Zdp2WQVz0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D&md5=70f8085ca6ac39316015b1c349312771</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009492%26sid%3Dliteratum%253Aachs%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DJ.%26aulast%3DPocock%26aufirst%3DS.%2BJ.%26aulast%3DPitt%26aufirst%3DB.%26atitle%3DEplerenone%2520in%2520patients%2520with%2520systolic%2520heart%2520failure%2520and%2520mild%2520symptoms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D11%26epage%3D21%26doi%3D10.1056%2FNEJMoa1009492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alderman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sealey, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laragh, J. H.</span></span> <span> </span><span class="NLM_article-title">Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypentension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1104</span>, <span class="refDoi"> DOI: 10.1056/NEJM199104183241605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJM199104183241605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1759997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADyaK3M7nvFClsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=1991&pages=1098-1104&author=M.+H.+Aldermanauthor=S.+Madhavanauthor=W.+L.+Ooiauthor=H.+Cohenauthor=J.+E.+Sealeyauthor=J.+H.+Laragh&title=Association+of+the+renin-sodium+profile+with+the+risk+of+myocardial+infarction+in+patients+with+hypentension&doi=10.1056%2FNEJM199104183241605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension</span></div><div class="casAuthors">Alderman M H; Madhavan S; Ooi W L; Cohen H; Sealey J E; Laragh J H</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1098-104</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  To test the prognostic value of plasma renin activity prospectively, we determined the pretreatment renin-sodium profile of 1717 subjects with mild-to-moderate hypertension (mean age, 53 years; 36 percent white; 67 percent men) in a systematic work-site treatment program.  METHODS:  Renin profiles, obtained by plotting plasma renin activity against the urinary excretion of sodium, were classified as high (12 percent of the subjects), normal (56 percent), and low (32 percent), and there were expected variations according to age, sex, and race.  Modified stepped-care treatment for hypertension, prescribed without reference to the renin profile, was similar in the three renin groups.  RESULTS:  Mean (+/- SD) blood pressure at entry was 151 +/- 19/100 +/- 10 mm Hg in the subjects with a high renin profile, 151 +/- 19/97 +/- 10 mm Hg in those with a normal profile, and 151 +/- 20/96 +/- 11 mm Hg in those with a low profile.  During 8.3 years of follow-up, there were 27 myocardial infarctions.  As adjusted for age, sex, and race, the incidence of myocardial infarction per 1000 person-years was 14.7 among the subjects with a high renin profile, 5.6 among those with a normal profile, and 2.8 among those with a low profile (rate ratio for high vs. low, 5.3; 95 percent confidence interval, 3.4 to 8.3).  The rate of mortality from all causes was 9.3 in the high-profile group, 5.3 in the normal-profile group, and 3.9 in the low-profile group.  The independent association of a high renin profile with myocardial infarction (but not with stroke or noncardiovascular events) was affirmed by Cox analyses (rate ratio for high vs. normal plus low, 3.2; 95 percent confidence interval, 1.2 to 8.4) after adjustment for race, sex, age at entry, serum cholesterol level, smoking status, electrocardiographic evidence of left ventricular hypertrophy, blood glucose level, body-mass index, history of cardiovascular disease or treatment, blood pressure, and use of beta-blockers.  CONCLUSIONS:  In the study population, whose blood pressure before and during treatment was in a narrow range, and after other cardiovascular risk factors had been considered, the renin profile before treatment remained independently associated with the subsequent risk of myocardial infarction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_J2lWA6pUO1w2ofyr07jXfW6udTcc2eY08NvnaeLP2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7nvFClsw%253D%253D&md5=23d944a68f431b4cc0e8d838be1e896c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM199104183241605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199104183241605%26sid%3Dliteratum%253Aachs%26aulast%3DAlderman%26aufirst%3DM.%2BH.%26aulast%3DMadhavan%26aufirst%3DS.%26aulast%3DOoi%26aufirst%3DW.%2BL.%26aulast%3DCohen%26aufirst%3DH.%26aulast%3DSealey%26aufirst%3DJ.%2BE.%26aulast%3DLaragh%26aufirst%3DJ.%2BH.%26atitle%3DAssociation%2520of%2520the%2520renin-sodium%2520profile%2520with%2520the%2520risk%2520of%2520myocardial%2520infarction%2520in%2520patients%2520with%2520hypentension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1991%26volume%3D324%26spage%3D1098%26epage%3D1104%26doi%3D10.1056%2FNEJM199104183241605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bomback, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemmer, P. J.</span></span> <span> </span><span class="NLM_article-title">The incidence and implications of aldosterone breakthrough</span>. <i>Nat. Clin. Pract. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1038/ncpneph0575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1038%2Fncpneph0575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=17717561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=486-492&author=A.+S.+Bombackauthor=P.+J.+Klemmer&title=The+incidence+and+implications+of+aldosterone+breakthrough&doi=10.1038%2Fncpneph0575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The incidence and implications of aldosterone breakthrough</span></div><div class="casAuthors">Bomback, Andrew S.; Klemmer, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Nephrology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">486-492</span>CODEN:
                <span class="NLM_cas:coden">NCPNC3</span>;
        ISSN:<span class="NLM_cas:issn">1745-8323</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interruption of the renin-angiotensin-aldosterone system has become a leading therapeutic strategy in the treatment of chronic heart and kidney disease.  Angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers do not, however, uniformly suppress the renin-angiotensin-aldosterone system.  Plasma aldosterone levels are elevated in a subset of patients despite therapy.  This phenomenon, known as 'aldosterone escape' or 'aldosterone breakthrough', has only been directly examd. in small nos. of patients.  The key questions of how often breakthrough occurs and whether breakthrough leads to worse outcomes have yet to be definitively answered.  In this Review, we summarize the reported data on the incidence and clin. implications of aldosterone breakthrough, and highlight areas of uncertainty that have yet to be adequately addressed in the literature.  Although the available evidence is not strong enough to support widespread screening for aldosterone breakthrough, our findings should prompt physicians to consider the phenomenon in select patients as well as guide future research efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFN5ofkTncrVg90H21EOLACvtfcHk0li2Zdp2WQVz0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtr7O&md5=f3bf536da1222852edec19ceecc8afaf</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fncpneph0575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncpneph0575%26sid%3Dliteratum%253Aachs%26aulast%3DBomback%26aufirst%3DA.%2BS.%26aulast%3DKlemmer%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520incidence%2520and%2520implications%2520of%2520aldosterone%2520breakthrough%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Nephrol.%26date%3D2007%26volume%3D3%26spage%3D486%26epage%3D492%26doi%3D10.1038%2Fncpneph0575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remme, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaigne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palensky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span> <span> </span><span class="NLM_article-title">The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1056/NEJM199909023411001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJM199909023411001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10471456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=709-717&author=B.+Pittauthor=F.+Zannadauthor=W.+J.+Remmeauthor=R.+Codyauthor=A.+Castaigneauthor=A.+Perezauthor=J.+Palenskyauthor=J.+Wittes&title=The+effect+of+spironolactone+on+morbidity+and+mortality+in+patients+with+severe+heart+failure.+Randomized+aldactone+evaluation+study+investigators&doi=10.1056%2FNEJM199909023411001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of spironolactone on morbidity and mortality in patients with severe heart failure</span></div><div class="casAuthors">Pitt, Bertram; Zannad, Faiez; Remme, Willem J.; Cody, Robert; Castaigne, Alain; Perez, Alfonso; Palensky, Jolie; Wittes, Janet</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-717</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Aldosterone is important in the pathophysiol. of heart failure.  In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin.  A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo.  The primary end point was death from all causes.  The trial was discontinued early, after a mean follow-up period of 24 mo, because an interim anal. detd. that spironolactone was efficacious.  There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001).  This 30 percent redn. in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes.  The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001).  In addn., patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Assocn. functional class (P<0.001).  Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001).  The incidence of serious hyperkalemia was minimal in both groups of patients.  Blockade of aldosterone receptors by spironolactone, in addn. to std. therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOy-U1QzrSbVg90H21EOLACvtfcHk0liM3X5m88dRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D&md5=3e34cf3cd2ac38b96cefdfda593a02f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909023411001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909023411001%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DRemme%26aufirst%3DW.%2BJ.%26aulast%3DCody%26aufirst%3DR.%26aulast%3DCastaigne%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DPalensky%26aufirst%3DJ.%26aulast%3DWittes%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520spironolactone%2520on%2520morbidity%2520and%2520mortality%2520in%2520patients%2520with%2520severe%2520heart%2520failure.%2520Randomized%2520aldactone%2520evaluation%2520study%2520investigators%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D709%26epage%3D717%26doi%3D10.1056%2FNEJM199909023411001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remme, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roniker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatlin, M.</span></span> <span> </span><span class="NLM_article-title">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1309</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa030207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJMoa030207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=12668699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1309-1321&author=B.+Pittauthor=F.+Zannadauthor=W.+Remmeauthor=J.+Neatonauthor=F.+Martinezauthor=B.+Ronikerauthor=R.+Bittmanauthor=S.+Hurleyauthor=J.+Kleimanauthor=M.+Gatlin&title=Eplerenone%2C+a+selective+aldosterone+blocker%2C+in+patients+with+left+ventricular+dysfunction+after+myocardial+infarction&doi=10.1056%2FNEJMoa030207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span></div><div class="casAuthors">Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie; Ambrosioni, E.; Anderson, J. L.; Apetrei, E.; Aschermann, M.; Banas, J.; Cardoso, S.; Caspi, A.; Chung, N.; Corbalan, R.; Dargie, H. J.; Bietz, R.; Erhardt, L.; Garcia-Castillo, A.; Gheorghiade, M.; Hernandez, E.; Hess, O.; Jamerson, K.; Kjekshus, J.; Klug, E.; Krum, H.; Lee, Y.-T.; Lopez, N.; Lopez-Sendon, J.-L.; Martinez, F.; Murin, J.; Neaton, J.; Nicolau, J.-C.; Ostor, E.; Parkhomenko, A.; Pitt, B.; Ross, H.; Stepinska, J.; Torp-Pedersen, C.; Van Mieghem, W.; van Veldhuisen, D.-J.; White, H.; Wilvox, R. G.; Willenbrock, R.; Yotov, Y.-T.; Zannad, F.; Boissel, J.-P.; Furberg, C.; Julian, D.; Kulbertus, H.; Pocock, S.; Wittes, J.; Battler, A.; Blumenfeld, J.; Brilla, C.; Duprez, D.; Fowler, M.; Gavazzi, A.; Hildebrandt, P.; Komajda, M.; Korewicki, J.; Kosturakis, D.; Marin-Neto, J. A.; Miller, A.; Munoz Aguilera, R.; Oliveri, R.; Remme, W.; White, M.; Widimsky, P.; Bakris, G.; Castaigne, A.; Deedwania, P.; Duprez, D.; Ketelslegers, J. M.; Liu, P.; Mancia, G.; Nicklas, J.; Rouleau, J.-L.; Ruilope, L.; Sasayama, S.; Schiffrin, E.; Spertus, J.; Struthers, A.; Vaughan, D.; Weber, M.; Williams, G.; Abinader, E.; Adams, J.; Adams, P. C.; Adamus, J.; Ahlstrom, P.; Akesson, H. S.; Akhmedzhanov, N.; Alcasena Juango, S.; Ali Khan, S.; Alonso Garcia, A.; Amat, G.; Amerena, J.; Arnosova, K. M.; Andreoli, L.; Angelo-Nielsen, K.; Antonio de Velasco, J.; Apetrei, E.; Aroutiounov, G.; Aschermann, M.; Asklund, M.; Assmann, I.; Aumont, M.-C.; Avtandilov, A.; Azarin, O.; Bada, V.; Bakoumov, P.; Balazovjech, L.; Baldjiev, E.; Baluda, M.; Barrazueta, R.; Barsi, B.; Bashir, Y.; Batin, P. D.; Belenky, D.; Belyi, Y.; Bendermacher, P. E. F.; Berget, K.; Bergmeier, C.; Berning, J.; Berrazueta-Fernandez, J. R.; Block, P.; Boberg, G.; Bocek, P.; Bohlscheid, V.; Bokarev, I.; Bolinska, H.; Boman, K.; Bondarev, S.; Bonzel, T.; Boreux, J.-L.; Borggrefe, M.; Borisov, M.; Boxho, G.; Boyarkin, M.; Brachmann, J.; Brack, M.; Branea, I.; Breivik, K.; Brigden, G. S.; Bronzwaer, P. N. A.; Bruce, D.; Bruckner, I.; Brunvand, H.; Bryukhovetski, A.; Buser, P.; Campbell, T.; Campeanu, A.; Capucci, A.; Carasca, E.; Cardoso, J.; Carrageta, M.; Caspi, A.; Cassim, S.; Caturla, J.; Ceia, F.; Cernosek, B.; Channer, K.; Chati, Z.; Christensen, P. D.; Chung, N. S.; Cinteza, M.; Cleland, J. G. F.; Cocchieri, M.; Commerford, P.; Conti, U.; Corsini, G.; Cortina Liosa, A.; Coupez, J.-M.; Cribier, A.; Csillag, J.; Cyran, J.; Dahlstrom, U.; Dalby, A.; Dalin, L. J.; Dalkowski, M.; Dargie, H. J.; Darius, H.; Datcu, D. M.; David, D.; De Myttenaere, M.; De Teresa, E.; De Velasco, J.; de Vries, A. G.; den Hartog, F. R.; Desjoyaux, E.; Dezerbi, A.; Dhawan, J.; Biaz Molina, B.; Dickstein, K.; Dorobantu, M.; Doschitsin, V.; Doubell, A.; Dovgalevsky, P.; Dragulescu, S. I.; Drapkina, O.; Dubourg, O.; Dunselman, P. H. J. M.; Dyadyk, O. I.; Dykun, Y. V.; Dzyak, G. V.; Egorova, L. P.; Egstrup, K.; Eha, J.; Ehrenbergerova, M.; El Allaf, D.; Elenkova, A.; Ellis, C. J.; Engbers, J. G.; Fainyk, A. F.; Falck, G.; Fanelli, R.; Farre-Mun, J.; Favier, J.; Ferrari, G.; Ferreira, I.; Rischer, H.; Fotyanov, S.; Freericks, M. P.; Froeland, G.; Galve, E.; Garcia, M. M.; Garcia, A. A.; Garnier, L. F.; Gazaryan, G.; Georgescu, C.; Geraedts, J.; Glezer, M. G.; Goloborodko, B. I.; Goloshchekin, B.; Gonsorcik, J.; Gotchev, D.; Gotcheva, N.; Gottwik, M. G.; Grande, P.; Gratsiansky, N.; Grishina, E. I.; Groch, L.; Gruzdev, A.; Guenova, D.; Gundersen, T.; Hagerman, I.; Hambrecht, R.; Hammermann, H.; Hansen, O.; Hansteen, V.; Hart, H.; Hauf, G. F.; Hecker, U.; Hegyi, I.; Herlitz, J.; Hertzberger, D. P.; Herweijer, A. H.; Heyndrickx, G. R.; Hittinger, L.; Hoang, V.; Hobbach, H.-P.; Hofman-Bang, C.; Holwerda, N. J.; Hong, K. P.; Horacek, T.; Hormann, J.; Horowitz, J. D.; Hradec, J.; Hurtig, U.; Ikram, H.; Ioan, A.; Jaarsma, W.; Jadraque, L. M.; Jakobsen, T. J.; Janicki, K. J.; Jankelow, D.; Janosi, A.; Jansky, P.; Janssens, L.; Janzen, I.; Jensen, P.; Jirmar, R.; Jobic, Y.; Jones, A.; Jonsson, J.; Kahles, H.; Kaliska, G.; Kamensky, G.; Kappenberger, L.; Karlsson, J. E.; Karpati, P.; Karpenko, O. I.; Karpov, Y.; Kawecka-Jaszcz, J.; Keeling, P. J.; Keren, G.; Khalife, K.; Khrakovskaya, M.; Khrustalev, O. A.; Klarlund, K. K.; Kleber, E.-X.; Klug, E.; Koenig, W.; Komarek, J.; Kononenko, L. G.; Konz, K.; Komacewicz-Jach, Z.; Kostenko, V.; Kotous, J.; Kovalsky, I.; Kozak, P.; Kreider-Stempfle, H. U.; Kromer, E. P.; Krum, H.; Krzeminska-Pakula, M.; Kuc, K.; Kucera, P.; Kurowski, M.; Lach, L.; Lai, C.; Lane, G.; Lang, E.; Lankes, W.; Lankisch, P.-G.; Laraudogoitia, E.; Larsen, J.; Larsson, L.-E.; Laruelle, C.; Lazar, A.; Lee, Y.-T.; Legkonogov, A. V.; Leitch, J.; Lengfelder, W.; Lescot, C. D.; Lewis, B. S.; Lewis, P.; Libov, I. A.; Liel-Cohen, N.; Lim, H. K.; Lin, C.-S.; Linssen, G. C. M.; Liu, C.-P.; Lok, D. J. A.; Lopatin, Y. M.; Lopez De Sa, E.; Lotan, C.; Lousada, N.; Lucas, C.; Lucatti, A.; Lusov, V.; Mabin, T. A.; Macleod, D. C.; Maeurer, W.; Magnusson, J.-O.; Maisch, B.; Malinski, A.; Maltchougine, M.; Manga, P.; Mantov, S.; Marchi, S.; Marcinowska-Suchowierska, E.; Marenne, F.; Maresca, F. S.; Markov, V.; Marmor, A. T.; Martines, C.; Martinez, A.; Martin-Jadraque, L.; Martins, L. F. R.; Martos Ferres, R.; Mary, D. A. S. G.; Masini, F.; Matta, F.; Maurer, W.; Mazzini, A. C.; McDonald, K. M. A.; Meeder, J. G.; Melandri, F.; Melin, J.; Menezes, C.; Michels, H. R.; Missault, L.; Mitrovic, V.; Mntla, P.; Mobilij, A.; Mogilevsky, A.; Moiseev, V.; Mokan, M.; Moeller, B.; Moreira, I.; Mouhoub, D.; Moura, B.; Muders, E.; Mudra, H.; Munz, J.; Murin, J.; Musial, W. J.; Myburgh, D. P.; Naqvi, N.; Naumann, G.; Nazimov, S. V.; Nadelec, G.; Nedogoda, S. V.; Nielsen, I.; Nielsen, T.; Nierop, P. R.; Nilsson, G.; Notaristefano, A.; Novitsky, I. N.; Nykl, L.; Ofner, P.; Olariu, C.; Olbrich, H. G.; Oldroyd, K. G.; Olinic, N.; Oliveira, J.; Omland, T.; Orus, J.; Owensby, D.; Page, A.; Park, K. S.; Parkhomenko, O. M.; Pasotti, C.; Pasowicz, M.; Pecce, P.; Pell, A. C. H.; Penkov, N. I.; Perez de Juan, M.; Perez, H.; Petersen, M.; Petrov, A. A.; Peuhkurinen, K.; Philonenko, X.; Pieper, M.; Pieske, B.; Pluta, W.; Podzemska, B.; Popeye, R.; Prost, C.; Purcaro, A.; Put, P.; Radchenko, V.; Radoi, M.; Rae, A. P.; Raev, D.; Ramik, C.; Rasmussen, S. L.; Reisin, L.; Renker, B.; Ribeiro, V. G.; Richardt, G.; Rjecansky, I.; Risenfors, M.; Rivis, I. A.; Robson, R. H.; Rocher, R.; Rodriquez Padial, L.; Rose, E. L.; Rosen, S. D.; Rosenfeld, T.; Rowlands, D. B.; Rozkovec, A.; Rudas, L.; Rudenko, L. V.; Ruiz-Rejon, F.; Rutsch, W.; Rybar, R.; Rybka, J.; Saetre, H. A.; Sarosi, I.; Savalle, L. H.; Schmidt, A.; Schuren, K. P.; Schwartz, Y.; Schwinger, R.; Schwob, J. P.; Scott, D.; Sechtem, U.; Sela, O.; Semrad, B.; Senni, M.; Shilkina, N. P.; Shpektor, A.; Silas, J.; Sindone, A.; Sinescu, C. J.; Sipila, R.; Sirek, J.; Skagen, K.; Shura, M.; Slanina, M.; Slowinski, S.; Smid, J.; Smielak-Korombel, W.; Solodky, A.; Spacek, R.; Squire, I.; Steingo, L.; Stepinska, J.; Stogowski, A.; Storzhakov, G.; Striouk, R.; Strunge, P.; Suter, T.; Svitil, P.; Swedberg, K.; Swidzinski, M.; Syvolap, V. D.; Sztajzel, J.; Tahk, S. J.; Tans, A. C.; Tans, J. G. M.; Targonski, R.; Tarjan, J.; Tartagni, F.; Tchartchoglian, R.; Tebloev, K.; Teesalu, R.; Ten Kate, J. B. L.; Terrosu, P.; Thompson, P. L.; Thybo, N. K.; Thygesen, K.; Tilon, P. A.; Timar, S.; Titkov, Y.; Titlbach, O. J.; Torp-Pedersen, C.; Torvik, D. T.; Touboul, P.; Trelawny, J. M.; Trillo Nouche, R.; Trochina, E.; Trojnar, R.; Tzekova, M. L.; Tzivoni, D.; Vahula, V.; Valagussa, F.; Valdes, M.; Van Der Heijden, R.; Van Der Sloot, J. A. P.; Van Hal, J. M. C.; Van Kempen, L. H. J.; Van Mieghem, W.; Van Rugge, F. P.; Van Veldhuisen, D. J.; Van Vlies, B.; Van Wijk, L. M.; Vasyuk, Y.; Vatutin, M.; Vered, Z.; Vergoni, W.; Vertkine, A.; Vigholt, E.; Vishnevskiy, A.; Voegelin, H.-P.; Voipio-Pulkki, L. M.; Von Mengden, H.-J.; Waites, J.; Watson, R. D. S.; Weiss, A. T.; Werner, H. A.; Wesdorp, J. C. L.; White, H.; Wiggers, P.; Wilcox, R. G.; Wilkinson, P.; Willems, A. R.; Willenbrock, R.; Wirth, M.; Wojciechowski, D.; Worth, H.; Wray, R.; Wu, C.-J.; Yakusevich, V. V.; Yang, S.-P.; Yarohno, N.; Zadionchenko, V. S.; Zaleska, T.; Zalewski, M.; Zannad, F.; Zateyshchikov, D.; Zeltin-Abramov, E.; Zeymer, U.; Zimmermann, R.; Albuquerque, D. C.; Alcaino, M.; Allall, O. A.; Beer, N.; Bortman, G.; Botero, R.; Cardoso, J. S.; Carrageta, M.; Carrillo, E.; Carvalho, A. C.; Castano, R.; Ceia, F.; Cesar, L. A. M.; Chevez, E.; Coelho, O. R.; Colombo, H. R.; Corbalan, R.; Doval, H.; Dutra, O.; Franken, R. A.; Gallardo, L.; Garcia, A.; Garcia, J.; Gomez, E. A.; Gomez, E.; Gonzalez, J.; Gonzalez, R. A.; Greque, G. V.; Guzman, L.; Haiek, J. C.; Hernandez, E.; Hominal, M. A.; Isea, J.; Lanas, F.; Leiva, J. L.; Lemus, J.; Llancaqueo, A.; Lopez, N.; Lousada, N.; Maia, L. N.; Maranhao, M. F.; Martinez, J. A.; Martinez, F. A.; Martins, F. A.; Martins, L.; Matadamas, N.; Matiz, H.; Mendoza, I.; Menezes, C.; Moises, O.; Moreira, J. I.; Moura, J. C.; Nicolau, J. C.; Nobrega, J.; Null, D.; Oliveira, M. S.; Palacios, A. O.; Pazin Filho, A.; Perrone, S. V.; Peigas, L. S.; Prieto, J. C.; Junior, A. R.; Rassi, S.; Ribeiro, V. G.; Rico, J. N.; Rivera, J. M.; Robledo, G.; Rodriguez, H.; Rosenthal, J.; Rossi, P. R. F.; Saraiva, J. F.; Soifer, S.; Sosa Liprandi, A.; Torres, H. G.; Uruchurtu, E.; Velasco, R. G.; Velasquez, J. G.; Vita, N.; Waich, S.; Zelaya, F. R.; Abariotis, N.; Abdollah, H.; Abraham, W.; Alaie, D.; Allison, W.; Ameen, A.; Amidi, M.; Anand, I.; Anderson, J. L.; Andreae, G. E.; Aquino, V.; Ballard, W.; Banas, J. S.; Baron, S. B.; Bata, I.; Berk, M. R.; Bhesania, T.; Binkley, P.; Booth, D. C.; Borts, D.; Brookfield, L. A.; Brown, C. S.; Browne, K. F.; Butman, S. M.; Capodilupo, R. C.; Caralis, D. G.; Carr, K. W.; Castan, R.; Chadow, H.; Chalavarya, G. K.; Chua, G. L.; Cinderella, J. A.; Clavette, P.; Clemson, B. S.; Cohen, T. J.; Colfer, H. T.; Corder, C. N.; Courtade, D. J.; Courtney, D. L.; Coutu, B.; Cucher, F. H.; Czarnecki, W.; Danisa, K.; D'Astous, M.; Dauber, I.; Davies, R.; Deedwania, P. C.; Delehanty, J. M.; Denny, D. M.; Denys, B. G.; DeYoung, P. J. P.; Dion, D.; Donohue, T. J.; El Shahawy, M.; Elkayam, U.; Escabi, J.; Essandoh, L. K.; Felicetta, J. V.; Fintel, D.; Fontaine, J. M.; Foster, R. E.; Frank, T. A.; Gin, K.; Goldberg, M. C.; Goldman, S.; Gossard, D.; Gosselin, G.; Gradman, A. H.; Grandmont, D.; Hack, T.; Hagar, J.; Haikal, M.; Hall, S. A.; Halpern, S.; Hanley, H. G.; Hanovich, G. D.; Hargrove, J. L.; Harlamert, E. A.; Hastings, T. E.; Hathaway, W. R.; Haught, W. H.; Hilliard, G. K.; Hodsden, J.; Hui, W.; Hurley, W.; Ibrahim, H. M.; Jafri, S.; Jain, A.; Jennison, S.; Jesse, R. L.; Joseph, J.; Kalman, J.; Karisberg, R. P.; Khant, R.; Koren, M.; Kosinski, E. J.; Kosolcharoen, P.; Kostuk, W. J.; Kouz, S. M.; Lai, C.; Langholz, D. E.; LeJemtel, T. H.; Leader, R.; Leblanc, M.-H.; Lee, H.; Lepage, S.; Lopez, M.; Lu, D. Y.; Lubelsky, B. J.; Luckasen, G. J.; Ma, P.-T.-S.; MacCallum, C. G.; Madu, E. C.; Maisel, A. S.; Mallis, G. I.; Mann, J. T.; Marr, D. R.; McGrew, F. A., III; McKay, R. J.; Mclellan, B.; Meisner, J.; Meyer, T.; Mikati, I.; Miller, L. A.; Miller, L. W.; Moe, G. W.; Mohiuddin, S. M.; Moir, G. D.; Morgan, A. W.; Morris, A.; Murphy, B. J.; Nallasivan, M.; Narula, J.; Nicklas, J. M.; Niederman, A. L.; Nitkin, R.; O'Keefe, J. H.; Oken, K. R.; O'Neill, P. G.; Orchard, R. C.; O'Riordan, W. D.; Paraboschi, C. F.; Patel, R. I.; Pennock, G.; Pesant, Y.; Phaneuf, D.; Phillips, D. F.; Plehn, J.; Promisloff, S.; Rajakumar, A. J.; Ramadurai, R.; Rashkow, A.; Rauh, R. A.; Rebane, T. M.; Riba, A. L.; Richard, C.; Riddle, J. C.; Ringuette, G.; Rivera, E.; Rockson, S.; Rogers, E.; Ross, H.; Roux, R.; Rupka, D.; Saenz, A.; Sampson, J.; Schulman, S. P.; Schuyler, G.; Sequeira, R. F.; Shah, A. R.; Shah, P. K.; Shakar, S. F.; Shalev, Y.; Sheikh, K. H.; Shettigar, U. R.; Siegel, R. M.; Sigal, S. L.; Singh, V. N.; Sotolongo, C. M.; Soucier, R. J.; Stagaman, D. J.; Stephan, W. J.; Stine, M.; Stoever, W. W.; Talano, J. V.; Tan, J. L.; Tanser, P. H.; Taussig, A. S.; Thadani, U.; Timmis, S. B. H.; Timothee, J. R.; Tragoon, S.; Tremblay, B.; Upadhya, K. J.; Vijay, N. K.; Wagoner, L. E.; Walker, J. L.; Wickemeyer, W. J.; Williams, G. A.; Williams, M. B.; Williams, R. E.; Wiseman, A. H.; Wool, K. J.; Yasin, M.; Zabalgoitia, M.; Zarich, S.; Zimmermann, R.; Zucker, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1309-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure.  We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.  Methods: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a max. of 50 mg per day; 3313 patients) or placebo (3319 patients) in addn. to optimal medical therapy.  The study continued until 1012 deaths occurred.  The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia.  Results: During a mean follow-up of 16 mo, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008).  Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P= 0.005).  The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02).  There was also a redn. in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03).  The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001).  Conclusions: The addn. of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXvg9fCdjlrVg90H21EOLACvtfcHk0liM3X5m88dRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D&md5=cee432bc75bcca5f33098fe3bc8575df</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030207%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DRemme%26aufirst%3DW.%26aulast%3DNeaton%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DRoniker%26aufirst%3DB.%26aulast%3DBittman%26aufirst%3DR.%26aulast%3DHurley%26aufirst%3DS.%26aulast%3DKleiman%26aufirst%3DJ.%26aulast%3DGatlin%26aufirst%3DM.%26atitle%3DEplerenone%252C%2520a%2520selective%2520aldosterone%2520blocker%252C%2520in%2520patients%2520with%2520left%2520ventricular%2520dysfunction%2520after%2520myocardial%2520infarction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1309%26epage%3D1321%26doi%3D10.1056%2FNEJMoa030207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, M. A.</span></span> <span> </span><span class="NLM_article-title">Progress towards clinically useful aldosterone synthase inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1401</span>, <span class="refDoi"> DOI: 10.2174/1568026611313120003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.2174%2F1568026611313120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=23688131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1385-1401&author=M.+A.+Cerny&title=Progress+towards+clinically+useful+aldosterone+synthase+inhibitors&doi=10.2174%2F1568026611313120003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Progress Towards Clinically Useful Aldosterone Synthase Inhibitors</span></div><div class="casAuthors">Cerny, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1385-1401</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Owing to the high degree of similarity between aldosterone synthase (CYP11B2) and cortisol synthase (CYP11B1), the design of selective inhibitors of one or the other of these two enzymes was, at one time, thought to be impossible.  Through development of novel enzyme screening assays and significant medicinal chem. efforts, highly potent inhibitors of CYP11B2 have been identified with selectivities approaching 1000-fold between the two enzymes.  Many of these mols. also possess selectivity against other steroidogenic cytochromes P 450 (e.g. CYP17A1 and CYP19A1) as well as hepatic drug metabolizing P450s.  Though not as well developed or explored, inhibitors of CYP11B1, with selectivities approaching 50-fold, have also been identified.  The therapeutic benefits of affecting the renin-angiotensin-aldosterone system have been well established with the therapeutically useful angiotensin-converting enzymes inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists.  Data regarding the addnl. benefits of an aldosterone synthase inhibitor (ASi) are beginning to emerge from animal models and human clin. trials.  Despite great promise and much progress, addnl. challenges still exist in the path towards development of a therapeutically useful ASi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrk4wlx7NurVg90H21EOLACvtfcHk0lirXYH3lSjfEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O&md5=bce9e566a086d1c2c58df2811ced6230</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568026611313120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313120003%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DM.%2BA.%26atitle%3DProgress%2520towards%2520clinically%2520useful%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1385%26epage%3D1401%26doi%3D10.2174%2F1568026611313120003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5011</span>– <span class="NLM_lpage">5022</span>, <span class="refDoi"> DOI: 10.1021/jm401430e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401430e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5011-5022&author=Q.+Huauthor=L.+Yinauthor=R.+W.+Hartmann&title=Aldosterone+synthase+inhibitors+as+promising+treatments+for+mineralocorticoid+dependent+cardiovascular+and+renal+diseases&doi=10.1021%2Fjm401430e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases</span></div><div class="casAuthors">Hu, Qingzhong; Yin, Lina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5011-5022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Besides the well-known roles of aldosterone as a mineralocorticoid in regulating homeostasis of electrolytes and vol., recent studies revealed that it is also a potent proinflammation factor inducing reactive oxygen species and up-regulating a panel of fibrosis related genes.  Under pathol. circumstances, excessive aldosterone is involved in a lot of chronic diseases, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and diabetic nephropathy.  Therefore, the inhibition of aldosterone synthase (CYP11B2), which is the pivotal enzyme in aldosterone biosynthesis, was proposed as a superior approach.  Expected pharmacodynamic effects have been demonstrated in both animal models and clin. trials after the application of CYP11B2 inhibitors.  The importance of selectivity over other steroidogenic CYP enzymes, in particular 11β-hydroxylase (CYP11B1), was also revealed.  Recently, much more selective CYP11B2 inhibitors have been reported, which could be promising drug candidates for the treatment of aldosterone related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22wShTUgyNrVg90H21EOLACvtfcHk0lirXYH3lSjfEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D&md5=585f8d88a1df8d22382e6a58ab0283b0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm401430e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401430e%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DAldosterone%2520synthase%2520inhibitors%2520as%2520promising%2520treatments%2520for%2520mineralocorticoid%2520dependent%2520cardiovascular%2520and%2520renal%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5011%26epage%3D5022%26doi%3D10.1021%2Fjm401430e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weldon, S. M.</span>; <span class="NLM_string-name">Brown, N. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of aldosterone synthase</span>. In  <i>Vitamins and Hormones</i>; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">109</span>, pp  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">239</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=211-239&author=S.+M.+Weldon&author=N.+F.+Brown&title=Vitamins+and+Hormones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26atitle%3DInhibitors%2520of%2520aldosterone%2520synthase%26btitle%3DVitamins%2520and%2520Hormones%26pub%3DAcademic%2520Press%26date%3D2019%26volume%3D109%26spage%3D211%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. S.</span></span> <span> </span><span class="NLM_article-title">Evolving research in nongenomic actions of aldosterone</span>. <i>Curr. Opin. Endocrinol. Diabetes Obes.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1097/MED.0b013e328360c200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1097%2FMED.0b013e328360c200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=23519092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=198-203&author=J.+S.+Williams&title=Evolving+research+in+nongenomic+actions+of+aldosterone&doi=10.1097%2FMED.0b013e328360c200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving research in nongenomic actions of aldosterone</span></div><div class="casAuthors">Williams, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Endocrinology, Diabetes and Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">COEDFK</span>;
        ISSN:<span class="NLM_cas:issn">1752-296X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Aldosterone is now recognized as an increasingly important contributor to cardiometabolic pathol. via inflammatory and fibrosis-related pathways in addn. to its classically described role in sodium and vol. regulation.  Consequently, much effort has been directed towards characterizing the mol. pathways involved in aldosterone-mediated fibrosis and inflammation.  What was once viewed as straightforward steroid hormone biol. is now appreciated as a highly complex and tightly regulated series of pathways and interactions.  These recognitions have fuelled a multidisciplinary effort to identify precisely how aldosterone mediates intracellular activation of both genomic (latent) and nongenomic (rapid) mechanisms of influence.  This review will explore recent novel pathways regulating aldosterone action, focusing on the nongenomic pathways.  Recent findings: Several recent discoveries have redefined our understanding of aldosterone interactions at the cellular level.  This includes activation of the mineralocorticoid receptor at the plasma membrane instead of via classical nuclear hormone receptor interaction, and identification of novel cofactor scaffolding proteins that modify aldosterone influence at the cellular level.  In addn., aldosterone activation of secondary messenger system cascades can occur directly and independent of mineralocorticoid receptor interaction.  Summary: Substantial progress in detailing the mol. biol. of aldosterone regulation and action should facilitate study of how it exerts detrimental effects in cardiometabolic diseases.  However, to date, the clin. impact of these discoveries has not been validated.  Translational efforts are now required to det. if novel therapeutic targets can be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAysZZicBVGbVg90H21EOLACvtfcHk0lirXYH3lSjfEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D&md5=a81a4387404a0cca288612daf8473973</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1097%2FMED.0b013e328360c200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMED.0b013e328360c200%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BS.%26atitle%3DEvolving%2520research%2520in%2520nongenomic%2520actions%2520of%2520aldosterone%26jtitle%3DCurr.%2520Opin.%2520Endocrinol.%2520Diabetes%2520Obes.%26date%3D2013%26volume%3D20%26spage%3D198%26epage%3D203%26doi%3D10.1097%2FMED.0b013e328360c200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mornet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">20961</span>– <span class="NLM_lpage">20967</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=2592361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADyaK3cXitFWktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1989&pages=20961-20967&author=E.+Mornetauthor=J.+Dupontauthor=A.+Vitekauthor=P.+C.+White&title=Characterization+of+two+genes+encoding+human+steroid+11+beta-hydroxylase+%28P-450%2811%29+beta%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of two genes encoding human steroid 11β-hydroxylase (P-45011β)</span></div><div class="casAuthors">Mornet, Etienne; Dupont, Jakob; Vitek, Alena; White, Perrin C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">20961-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Steroid 11β-hydroxylase (P-45011β) is a mitochondrial cytochrome P-450 enzyme necessary for cortisol biosynthesis.  Deficiency of 11β-hydroxylase causes a hypertensive form of congenital adrenal hyperplasia.  A partial cDNA clone encoding this enzyme was previously isolated and the corresponding gene, CYP11B1, mapped to human chromosome 8q.  This gene has now been isolated along with a second linked homologous gene, CYP11B2.  Each gene contains 9 exons.  The 8 introns are identical in location to the introns of the CYP11A gene encoding another mitochondrial P-450 enzyme, cholesterol desmolase, confirming that 11β-hydroxylase and cholesterol desmolase are in the same gene family within the P-450 superfamily.  The nucleotide sequences of CYP11B1 and B2 are 95% identical in coding regions and about 90% identical in introns.  The putative proteins encoded by CYP11B1 and B2 each contain 503 amino acids, including a 24-residue signal peptide, and have sequences that are 93% identical to each other and 75% identical to the predicted sequence of bovine P-45011β.  There are no obviously deleterious mutations in coding sequences of CYP11B2.  However, the 5'-flanking regions of CYP11B1 and B2 have diverged considerably, and B2 transcripts were not detected in human adrenal mRNA or among cDNA clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBAvV2I6oAobVg90H21EOLACvtfcHk0lhTaBp3Owjjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitFWktr0%253D&md5=658e13b32eaf0fb2a236d32074454c80</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMornet%26aufirst%3DE.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DVitek%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DP.%2BC.%26atitle%3DCharacterization%2520of%2520two%2520genes%2520encoding%2520human%2520steroid%252011%2520beta-hydroxylase%2520%2528P-450%252811%2529%2520beta%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1989%26volume%3D264%26spage%3D20961%26epage%3D20967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouin, P.-F.</span></span> <span> </span><span class="NLM_article-title">Aldosterone synthase inhibition with LCI699: A proof-of concept study in patients with primary aldosteronism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.110.157271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1161%2FHYPERTENSIONAHA.110.157271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=20837883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSqurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=831-838&author=L.+Amarauthor=M.+Aziziauthor=J.+Menardauthor=S.+Peyrardauthor=C.+Watsonauthor=P.-F.+Plouin&title=Aldosterone+synthase+inhibition+with+LCI699%3A+A+proof-of+concept+study+in+patients+with+primary+aldosteronism&doi=10.1161%2FHYPERTENSIONAHA.110.157271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism</span></div><div class="casAuthors">Amar, Laurence; Azizi, Michel; Menard, Joel; Peyrard, Severine; Watson, Catherine; Plouin, Pierre-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">831-838</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We report the first administration of an orally active aldosterone synthase inhibitor, LCI699, to 14 patients with primary aldosteronism.  After a 2-wk placebo run-in, patients received oral LCI699 (0.5 mg BID) for 2 wk, LCI699 (1.0 mg BID) for 2 wk, and placebo for 1 wk.  We assessed changes in hormone concns., plasma potassium levels, and 24-h ambulatory systolic blood pressure and safety.  The supine plasma aldosterone concn. decreased from 540 pmol/L (95% CI: 394 to 739 pmol/L) to 171 pmol/L (95% CI: 128 to 230 pmol/L) after 0.5 mg of LCI699 (-68%; P < 0.0001) and to 133 pmol/L (95% CI: 100 to 177 pmol/L) after 1.0 mg of LCI699 (-75%; P < 0.0001).  Plasma 11-deoxycorticosterone concns. increased by 710% after 0.5 mg of LCI699 (P < 0.0001) and by 1427% after 1.0 mg of LCI699 (P < 0.0001).  The plasma potassium concn. increased from 3.27 ± 0.31 to 4.03 ± 0.33 mmol/L (P < 0.0001) after only 1 wk on 0.5 mg of LCI699.  Twenty-four-hour ambulatory systolic blood pressure decreased by -4.1 mm Hg (95% CI: -8.1 to -0.1 mm Hg) after 4 wk of treatment (P = 0.046).  Basal plasma cortisol concns. remained unchanged, whereas plasma adrenocorticotropic hormone concns. increased by 35% after 0.5 mg of LCI699 (P = 0.08) and by 113% after 1.0 mg of LCI699 (P < 0.0001), and the plasma cortisol response to an adrenocorticotropic hormone test was blunted.  All of the variables except plasma 11-deoxycorticosterone concn. returned to initial levels after the placebo.  LCI699 was well tolerated.  In conclusion, the administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.  This 4-wk treatment cor. the hypokalemia and mildly decreased blood pressure.  The effects on the glucocorticoid axis were consistent with a latent inhibition of cortisol synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZwuj3BojUqrVg90H21EOLACvtfcHk0lhTaBp3Owjjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSqurfK&md5=ae64ff66f93f94628a52570bf0e74a8a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.110.157271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.110.157271%26sid%3Dliteratum%253Aachs%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DMenard%26aufirst%3DJ.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DPlouin%26aufirst%3DP.-F.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520with%2520LCI699%253A%2520A%2520proof-of%2520concept%2520study%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DHypertension%26date%3D2010%26volume%3D56%26spage%3D831%26epage%3D838%26doi%3D10.1161%2FHYPERTENSIONAHA.110.157271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowita, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménard, J.</span></span> <span> </span><span class="NLM_article-title">Effects of a novel aldosterone synthease inhibitor of treatment of primary hypertension: Results of a randomized, double-blind, placeo- and active-control phase 2 trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1945</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.029892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1161%2FCIRCULATIONAHA.111.029892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=21986283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ku7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=1945-1955&author=D.+A.+Calhounauthor=W.+B.+Whiteauthor=H.+Krumauthor=W.+Guoauthor=G.+Bermannauthor=A.+Trapaniauthor=M.+P.+Lefkowitaauthor=J.+M%C3%A9nard&title=Effects+of+a+novel+aldosterone+synthease+inhibitor+of+treatment+of+primary+hypertension%3A+Results+of+a+randomized%2C+double-blind%2C+placeo-+and+active-control+phase+2+trial&doi=10.1161%2FCIRCULATIONAHA.111.029892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial</span></div><div class="casAuthors">Calhoun, David A.; White, William B.; Krum, Henry; Guo, Weinong; Bermann, Georgina; Trapani, Angelo; Lefkowitz, Martin P.; Menard, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1945-1955</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: LCI699, a novel inhibitor of aldosterone synthase, reduces serum aldosterone, and may have benefit in the treatment of hypertension.  METHODS AND RESULTS: We performed the first double-blind, randomized trial with LCI699 in patients with primary hypertension.  We randomized 524 patients to LCI699 0.25 mg once daily (n=92), 0.5 mg once daily (n=88), 1.0 mg once daily (n=86), and 0.5 mg twice daily (n=97); eplerenone 50 mg twice daily (n=84); or placebo (n=77) for 8 wk.  Adrenocorticotropic hormone (250 μg IV) stimulation testing was performed in a subset of patients to quantify the selectivity of LCI699 for aldosterone synthase compared with 11-β-hydroxylase.  Redns. in clinic diastolic blood pressure were significant for LCI699 1.0 mg (-7.1 mm Hg; P=0.0012) and eplerenone 50 mg twice daily (-7.9 mm Hg; P<0.0001) compared with placebo (-2.6 mm Hg) but not other doses of LCI699.  Significant redns. in clinic systolic blood pressure were obsd. with all doses of LCI699 (P<0.005 or better) and eplerenone (P<0.0001).  All doses of LCI699 significantly reduced 24-h ambulatory blood pressure compared with placebo (P<0.01).  Adrenocorticotropic hormone stimulation of cortisol was suppressed in ≈20% of subjects receiving LCI699 at a total daily dose of 1.0 mg.  Safety and tolerability were similar among LCI699, placebo, and eplerenone.  CONCLUSIONS: Aldosterone synthase inhibition with LCI699 significantly lowered clinic and ambulatory blood pressure.  A minority of subjects developed blunted adrenocorticotropic hormone-stimulated release of cortisol.  These results support addnl. research to evaluate use of aldosterone synthase inhibition in primary hypertension and/or patients characterized by aldosterone excess.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGByhACTf6bVg90H21EOLACvtfcHk0lhTaBp3Owjjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ku7nP&md5=17a0d159894d6735707197bc6e7bf625</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.029892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.029892%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26aulast%3DWhite%26aufirst%3DW.%2BB.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DBermann%26aufirst%3DG.%26aulast%3DTrapani%26aufirst%3DA.%26aulast%3DLefkowita%26aufirst%3DM.%2BP.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520a%2520novel%2520aldosterone%2520synthease%2520inhibitor%2520of%2520treatment%2520of%2520primary%2520hypertension%253A%2520Results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placeo-%2520and%2520active-control%2520phase%25202%2520trial%26jtitle%3DCirculation%26date%3D2011%26volume%3D124%26spage%3D1945%26epage%3D1955%26doi%3D10.1161%2FCIRCULATIONAHA.111.029892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delporte, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudrt, M. C. D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferber, P.</span></span> <span> </span><span class="NLM_article-title">Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.116.07716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1161%2FHYPERTENSIONAHA.116.07716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=27872236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=189-196&author=K.+Bogmanauthor=D.+Schwabauthor=M.-L.+Delporteauthor=G.+Palermoauthor=K.+Amreinauthor=S.+Mohrauthor=M.+C.+D.+V.+Mudrtauthor=M.+J.+Brownauthor=P.+Ferber&title=Preclinical+and+early+clinical+profile+of+a+highly+selective+and+potent+oral+inhibitor+of+aldosterone+synthase+%28CYP11B2%29&doi=10.1161%2FHYPERTENSIONAHA.116.07716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)</span></div><div class="casAuthors">Bogman, Katrijn; Schwab, Dietmar; Delporte, Marie-Laure; Palermo, Giuseppe; Amrein, Kurt; Mohr, Susanne; De Vera Mudry, Maria Cristina; Brown, Morris J.; Ferber, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-196</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Primary hyperaldosteronism is a common cause of resistant hypertension.  Aldosterone is produced in the adrenal by aldosterone synthase (AS, encoded by the gene CYP11B2).  AS shares 93% homol. to 11β-hydroxylase (encoded by the gene CYP11B1), responsible for cortisol prodn.  This homol. has hitherto impeded the development of a drug, which selectively suppresses aldosterone but not cortisol prodn., as a new treatment for primary hyperaldosteronism.  We now report the development of RO6836191 as a potent (Ki 13 nmol/L) competitive inhibitor of AS, with in vitro selectivity >100-fold over 11β-hydroxylase.  In cynomolgus monkeys challenged with synthetic adrenocorticotropic hormone, single doses of RO6836191 inhibited aldosterone synthesis without affecting the adrenocorticotropic hormone-induced rise in cortisol.  In repeat-dose toxicity studies in monkeys, RO6836191 reproduced the adrenal changes of the AS mouse: expansion of the zona glomerulosa; increased expression of AS (or disrupted green fluorescent protein gene in the AS mouse); hypertrophy, proliferation, and apoptosis of zona glomerulosa cells.  These changes in the monkey were partially reversible and partially preventable by electrolyte supplementation and treatment with an angiotensin-converting enzyme inhibitor.  In healthy subjects, single doses of RO6836191, across a 360-fold dose range, reduced plasma and urine aldosterone levels with max. suppression at a dose of 10 mg, but unchanged cortisol, on adrenocorticotropic hormone challenge, up to 360 mg, and increase in the precursors 11-deoxycorticosterone and 11-deoxycortisol only at or >90 mg.  In conclusion, RO6836191 demonstrates that it is possible to suppress aldosterone prodn. completely in humans without affecting cortisol prodn.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT01995383.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYz7MQIXbBrVg90H21EOLACvtfcHk0lj8xmFDDWaObQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegtrrL&md5=e1f0817077a1495be20e1137bdd8318f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.116.07716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.116.07716%26sid%3Dliteratum%253Aachs%26aulast%3DBogman%26aufirst%3DK.%26aulast%3DSchwab%26aufirst%3DD.%26aulast%3DDelporte%26aufirst%3DM.-L.%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DAmrein%26aufirst%3DK.%26aulast%3DMohr%26aufirst%3DS.%26aulast%3DMudrt%26aufirst%3DM.%2BC.%2BD.%2BV.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%26aulast%3DFerber%26aufirst%3DP.%26atitle%3DPreclinical%2520and%2520early%2520clinical%2520profile%2520of%2520a%2520highly%2520selective%2520and%2520potent%2520oral%2520inhibitor%2520of%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DHypertension%26date%3D2017%26volume%3D69%26spage%3D189%26epage%3D196%26doi%3D10.1161%2FHYPERTENSIONAHA.116.07716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demers, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melby, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santen, R. J.</span></span> <span> </span><span class="NLM_article-title">The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=2156889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADyaK3c3gtlWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1990&pages=1162-1166&author=L.+M.+Demersauthor=J.+C.+Melbyauthor=T.+E.+Wilsonauthor=A.+Liptonauthor=H.+A.+Harveyauthor=R.+J.+Santen&title=The+effects+of+CGS+16949A%2C+an+aromatase+inhibitor+on+adrenal+mineralocorticoid+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis</span></div><div class="casAuthors">Demers L M; Melby J C; Wilson T E; Lipton A; Harvey H A; Santen R J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical endocrinology and metabolism</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1162-6</span>
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">The family of cytochrome P450 enzymes that mediates steroid hydroxylations are distinct but structurally related proteins.  Inhibitors of these steroidogenic steps generally exhibit only relative and dose-related specificity.  We evaluated an imidazole, cytochrome P450-related inhibitor, CGS 16949A, in postmenopausal patients with metastatic breast cancer.  While a relatively specific aromatase inhibitor at daily dosages of 1-2 mg, CGS 16949A significantly blunted cortisol responses to ACTH at a dose of 16 mg daily.  To further evaluate other inhibitory effects of this drug, we determined blood levels of aldosterone (ALDO) and 18-hydroxycorticosterone and their respective urinary metabolites, tetrahydroaldosterone and tetrahydro-18-hydroxy-11-dehydrocorticosterone in 16 postmenopausal women receiving CGS 16949A.  At a dose of 16 mg/day, CGS 16949A produced significant (P less than 0.001) suppression of both basal and ACTH-stimulated ALDO production.  This was accompanied by a significant rise in the blood 18-hydroxycorticosterone/ALDO ratio (11.4 +/- 0.19; normal, less than 2; P less than 0.001), consistent with a corticosterone methyloxidase type II inhibition.  A similar significant elevation (7.5 +/- 1.2; normal, less than 5; P less than 0.001) in the urinary tetrahydro-18-hydroxy-11-dehydrocorticosterone/tetrahydroaldosterone ratio was also observed.  These results suggest that CGS 16949A is a potent inhibitor of the corticosterone methyloxidase type II enzyme at a dose of 16 mg daily.  At doses of 1-2 mg daily, CGS 16949A blocks aromatase without altering basal aldosterone production and, thus, exhibits dose-related specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9Ux-hB5ma9UNoizSOkG_FfW6udTcc2ebHv6EzbBcqq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c3gtlWnug%253D%253D&md5=b2ce73daab3c1a84b2133f3d60ec152f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDemers%26aufirst%3DL.%2BM.%26aulast%3DMelby%26aufirst%3DJ.%2BC.%26aulast%3DWilson%26aufirst%3DT.%2BE.%26aulast%3DLipton%26aufirst%3DA.%26aulast%3DHarvey%26aufirst%3DH.%2BA.%26aulast%3DSanten%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520effects%2520of%2520CGS%252016949A%252C%2520an%2520aromatase%2520inhibitor%2520on%2520adrenal%2520mineralocorticoid%2520biosynthesis%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1990%26volume%3D70%26spage%3D1162%26epage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monovich, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papillon, J. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigel, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaSala, D.</span></span> <span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.1021/ml400324c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400324c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1203-1207&author=E.+L.+Meredithauthor=G.+Ksanderauthor=L.+G.+Monovichauthor=J.+P.+N.+Papillonauthor=Q.+Liuauthor=K.+Mirandaauthor=P.+Morrisauthor=C.+Raoauthor=R.+Burgisauthor=M.+Capparelliauthor=Q.-Y.+Huauthor=A.+Singhauthor=D.+F.+Rigelauthor=A.+Y.+Jengauthor=M.+Beilauthor=F.+Fuauthor=C.-W.+Huauthor=D.+LaSala&title=Discovery+and+in+vivo+evaluation+of+potent+dual+CYP11B2+%28aldosterone+synthase%29+and+CYP11B1+inhibitors&doi=10.1021%2Fml400324c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors</span></div><div class="casAuthors">Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; LaSala, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1203-1207</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathol. such as hypertension and heart failure.  Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target.  A series of imidazole derived inhibitors, including clin. candidate I, have been identified through design and structure-activity relationship studies both in vitro and in vivo.  Compd. I was also found to be a potent inhibitor of 11β-hydroxylase (CYP11B1), which is responsible for cortisol prodn.  Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZqZXmMc5qE7Vg90H21EOLACvtfcHk0lj8xmFDDWaObQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP&md5=3f2301a71dfd1bf91a99ac68f5ca91ff</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml400324c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400324c%26sid%3Dliteratum%253Aachs%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DKsander%26aufirst%3DG.%26aulast%3DMonovich%26aufirst%3DL.%2BG.%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMiranda%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DBurgis%26aufirst%3DR.%26aulast%3DCapparelli%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLaSala%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520potent%2520dual%2520CYP11B2%2520%2528aldosterone%2520synthase%2529%2520and%2520CYP11B1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1203%26epage%3D1207%26doi%3D10.1021%2Fml400324c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roumen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmen, J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beugels, I. P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Custers, E. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Gooyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieterse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilbers, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, J. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vekemans, J. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottenheijm, H. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, J. J. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1712</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1021/jm901356d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901356d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1712-1725&author=L.+Roumenauthor=J.+W.+Peetersauthor=J.+M.+A.+Emmenauthor=I.+P.+E.+Beugelsauthor=E.+M.+G.+Custersauthor=M.+de%0AGooyerauthor=R.+Plateauthor=K.+Pieterseauthor=P.+A.+J.+Hilbersauthor=J.+F.+M.+Smitsauthor=J.+A.+J.+Vekemansauthor=D.+Leysenauthor=H.+C.+J.+Ottenheijmauthor=H.+M.+Janssenauthor=J.+J.+R.+Hermans&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+1-benzyl-1H-imidazoles+as+selective+inhibitors+of+aldosterone+synthase+%28CYP11B2%29&doi=10.1021%2Fjm901356d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Molecular Modeling of 1-Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)</span></div><div class="casAuthors">Roumen, Luc; Peeters, Joris W.; Emmen, Judith M. A.; Beugels, Ilona P. E.; Custers, Erica M. G.; de Gooyer, Marcel; Plate, Ralf; Pieterse, Koen; Hilbers, Peter A. J.; Smits, Jos F. M.; Vekemans, Jef A. J.; Leysen, Dirk; Ottenheijm, Harry C. J.; Janssen, Henk M.; Hermans, J. J. Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1712-1725</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reducing aldosterone action is beneficial in various major diseases such as heart failure.  Currently, this is achieved with mineralocorticoid receptor antagonists, however, aldosterone synthase (CYP11B2) inhibitors may offer a promising alternative.  In this study, three-dimensional modeling of CYP11B2 was used to model the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole (I) as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles.  Their syntheses, in vitro inhibitor potencies, and in silico docking are described.  Some promising CYP11B2 inhibitors were identified, with the novel lead MOERAS115 (II) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (vs. CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC50 for CYP11B2 6.0 nM, selectivity 19.8).  Mol. docking of the inhibitors in the models enabled the generation of posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz3kri2YpzBLVg90H21EOLACvtfcHk0lh7tibVzNSyrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D&md5=95b05f5ad57464a12715c4cf15502b83</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm901356d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901356d%26sid%3Dliteratum%253Aachs%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DPeeters%26aufirst%3DJ.%2BW.%26aulast%3DEmmen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DBeugels%26aufirst%3DI.%2BP.%2BE.%26aulast%3DCusters%26aufirst%3DE.%2BM.%2BG.%26aulast%3Dde%2BGooyer%26aufirst%3DM.%26aulast%3DPlate%26aufirst%3DR.%26aulast%3DPieterse%26aufirst%3DK.%26aulast%3DHilbers%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DSmits%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DVekemans%26aufirst%3DJ.%2BA.%2BJ.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DOttenheijm%26aufirst%3DH.%2BC.%2BJ.%26aulast%3DJanssen%26aufirst%3DH.%2BM.%26aulast%3DHermans%26aufirst%3DJ.%2BJ.%2BR.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%25201-benzyl-1H-imidazoles%2520as%2520selective%2520inhibitors%2520of%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1712%26epage%3D1725%26doi%3D10.1021%2Fjm901356d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto-Bazurco
Mendieta, M. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagusch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller-Vieira, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauterbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5009</span>– <span class="NLM_lpage">5018</span>, <span class="refDoi"> DOI: 10.1021/jm800355c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800355c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2huro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5009-5018&author=M.+A.+E.+Pinto-Bazurco%0AMendietaauthor=M.+Negriauthor=C.+Jaguschauthor=U.+Mueller-Vieiraauthor=T.+Lauterbachauthor=R.+W.+Hartmann&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+abiraterone+analogues%3A+novel+CYP17+inhibitors+for+the+treatment+of+prostate+cancer&doi=10.1021%2Fjm800355c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer</span></div><div class="casAuthors">Pinto-Bazurco Mendieta, Mariano A. E.; Negri, Matthias; Jagusch, Carsten; Mueller-Vieira, Ursula; Lauterbach, Thomas; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5009-5018</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clin. trials as a potential drug for the treatment of androgen-dependent prostate cancer.  Since steroidal compds. often show side effects attributable to their structure, we have tried to replace the sterane scaffold by nonsteroidal core structures.  The design and synthesis of 20 new abiraterone mimetics are described.  Their activities have been tested with recombinant human CYP17 expressed in E. coli.  Promising compds. were further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4.  Compds. I and II showed comparable activity to abiraterone (IC50 values of 144 and 64 nM vs 72 nM) and similar or even better selectivity against the other CYP enzymes.  Selected compds. were also docked into our homol. model, and the same binding modes as for abiraterone were found.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUdezwVmhvrVg90H21EOLACvtfcHk0lh7tibVzNSyrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2huro%253D&md5=c4db0a4f38ff6ac36ff05fb0c8cdc2fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm800355c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800355c%26sid%3Dliteratum%253Aachs%26aulast%3DPinto-Bazurco%2BMendieta%26aufirst%3DM.%2BA.%2BE.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DJagusch%26aufirst%3DC.%26aulast%3DMueller-Vieira%26aufirst%3DU.%26aulast%3DLauterbach%26aufirst%3DT.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520abiraterone%2520analogues%253A%2520novel%2520CYP17%2520inhibitors%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5009%26epage%3D5018%26doi%3D10.1021%2Fjm800355c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brixius-Anderko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. E.</span></span> <span> </span><span class="NLM_article-title">Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.006214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1074%2Fjbc.RA118.006214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=30425102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=453-460&author=S.+Brixius-Anderkoauthor=E.+E.+Scott&title=Structure+of+human+cortisol-producing+cytochrome+P450+11B1+bound+to+the+breast+cancer+drug+fadrozole+provides+insights+for+drug+design&doi=10.1074%2Fjbc.RA118.006214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design</span></div><div class="casAuthors">Brixius-Anderko, Simone; Scott, Emily E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">453-460</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Human cytochrome P 450 11B1 (CYP11B1) is responsible for the final step generating the steroid hormone cortisol, which controls stress and immune responses and glucose homeostasis.  CYP11B1 is a promising drug target to manage Cushing's disease, a disorder arising from excessive cortisol prodn.  However, the design of selective inhibitors has been hampered because structural information for CYP11B1 is unavailable and the enzyme has high amino acid sequence identity (93%) to a closely related enzyme, the aldosterone-producing CYP11B2.  Here the authors report the x-ray crystal structure of human CYP11B1 (at 2.1 Å resoln.) in complex with fadrozole, a racemic compd. normally used to treat breast cancer by inhibiting estrogen-producing CYP19A1.  Comparison of fadrozole-bound CYP11B1 with fadrozole-bound CYP11B2 revealed that despite conservation of the active-site residues, the overall structures and active sites had structural rearrangements consistent with distinct protein functions and inhibition.  Whereas fadrozole binds to both CYP11B enzymes by coordinating the heme iron, CYP11B2 binds to the R enantiomer of fadrozole, and CYP11B1 binds to the S enantiomer, each with distinct orientations and interactions.  These results provide insights into the cross-reactivity of drugs across multiple steroidogenic cytochrome P 450 enzymes, provide a structural basis for understanding human steroidogenesis, and pave the way for the design of more selective inhibitors of each human CYP11B enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTP9ulILGhLVg90H21EOLACvtfcHk0lh7tibVzNSyrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjurg%253D&md5=d8b75ec9b273e63a2ff26bfbcf4b60ef</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.006214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.006214%26sid%3Dliteratum%253Aachs%26aulast%3DBrixius-Anderko%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DE.%2BE.%26atitle%3DStructure%2520of%2520human%2520cortisol-producing%2520cytochrome%2520P450%252011B1%2520bound%2520to%2520the%2520breast%2520cancer%2520drug%2520fadrozole%2520provides%2520insights%2520for%2520drug%2520design%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D453%26epage%3D460%26doi%3D10.1074%2Fjbc.RA118.006214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">Compounds <b>1</b>–<b>4</b> were also reported as CYP11B2 inhibitor by another research group.</p></div><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vock, C. A.</span></span> <span> </span><span class="NLM_article-title">N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.bmcl.2010.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=21129965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=186-190&author=C.+Zimmerauthor=M.+Hafnerauthor=M.+Zenderauthor=D.+Ammannauthor=R.+W.+Hartmannauthor=C.+A.+Vock&title=N-%28Pyridin-3-yl%29benzamides+as+selective+inhibitors+of+human+aldosterone+synthase+%28CYP11B2%29&doi=10.1016%2Fj.bmcl.2010.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)</span></div><div class="casAuthors">Zimmer, Christina; Hafner, Marieke; Zender, Michael; Ammann, Dominic; Hartmann, Rolf W.; Vock, Carsten A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-190</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 23 N-(pyridin-3-yl)benzamides was synthesized and evaluated for their potential to inhibit human steroid-11β-hydroxylase (CYP11B1) and human aldosterone synthase (CYP11B2).  The most potent and selective CYP11B2 inhibitors (IC50 values 53-166 nM) were further evaluated for their potential to inhibit human CYP17 and CYP19, and no inhibition was obsd.  Clear evidence was shown for N-(pyridin-3-yl)benzamides to be a highly selective class of CYP11B2 inhibitors in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2o811K_snXbVg90H21EOLACvtfcHk0lib0QgrNQ9cQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsLfP&md5=7df67fe9c17bf80a16b0d4983650f49d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DZender%26aufirst%3DM.%26aulast%3DAmmann%26aufirst%3DD.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DVock%26aufirst%3DC.%2BA.%26atitle%3DN-%2528Pyridin-3-yl%2529benzamides%2520as%2520selective%2520inhibitors%2520of%2520human%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D186%26epage%3D190%26doi%3D10.1016%2Fj.bmcl.2010.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornsperger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Märki, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riboulet, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayway, A. V.</span></span> <span> </span><span class="NLM_article-title">Discovery 4-aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: <i>in vivo</i> evaluation in rodents and cynomolgus monkeys</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8054</span>– <span class="NLM_lpage">8065</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00851</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00851" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGltb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8054-8065&author=R.+E.+Martinauthor=J.+D.+Aebiauthor=B.+Hornspergerauthor=H.-J.+Krebsauthor=B.+Kuhnauthor=A.+Kuglstatterauthor=A.+M.+Alkerauthor=H.-P.+M%C3%A4rkiauthor=S.+M%C3%BCllerauthor=D.+Burgerauthor=G.+Ottavianiauthor=W.+Ribouletauthor=P.+Verryauthor=X.+Tanauthor=K.+Amreinauthor=A.+V.+Mayway&title=Discovery+4-aryl-5%2C6%2C7%2C8-tetrahydroisoquinolines+as+potent%2C+selective%2C+and+orally+active+aldosterone+synthase+%28CYP11B2%29+inhibitors%3A+in+vivo+evaluation+in+rodents+and+cynomolgus+monkeys&doi=10.1021%2Facs.jmedchem.5b00851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys</span></div><div class="casAuthors">Martin, Rainer E.; Aebi, Johannes D.; Hornsperger, Benoit; Krebs, Hans-Jakob; Kuhn, Bernd; Kuglstatter, Andreas; Alker, Andre M.; Marki, Hans Peter; Muller, Stephan; Burger, Dominique; Ottaviani, Giorgio; Riboulet, William; Verry, Philippe; Tan, Xuefei; Amrein, Kurt; Mayweg, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8054-8065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inappropriately high levels of aldosterone are assocd. with many serious medical conditions, including renal and cardiac failure.  A focused screen hit has been optimized into a potent and selective aldosterone synthase (CYP11B2) inhibitor with in vitro activity against rat, mouse, human, and cynomolgus monkey enzymes, showing a selectivity factor of 160 against cytochrome CYP11B1 in the last species.  The novel tetrahydroisoquinoline compd. (I) selectively reduced aldosterone plasma levels in vivo in a dose-dependent manner in db/db mice and cynomolgus monkeys.  The selectivity against CYP11B1 as predicted by cellular inhibition data and free plasma fraction translated well to Synacthen challenged cynomolgus monkeys up to a dose of 0.1 mg kg-1.  This compd., displaying good in vivo potency and selectivity in mice and monkeys, is ideally suited to perform mechanistic studies in relevant rodent models and to provide the information necessary for translation to non-human primates and ultimately to man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXeatPr5nOtrVg90H21EOLACvtfcHk0lib0QgrNQ9cQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGltb7K&md5=ce9a9f7af76a7d63429d3ec282068395</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00851%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DHornsperger%26aufirst%3DB.%26aulast%3DKrebs%26aufirst%3DH.-J.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DAlker%26aufirst%3DA.%2BM.%26aulast%3DM%25C3%25A4rki%26aufirst%3DH.-P.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DD.%26aulast%3DOttaviani%26aufirst%3DG.%26aulast%3DRiboulet%26aufirst%3DW.%26aulast%3DVerry%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DAmrein%26aufirst%3DK.%26aulast%3DMayway%26aufirst%3DA.%2BV.%26atitle%3DDiscovery%25204-aryl-5%252C6%252C7%252C8-tetrahydroisoquinolines%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%2520inhibitors%253A%2520in%2520vivo%2520evaluation%2520in%2520rodents%2520and%2520cynomolgus%2520monkeys%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8054%26epage%3D8065%26doi%3D10.1021%2Facs.jmedchem.5b00851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csengery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmenk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K.</span></span> <span> </span><span class="NLM_article-title">Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: utility of money as a surrogate for human</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2015.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.jsbmb.2015.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=26303746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVagtL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2015&pages=197-205&author=M.+A.+Cernyauthor=A.+Csengeryauthor=J.+Schmenkauthor=K.+Frederick&title=Development+of+CYP11B1+and+CYP11B2+assays+utilizing+homogenates+of+adrenal+glands%3A+utility+of+money+as+a+surrogate+for+human&doi=10.1016%2Fj.jsbmb.2015.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human</span></div><div class="casAuthors">Cerny, Matthew A.; Csengery, Alexander; Schmenk, Jennifer; Frederick, Kosea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">197-205</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Elevated levels of aldosterone are assocd. with arterial hypertension, congestive heart failure, chronic kidney disease, and obesity.  Aldosterone is produced predominantly in the zona glomerulosa of the cortex of the adrenal gland by the enzyme aldosterone synthase (CYP11B2).  Treatment of the above indications by decreasing prodn. of aldosterone is thought to be of therapeutic benefit by lessening the deleterious effects of aldosterone mediated through both the mineralocorticoid receptor and also through so called non-genomic pathways.  However, inhibition of the highly similar enzyme, CYP11B1, which is responsible for the prodn. of cortisol, must be avoided in the development of clin. useful aldosterone synthase inhibitors due to the resulting impairment of the cortisol-induced stress response.  In efforts to assess the interactions of compds. with the CYP11B enzymes, a variety of cell-based inhibitor screening assays for both CYP11B1 and CYP11B2 have been reported.  Herein we report details of assays employing both cynomolgus monkey adrenal homogenate (CAH) and human adrenal homogenate (HAH) as sources of CYP11B1 and CYP11B2 enzymes.  Utilizing both CAH and HAH, we have characterized the kinetics of the CYP11B1-mediated conversion of 11-deoxycortisol to cortisol and the CYP11B2-mediated oxidn. of corticosterone to aldosterone.  Inhibition assays for both CYP11B1 and CYP11B2 were subsequently developed.  Based on a comparison of human and monkey amino acid sequences, kinetics data, and inhibition values derived from the HAH and CAH assays, evidence is provided in support of using cynomolgus monkey tissue-derived cell homogenates as suitable surrogates for the human enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpcI8q0Ww1R7Vg90H21EOLACvtfcHk0lgah0-oIVYM6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVagtL%252FJ&md5=8b2c5d217c353e0e7ec0e5cef071ef5f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2015.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DM.%2BA.%26aulast%3DCsengery%26aufirst%3DA.%26aulast%3DSchmenk%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520CYP11B1%2520and%2520CYP11B2%2520assays%2520utilizing%2520homogenates%2520of%2520adrenal%2520glands%253A%2520utility%2520of%2520money%2520as%2520a%2520surrogate%2520for%2520human%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D154%26spage%3D197%26epage%3D205%26doi%3D10.1016%2Fj.jsbmb.2015.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weldon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueneva-Boucheva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. F.</span></span> <span> </span><span class="NLM_article-title">Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.236463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1124%2Fjpet.116.236463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=27481775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2jtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2016&pages=142-150&author=S.+M.+Weldonauthor=M.+A.+Cernyauthor=K.+Gueneva-Bouchevaauthor=D.+Coganauthor=X.+Guoauthor=N.+Mossauthor=J.-H.+Parmentierauthor=J.+R.+Richmanauthor=G.+A.+Reinhartauthor=N.+F.+Brown&title=Selectivity+of+BI+689648%2C+a+novel%2C+highly+selective+aldosterone+synthase+inhibitor%3A+comparison+with+FAD286+and+LCI699+in+nonhuman+primates&doi=10.1124%2Fjpet.116.236463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates</span></div><div class="casAuthors">Weldon, Steven M.; Cerny, Matthew A.; Gueneva-Boucheva, Kristina; Cogan, Derek; Guo, Xin; Moss, Neil; Parmentier, Jean-Hugues; Richman, Jeremy R.; Reinhart, Glenn A.; Brown, Nicholas F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-150</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The mineralocorticoid aldosterone is an important regulator of blood pressure, vol., and electrolyte balance.  However, excess aldosterone can be deleterious as a driver of vascular remodeling and tissue fibrosis assocd. with cardiometabolic diseases.  Aldosterone synthase (AS) inhibitors (ASI) attenuate the prodn. of aldosterone directly and have been proposed as an alternative to mineralocorticoid receptor antagonists for blocking the pathol. effects of excess aldosterone.  Discovery of selective ASIs has been challenging because of the high sequence identity (93%) AS shares with cortisol synthase (CS), and the low identity of rodent AS compared with human (63%).  Using cynomolgus (cyno) monkey-based models, we identified BI 689648 [6-(5-methoxymethyl-pyridin-3-yl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid amide], a novel, highly selective ASI that exhibits an in vitro IC50 of 2 nMagainst AS and 300 nm against CS (150-fold selectivity) compared with the recently described ASIs FAD286 [4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile] (3 nM AS; 90 nM CS; 40-fold) and LCI699 (4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile) (10 nM AS; 80 nM CS; 8-fold).  After oral administration in cyno monkeys, BI 689648 (5 mg/kg) exhibits a peak plasma concn. of ∼500 nM.  For in vivo profiling we used an ACTH-challenge model in which BI 689648 was.20-fold more selective compared with FAD286 and LCI699.  Because both FAD286 and LCI699 failed to provide adequate selectivity for CS when tested in patients, the desire for more selective mols. to test the ASI hypothesis remains high.  Therefore, highly selective aldosterone synthase inhibitors such as BI 689648 represent an important step forward toward developing ASIs with greater potential for clin. success in cardiometabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5pUr1dc_oLVg90H21EOLACvtfcHk0lgah0-oIVYM6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2jtLrK&md5=584b931b62922f854df7b68b288d5d19</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236463%26sid%3Dliteratum%253Aachs%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DCerny%26aufirst%3DM.%2BA.%26aulast%3DGueneva-Boucheva%26aufirst%3DK.%26aulast%3DCogan%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DParmentier%26aufirst%3DJ.-H.%26aulast%3DRichman%26aufirst%3DJ.%2BR.%26aulast%3DReinhart%26aufirst%3DG.%2BA.%26aulast%3DBrown%26aufirst%3DN.%2BF.%26atitle%3DSelectivity%2520of%2520BI%2520689648%252C%2520a%2520novel%252C%2520highly%2520selective%2520aldosterone%2520synthase%2520inhibitor%253A%2520comparison%2520with%2520FAD286%2520and%2520LCI699%2520in%2520nonhuman%2520primates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D359%26spage%3D142%26epage%3D150%26doi%3D10.1124%2Fjpet.116.236463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stribling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenot, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinsanya, K. O.</span></span> <span> </span><span class="NLM_article-title">Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmocodynamics of aldosterone synthase inhibitors</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2014.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.vascn.2014.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=25304940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=137-146&author=T.-Q.+Caiauthor=S.+Striblingauthor=X.+Tongauthor=L.+Xuauthor=T.+Wisniewskiauthor=J.+A.+Fontenotauthor=M.+Struthersauthor=K.+O.+Akinsanya&title=Rhesus+monkey+model+for+concurrent+analyses+of+in+vivo+selectivity%2C+pharmacokinetics+and+pharmocodynamics+of+aldosterone+synthase+inhibitors&doi=10.1016%2Fj.vascn.2014.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors</span></div><div class="casAuthors">Cai, Tian-Quan; Stribling, Sloan; Tong, Xinchun; Xu, Ling; Wisniewski, Thomas; Fontenot, Jane A.; Struthers, Mary; Akinsanya, Karen O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vivo profiles of aldosterone synthase inhibitors (ASIs) have been investigated utilizing various rodent models.  Due to lack of CYP17 activity, rodents produce corticosterone rather than cortisol as that of humans, which raised concern to their effectiveness in translational pharmacol. characterization of ASI.  A rhesus monkey model that combines a low sodium diet with ACTH (ACTH) treatment was developed.  Plasma concns. of steroid metabolites assocd. with reactions catalyzed by CYP11B2 and CYP11B1 were measured concurrently by a UPLC/MS method.  Plasma concn. of aldosterone in regular diet fed rhesus monkeys was low at 109 pg/mL.  Aldosterone concns. were increased to 252 pg/mL when animals were maintained on a low sodium diet for 3 wk, and to 300 pg/mL with ACTH treatment at 0.3 mg/kg.  The combination of low sodium diet with ACTH treatment further increased plasma concn. of aldosterone to 730 pg/mL and other steroid metabolites at various levels.  I.v. administration of ASI, fadrozole (0.001-1 mg/kg) or LCI699 (0.003-3 mg/kg), led to dose-dependent redns. in aldosterone and 18-hydroxycorticosterone, increases in 11-deoxycorticosterone and 11-deoxycortisol, and bell-shaped changes in cortisol and corticosterone.  In vivo selectivity of CYP11B2/CYP11B1 for fadrazole was 26-fold and LCI-699 was 27-fold, which was consistent with relative selectivity using in vitro values from recombinant cells transfected with rhesus monkey CYP11B2 and CYP11B1.  This model enables concurrent characterization of pharmacokinetics, pharmacodynamics and selectivity of CYP11B2 over CYP11B1 inhibition in the same animal.  It may be used as a translational model for pharmacol. characterization of ASI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgHmCwgc290bVg90H21EOLACvtfcHk0lgah0-oIVYM6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K&md5=912a384735308d52a410cc2397ff9e83</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2014.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2014.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DStribling%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DFontenot%26aufirst%3DJ.%2BA.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DAkinsanya%26aufirst%3DK.%2BO.%26atitle%3DRhesus%2520monkey%2520model%2520for%2520concurrent%2520analyses%2520of%2520in%2520vivo%2520selectivity%252C%2520pharmacokinetics%2520and%2520pharmocodynamics%2520of%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2015%26volume%3D71%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.vascn.2014.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papillon, J. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beil, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung-Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaSala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigel, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vest, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9382</span>– <span class="NLM_lpage">9394</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01545</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01545" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyisbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9382-9394&author=J.+P.+N.+Papillonauthor=C.+Louauthor=A.+K.+Singhauthor=C.+M.+Adamsauthor=G.+M.+Ksanderauthor=M.+E.+Beilauthor=W.+Chenauthor=J.+Leung-Chuauthor=F.+Fuauthor=L.+Ganauthor=C.-W.+Huauthor=A.+Y.+Jengauthor=D.+LaSalaauthor=G.+Liangauthor=D.+F.+Rigelauthor=K.+S.+Russellauthor=J.+A.+Vestauthor=C.+Watson&title=Discovery+of+N-%5B5-%286-chloro-3-cyano-1-methyl-1H-indol-2-yl%29-pyridin-3-ylmethyl%5D-ethanesulfonamide%2C+a+cortisol-sparing+CYP11B2+inhibitor+that+lowers+aldosterone+in+human+subjects&doi=10.1021%2Facs.jmedchem.5b01545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects</span></div><div class="casAuthors">Papillon, Julien P. N.; Lou, Changgang; Singh, Alok K.; Adams, Christopher M.; Ksander, Gary M.; Beil, Michael E.; Chen, Wei; Leung-Chu, Jennifer; Fu, Fumin; Gan, Lu; Hu, Chii-Whei; Jeng, Arco Y.; LaSala, Daniel; Liang, Guiqing; Rigel, Dean F.; Russell, Kerry S.; Vest, John A.; Watson, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9382-9394</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human clin. studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure.  However, LCI699's low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion.  This property of LCI699 prompted its development in Cushing's disease, but limited more extensive clin. studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors.  This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclin. species and human subjects of the selective CYP11B2 inhibitor 8(I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFKKZ5bXRjrLVg90H21EOLACvtfcHk0lilSjemErTO6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyisbbO&md5=be9aeef496bdfe7a2e9ca0e70eff1b56</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01545%26sid%3Dliteratum%253Aachs%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DLou%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DBeil%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLeung-Chu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DRussell%26aufirst%3DK.%2BS.%26aulast%3DVest%26aufirst%3DJ.%2BA.%26aulast%3DWatson%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520N-%255B5-%25286-chloro-3-cyano-1-methyl-1H-indol-2-yl%2529-pyridin-3-ylmethyl%255D-ethanesulfonamide%252C%2520a%2520cortisol-sparing%2520CYP11B2%2520inhibitor%2520that%2520lowers%2520aldosterone%2520in%2520human%2520subjects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9382%26epage%3D9394%26doi%3D10.1021%2Facs.jmedchem.5b01545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaw, A.</span>; <span class="NLM_string-name">Cowan, R. A.</span>; <span class="NLM_string-name">O’Reilley, D. S. J.</span>; <span class="NLM_string-name">Stewart, M. J.</span>; <span class="NLM_string-name">Shepherd, J.</span></span> <span> </span><span class="NLM_article-title">Endocrinology</span>. In  <i>Clinical Biochemistry</i>; <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">Churchill Livingston</span>: <span class="NLM_publisher-loc">Edinburgh</span>, <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=86-91&author=A.+Gaw&author=R.+A.+Cowan&author=D.+S.+J.+O%E2%80%99Reilley&author=M.+J.+Stewart&author=J.+Shepherd&title=Clinical+Biochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGaw%26aufirst%3DA.%26atitle%3DEndocrinology%26btitle%3DClinical%2520Biochemistry%26pub%3DChurchill%2520Livingston%26date%3D1999%26spage%3D86%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haggard, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmaus, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow
Setzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, K. P.</span></span> <span> </span><span class="NLM_article-title">High-throughput H295R steroidogenesis assay: utility as an alternative and a statistical approach to characterize effects on steroidogenesis</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1093%2Ftoxsci%2Fkfx274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=29216406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=509-534&author=D.+E.+Haggardauthor=A.+L.+Karmausauthor=M.+T.+Martinauthor=R.+S.+Judsonauthor=R.+Woodrow%0ASetzerauthor=K.+P.+Friedman&title=High-throughput+H295R+steroidogenesis+assay%3A+utility+as+an+alternative+and+a+statistical+approach+to+characterize+effects+on+steroidogenesis&doi=10.1093%2Ftoxsci%2Fkfx274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput H295R steroidogenesis assay: utility as an alternative and a statistical approach to characterize effects on steroidogenesis</span></div><div class="casAuthors">Haggard, Derik E.; Karmaus, Agnes L.; Martin, Matthew T.; Judson, Richard S.; Setzer, R. Woodrow; Friedman, Katie Paul</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">509-534</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The U.S. Environmental Protection Agency Endocrine Disruptor Screening Program and the Organization for Economic Co-operation and Development (OECD) have used the human adrenocarcinoma (H295R) cell-based assay to predict chem. perturbation of androgen and estrogen prodn.  Recently, a high-throughput H295R (HT-H295R) assay was developed as part of the ToxCast program that includes measurement of 11 hormones, including progestagens, corticosteroids, androgens, and estrogens.  To date, 2012 chems. have been screened at 1 concn.; of these, 656 chems. have been screened in concn.-response.  The objectives of this work were to: (1) develop an integrated anal. of chem.-mediated effects on steroidogenesis in the HT-H295R assay and (2) evaluate whether the HT-H295R assay predicts estrogen and androgen prodn. specifically via comparison with the OECD-validated H295R assay.  To support application of HT-H295R assay data to wt.-of-evidence and prioritization tasks, a single numeric value based on Mahalanobis distances was computed for 654 chems. to indicate the magnitude of effects on the synthesis of 11 hormones.  The max. mean Mahalanobis distance (maxmMd) values were high for strong modulators (prochloraz, mifepristone) and lower for moderate modulators (atrazine, molinate).  Twenty-five of 28 ref. chems. used for OECD validation were screened in the HT-H295R assay, and produced qual. similar results, with accuracies of 0.90/0.75 and 0.81/0.91 for increased/decreased testosterone and estradiol prodn., resp.  The HT-H295R assay provides robust information regarding estrogen and androgen prodn., as well as addnl. hormones.  The maxmMd from this integrated anal. may provide a data-driven approach to prioritizing lists of chems. for putative effects on steroidogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFY1QUcArL6bVg90H21EOLACvtfcHk0lilSjemErTO6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjurfF&md5=33d40dab23c67650ce8db22bb45cff0e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx274%26sid%3Dliteratum%253Aachs%26aulast%3DHaggard%26aufirst%3DD.%2BE.%26aulast%3DKarmaus%26aufirst%3DA.%2BL.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DWoodrow%2BSetzer%26aufirst%3DR.%26aulast%3DFriedman%26aufirst%3DK.%2BP.%26atitle%3DHigh-throughput%2520H295R%2520steroidogenesis%2520assay%253A%2520utility%2520as%2520an%2520alternative%2520and%2520a%2520statistical%2520approach%2520to%2520characterize%2520effects%2520on%2520steroidogenesis%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26spage%3D509%26epage%3D534%26doi%3D10.1093%2Ftoxsci%2Fkfx274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J.</span>; <span class="NLM_string-name">Amrein, K.</span>; <span class="NLM_string-name">Chen, W.</span>; <span class="NLM_string-name">Hornsperger, B.</span>; <span class="NLM_string-name">Kuhn, B.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Märki, H.-P.</span>; <span class="NLM_string-name">Mayweg, A. V.</span>; <span class="NLM_string-name">Mohr, P.</span>; <span class="NLM_string-name">Tan, X.</span>; <span class="NLM_string-name">Wang, Z.</span>; <span class="NLM_string-name">Zhou, M.</span></span> <span> </span><span class="NLM_article-title">New Bicyclic Dihydroisoquinoline-1-one Derivatives</span>. <span class="NLM_patent">WO2013/079452 A1</span>, June 6, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Aebi&author=K.+Amrein&author=W.+Chen&author=B.+Hornsperger&author=B.+Kuhn&author=Y.+Liu&author=H.-P.+M%C3%A4rki&author=A.+V.+Mayweg&author=P.+Mohr&author=X.+Tan&author=Z.+Wang&author=M.+Zhou&title=New+Bicyclic+Dihydroisoquinoline-1-one+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAebi%26aufirst%3DJ.%26atitle%3DNew%2520Bicyclic%2520Dihydroisoquinoline-1-one%2520Derivatives%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assmus, F.</span></span> <span> </span><span class="NLM_article-title">Carrier mediated distribution system (CAMDIS): a new approach for the measurement of octanol/water distribution coefficients</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.ejps.2014.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=25513709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2015&pages=68-77&author=B.+Wagnerauthor=H.+Fischerauthor=M.+Kansyauthor=A.+Seeligauthor=F.+Assmus&title=Carrier+mediated+distribution+system+%28CAMDIS%29%3A+a+new+approach+for+the+measurement+of+octanol%2Fwater+distribution+coefficients&doi=10.1016%2Fj.ejps.2014.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Carrier Mediated Distribution System (CAMDIS): A new approach for the measurement of octanol/water distribution coefficients</span></div><div class="casAuthors">Wagner, Bjoern; Fischer, Holger; Kansy, Manfred; Seelig, Anna; Assmus, Frauke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-77</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we present a miniaturized assay, referred to as Carrier-Mediated Distribution System (CAMDIS) for fast and reliable measurement of octanol/water distribution coeffs., log Doct.  By introducing a filter support for octanol, phase sepn. from water is facilitated and the tendency of emulsion formation (emulsification) at the interface is reduced.  A guideline for the best practice of CAMDIS is given, describing a strategy to manage drug adsorption at the filter-supported octanol/buffer interface.  We validated the assay on a set of 52 structurally diverse drugs with known shake flask logDoct values.  Excellent agreement with literature data (r2 = 0.996, std. error of est., SEE = 0.111), high reproducibility (std. deviation, SD < 0.1 log Doct units), minimal sample consumption (10 μL of 100 μM DMSO stock soln.) and a broad anal. range (log Doct range = -0.5 to 4.2) make CAMDIS a valuable tool for the high-throughput assessment of log Doct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsNSPSNv4bP7Vg90H21EOLACvtfcHk0li5rgDUaen1BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVChtQ%253D%253D&md5=e0631985c73afe8838fce2eb24ccf686</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DSeelig%26aufirst%3DA.%26aulast%3DAssmus%26aufirst%3DF.%26atitle%3DCarrier%2520mediated%2520distribution%2520system%2520%2528CAMDIS%2529%253A%2520a%2520new%2520approach%2520for%2520the%2520measurement%2520of%2520octanol%252Fwater%2520distribution%2520coefficients%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D68%26spage%3D68%26epage%3D77%26doi%3D10.1016%2Fj.ejps.2014.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Cong-Hai Zhang, Rong Huang, Zhong-Wei Zhang, Jun Lin, <span class="NLM_string-name hlFld-ContribAuthor">Sheng-Jiao Yan</span>. </span><span class="cited-content_cbyCitation_article-title">An Environmentally Benign Cascade Reaction of 1,1-Enediamines (EDAMs) for Site-Selective Synthesis of Highly Functionalized 2,10-Dihydro-1H-imidazo[1′,2′:1,6]pyrido[2,3-b]indoles and Pyrroles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (8)
                                     , 5744-5756. <a href="https://doi.org/10.1021/acs.joc.1c00211" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00211</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00211%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAn%252BEnvironmentally%252BBenign%252BCascade%252BReaction%252Bof%252B1%25252C1-Enediamines%252B%252528EDAMs%252529%252Bfor%252BSite-Selective%252BSynthesis%252Bof%252BHighly%252BFunctionalized%252B2%25252C10-Dihydro-1H-imidazo%25255B1%2525E2%252580%2525B2%25252C2%2525E2%252580%2525B2%25253A1%25252C6%25255Dpyrido%25255B2%25252C3-b%25255Dindoles%252Band%252BPyrroles%26aulast%3DZhang%26aufirst%3DCong-Hai%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D27032021%26volume%3D86%26issue%3D8%26spage%3D5744%26epage%3D5756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Brixius-Anderko</span>, <span class="hlFld-ContribAuthor ">Emily E.  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Aldosterone Synthase Structure With Cushing Disease Drug LCI699 Highlights Avenues for Selective CYP11B Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Hypertension</span><span> <strong>2021,</strong> <em>186 </em><a href="https://doi.org/10.1161/HYPERTENSIONAHA.121.17615" title="DOI URL">https://doi.org/10.1161/HYPERTENSIONAHA.121.17615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/HYPERTENSIONAHA.121.17615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FHYPERTENSIONAHA.121.17615%26sid%3Dliteratum%253Aachs%26jtitle%3DHypertension%26atitle%3DAldosterone%252BSynthase%252BStructure%252BWith%252BCushing%252BDisease%252BDrug%252BLCI699%252BHighlights%252BAvenues%252Bfor%252BSelective%252BCYP11B%252BDrug%252BDesign%26aulast%3DBrixius-Anderko%26aufirst%3DSimone%26date%3D2021%26date%3D2021%26volume%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine S. W.  Law</span>, <span class="hlFld-ContribAuthor ">Keng Y.  Yeong</span>. </span><span class="cited-content_cbyCitation_article-title">Benzimidazoles in Drug Discovery: A Patent Review. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>49 </em><a href="https://doi.org/10.1002/cmdc.202100004" title="DOI URL">https://doi.org/10.1002/cmdc.202100004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100004%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DBenzimidazoles%252Bin%252BDrug%252BDiscovery%25253A%252BA%252BPatent%252BReview%26aulast%3DLaw%26aufirst%3DChristine%2BS.%2BW.%26date%3D2021%26date%3D2021%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0001.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Terminal steroidogenesis pathways leading to aldosterone and cortisol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0002.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of the modeled binding mode of compound <b>13</b> (magenta) with the X-ray cocrystal structure of human CYP11B2 with deoxycorticosterone (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVQ">4DVQ</a>; protein in green, and heme and steroid ligand in cyan). In the model, the pyridine nitrogen atom engages in a short contact with the heme iron atom (dashed line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0003.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of human CYP11B2 in complex with compound <b>45</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8">6XZ8</a>). The protein is displayed in green, and the heme cofactor and compound <b>45</b> are shown as cyan sticks. Protein residues with short contacts to the ligand (<i>d</i> < 4.0 Å) are highlighted as green sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0004.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overlay of X-ray structures of human CYP11B2 with compounds <b>45</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8">6XZ8</a>; protein in green, and heme and ligand in cyan) and <b>58</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ9">6XZ9</a>; protein in orange, and heme and ligand in magenta) illustrating protein-induced fit around the pyrazole tail. The heme iron–pyridine nitrogen contact and the hydrogen bond between the ligand pyrazole and Tyr 485 are shown as dashed lines. At position 404, the Gln residue CYP11B2 is mutated to Arg in CYP11B1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0005.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Steroid levels in cynomolgus monkeys 60 min post ACTH challenge and treatment with compound <b>52</b> are compared to the changes of steroid levels induced by LCI699, a less selective ASI. Note that the three highest doses of compound <b>52</b> lowered the aldosterone clearly below basal levels (vehicle <i>t</i> = 0 min). <b>LCI699</b> treatment led to a dramatic increase in deoxycorticosterone and deoxycortisol levels. Enzymatic steps mediated by CYP11B1 or CYP11B2 are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0006.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK/PD prediction in cynomolgus monkeys. Different doses of compound <b>52</b> were applied, and the PK profile was determined (see also the SI, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf" class="ext-link">Table S8</a>). For each dose, the average free exposure was calculated from AUC<sub>0–7h</sub> and corrected for plasma protein binding. Overall, a good linear correlation between applied doses and achieved free plasma exposures was observed. Horizontal crosslines mark the IC<sub>50</sub> values for CYP11B2 and CYP11B1. This predicts that the doses of 0.1, 1, and 10 mg/kg display significant and selective inhibition of aldosterone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Syntheses of Aldosterone Synthase Inhibitors, <b>10–23</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-bromopyridine, CuI, K<sub>2</sub>CO<sub>3</sub> (or Cs<sub>2</sub>CO<sub>3</sub>), <i>N</i>,<i>N</i>′-dimethylethylenediamine (or (+)-(<i>S,S</i>)-1,2-diaminocyclohexane), 1,4-dioxane, 110–150 °C.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of 3,4-Dihydroisoquinolin-1-one Intermediates, <b>63</b> and <b>64</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl chloroformate, Et<sub>3</sub>N, dichloromethane (DCM), room temperature (rt); (b) neat PPA, 120 °C; (c) PBr<sub>3</sub>, DCM, 0 °C; (d) trimethylsilyl cyanide, tetrabutylammonium fluoride (TBAF), CH<sub>3</sub>CN, reflux; (e) BH<sub>3</sub>-THF, reflux; (f) trifluoroacetic anhydride, Et<sub>3</sub>N, DCM, rt; (g) paraformaldehyde, AcOH, H<sub>2</sub>SO<sub>4</sub>, rt; (h) K<sub>2</sub>CO<sub>3</sub>, MeOH-H<sub>2</sub>O, rt; (i) KBr, iodosylbenzene, H<sub>2</sub>O, rt.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Isoindolin-one Intermediate, <b>67</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCl<sub>2</sub>, MeOH, 70 °C; (b) CuCN, 1-methyl-pyrrolidin-2-one, 180 °C; (c) NBS, BPO, CCl<sub>4</sub>, reflux; (d) PMBNH<sub>2</sub>, THF, rt; (e) CAN, CH<sub>3</sub>CN, 0 °C.</p></p></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Isoindolin-one Intermediates, <b>68–72</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeMgBr (or EtMgBr, or cyclopropyl MgBr), THF, 0 °C, and then NaBH<sub>4</sub>, rt; (b) MeMgBr, THF, 0 °C, and then Ti(Oi-Pr)<sub>4</sub>, rt; (c) Ti(Oi-Pr)<sub>4</sub>, EtMgBr, −78 °C to rt, and then BF<sub>3</sub>-Et<sub>2</sub>O; (d) Pd(dppf)Cl<sub>2</sub>, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), CO, 130 °C.</p></p></figure><figure data-id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Isoindolin-one Intermediate, <b>73</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzylmagnesium chloride, DCM, 0 °C; (b) Et<sub>3</sub>SiH, trifluoroacetic acid (TFA), rt.</p></p></figure><figure data-id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Syntheses of Bicyclic Tetrahydroisoquinoline Series of Isoindolin-one Aldosterone Synthase Inhibitors, <b>24–28</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, EDCI, DMAP, DCM, rt; (b) LDA, methyl acrylate, THF and then 10% AcOH; (c) 6 M HCl, reflux; (d) Ti(Oi-Pr)<sub>4</sub>, NH<sub>3</sub>-MeOH, 0 °C, and then NaBH<sub>4</sub>; (e) CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, Cs<sub>2</sub>CO<sub>3</sub>, <b>(−)-(</b><i><b>S</b></i><b>)-83</b> (or <b>(+)-(</b><i><b>R</b></i><b>)-83</b>), 1,4-dioxane, microwave 150 °C; (f) acetyl chloride (or propanoyl propanoate, methanesulfonyl chloride, ethanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C.</p></p></figure><figure data-id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Syntheses of Bicyclic Tetrahydroisoquinoline Series of Isoindolin-one Aldosterone Synthase Inhibitors, <b>29–41</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) acetyl chloride (or propanoyl propanoate, methanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C; (b) <b>68</b> (or <b>69</b>, <b>72</b>), CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave 150 °C; (c) chiral column separation; (d) <b>63</b>, CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave 150 °C.</p></p></figure><figure data-id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>42–47</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCl<sub>2</sub>, DCM, rt; (b) NH<sub>3</sub>-MeOH, 60 °C; (c) intermediate <b>62</b>, CuI, Cs<sub>2</sub>CO<sub>3</sub>, (+)-(<i>S,S</i>)-1,2-diaminocyclohexane, 1,4-dioxane, 150 °C; (d) acetyl chloride (or propanoyl propanoate, methanesulfonyl chloride, ethanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C; (e) 3-methylpyridine-2-carboxylic acid, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU), DIPEA, DCM, rt.</p></p></figure><figure data-id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0017.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>48–49</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>3</sub>N, ethanesulfonyl chloride (or acetyl chloride), DCM, 0 °C; (b) 3-bromo-5-iodo-pyrdine, palladium(II)bis(triphenylphosphine) dichloride, Et<sub>3</sub>N, formic acid, DMF, 90 °C; (c) intermediate 62, CuI, Cs<sub>2</sub>CO<sub>3</sub>, <i>trans</i>-cyclohexane-1,2-diamine, 1,4-dioxane, 150 °C.</p></p></figure><figure data-id="sch10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>50–51</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) piperazine-1-carboxylic acid <i>tert-</i>butyl ester, palladium(II) acetate, XPhos, sodium <i>tert</i>-butoxide, 1,4-dioxane, microwave, 130 °C; (c) TFA, DCM, rt; (d) acetyl chloride (or methanesulfonyl chloride), Et<sub>3</sub>N, DCM, 0 °C.</p></p></figure><figure data-id="sch11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/medium/jm0c00233_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Syntheses of 5-Chloro-3,3-dimethyl-isoindolin-1-one-Derived Aldosterone Synthase Inhibitors, <b>52–62</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00233/20200701/images/large/jm0c00233_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00233&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3,5-diiodo-pyridine, CuI, (1<i>S</i>,2<i>S</i>)-cyclohexane-1,2-diamine, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C; (b) CuI, 1,10-phenanthroline, Cs<sub>2</sub>CO<sub>3</sub>, <i>tert</i>-butyl 3-hydroxyazetidine-1-carboxylate (or (<i>R</i>)-3-hydroxy-pyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester, (<i>S</i>)-3-hydroxy-pyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester, <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate), toluene, 110 °C; then, TFA, DCM, rt; (c) Et<sub>3</sub>N, DCM, ethanesulfonyl chloride (or acetyl chloride); (d) 3-chloropyridine-2-carboxylic acid (or 4-methylpyridine-3-carboxylic acid, 1-methylpyrazole-4-carboxylic acid), HATU, DIPEA, DCM, 0 °C; (e) <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate, Pd<sub>2</sub>dba<sub>3</sub>, BINAP, <i><sup>t</sup></i>BuONa, Et<sub>3</sub>N, toluene, 85 °C; (f) TFA, DCM, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mentz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakris, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghiade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruilope, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggioni, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piña, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiuzat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span> <span> </span><span class="NLM_article-title">The present, past, and future of renin-angiotensin aldosterone system inhibition</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1677</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.ijcard.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=23121914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADC%252BC3s7gsVKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2013&pages=1677-1687&author=R.+J.+Mentzauthor=G.+L.+Bakrisauthor=B.+Waeberauthor=J.+J.+V.+McMurrayauthor=M.+Gheorghiadeauthor=L.+M.+Ruilopeauthor=A.+P.+Maggioniauthor=K.+Swedbergauthor=I.+L.+Pi%C3%B1aauthor=M.+Fiuzatauthor=C.+M.+O%E2%80%99Connorauthor=F.+Zannadauthor=B.+Pitt&title=The+present%2C+past%2C+and+future+of+renin-angiotensin+aldosterone+system+inhibition&doi=10.1016%2Fj.ijcard.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The past, present and future of renin-angiotensin aldosterone system inhibition</span></div><div class="casAuthors">Mentz Robert J; Bakris George L; Waeber Bernard; McMurray John J V; Gheorghiade Mihai; Ruilope Luis M; Maggioni Aldo P; Swedberg Karl; Pina Ileana L; Fiuzat Mona; O'Connor Christopher M; Zannad Faiez; Pitt Bertram</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1677-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease.  RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction.  This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials.  Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies.  Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR75G_qn1L8TLjnyZkbE8yXfW6udTcc2eY4ZZAsBhCOOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7gsVKmtg%253D%253D&md5=07628ed63ea52e65ab86b7b79577ac20</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DMentz%26aufirst%3DR.%2BJ.%26aulast%3DBakris%26aufirst%3DG.%2BL.%26aulast%3DWaeber%26aufirst%3DB.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DGheorghiade%26aufirst%3DM.%26aulast%3DRuilope%26aufirst%3DL.%2BM.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DPi%25C3%25B1a%26aufirst%3DI.%2BL.%26aulast%3DFiuzat%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DC.%2BM.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DPitt%26aufirst%3DB.%26atitle%3DThe%2520present%252C%2520past%252C%2520and%2520future%2520of%2520renin-angiotensin%2520aldosterone%2520system%2520inhibition%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2013%26volume%3D167%26spage%3D1677%26epage%3D1687%26doi%3D10.1016%2Fj.ijcard.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Funder, J. W.</span></span> <span> </span><span class="NLM_article-title">New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">S8</span>– <span class="NLM_lpage">S11</span>, <span class="refDoi"> DOI: 10.1067/mhj.2002.129971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1067%2Fmhj.2002.129971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=12422135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVWntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2002&pages=S8-S11&author=J.+W.+Funder&title=New+biology+of+aldosterone%2C+and+experimental+studies+on+the+selective+aldosterone+blocker+eplerenone&doi=10.1067%2Fmhj.2002.129971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone</span></div><div class="casAuthors">Funder, John W.</div><div class="citationInfo"><span class="NLM_cas:title">American Heart Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5, Suppl.</span>),
    <span class="NLM_cas:pages">S8-S11</span>CODEN:
                <span class="NLM_cas:coden">AHJOA2</span>;
        ISSN:<span class="NLM_cas:issn">0002-8703</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, the effect of aldosterone/salt on a variety of cardiovascular functions has been shown to reflect direct effects through mineralocorticoid receptors in nonepithelial tissue as well as classic effects on sodium retention and potassium excretion at epithelia.  The clin. importance of aldosterone receptor blockade has been convincingly shown for heart failure by the RALES trial.  Exptl. studies in a variety of hyperaldosteronemic models of hypertension have shown that selective aldosterone blockade by eplerenone attenuates the proinflammatory effect of aldosterone/salt imbalance and confers substantial end-organ (brain. kidney, heart) protection, even in the presence of elevated angiotensin levels.  In a normoaldosteronemic model (pig angioplasty), eplerenone is similarly protective of coronary arteries.  Although the extent of end-organ protection in clin. practice awaits outcome trials, the results of preclin. studies suggest a crit. role for eplerenone in the optimal treatment of hypertension as well as heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtcMEsw-7zALVg90H21EOLACvtfcHk0lgBDlx2K19dHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVWntL4%253D&md5=812424980d3e310255d29cae35895d8e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1067%2Fmhj.2002.129971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmhj.2002.129971%26sid%3Dliteratum%253Aachs%26aulast%3DFunder%26aufirst%3DJ.%2BW.%26atitle%3DNew%2520biology%2520of%2520aldosterone%252C%2520and%2520experimental%2520studies%2520on%2520the%2520selective%2520aldosterone%2520blocker%2520eplerenone%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2002%26volume%3D144%26spage%3DS8%26epage%3DS11%26doi%3D10.1067%2Fmhj.2002.129971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoogwerf, B. J.</span></span> <span> </span><span class="NLM_article-title">Renin-angiotensin system blockade and cardiovascular and renal protection</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">30A</span>– <span class="NLM_lpage">35A</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.amjcard.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=20102971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyitLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2010&pages=30A-35A&author=B.+J.+Hoogwerf&title=Renin-angiotensin+system+blockade+and+cardiovascular+and+renal+protection&doi=10.1016%2Fj.amjcard.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Renin-Angiotensin System Blockade and Cardiovascular and Renal Protection</span></div><div class="casAuthors">Hoogwerf, Byron J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1, Suppl.</span>),
    <span class="NLM_cas:pages">30A-35A</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of a variety of clin. conditions, including atherosclerosis, hypertension, left ventricular hypertrophy, myocardial infarction, and heart failure.  Inhibition of the RAAS with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) has been shown to be effective in lowering blood pressure and reducing cardiovascular mortality and morbidity in various at-risk patient populations.  A no. of studies have shown that these 2 classes are effective in reducing the rate of renal disease progression in patients with diabetic nephropathy, although more long-term vascular outcome studies are needed in patients with chronic kidney disease.  The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) was the first study to show comparable reno- and cardioprotective effects between an ARB (telmisartan) and ramipril in a broad section of at-risk patients, on top of usual std. care.  However, telmisartan showed better tolerability than ramipril in ONTARGET, with less cough and angioedema.  This difference was obtained despite patients having been selected for tolerability to both drugs at study entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwwUoM9Hf3NbVg90H21EOLACvtfcHk0lgBDlx2K19dHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyitLzM&md5=597d07f5301d1ee06ae000cdf68b763d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DHoogwerf%26aufirst%3DB.%2BJ.%26atitle%3DRenin-angiotensin%2520system%2520blockade%2520and%2520cardiovascular%2520and%2520renal%2520protection%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2010%26volume%3D105%26spage%3D30A%26epage%3D35A%26doi%3D10.1016%2Fj.amjcard.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leoncini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viazzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontremoli, R.</span></span> <span> </span><span class="NLM_article-title">RAAS inhibition and renal protection</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.2174/138161212799436520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.2174%2F138161212799436520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=22283776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADC%252BC383ltFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=971-980&author=G.+Leonciniauthor=F.+Viazziauthor=R.+Pontremoli&title=RAAS+inhibition+and+renal+protection&doi=10.2174%2F138161212799436520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">RAAS inhibition and renal protection</span></div><div class="casAuthors">Leoncini Giovanna; Giovanna Leoncini; Viazzi Francesca; Francesca Viazzi; Pontremoli Roberto; Roberto Pontremoli</div><div class="citationInfo"><span class="NLM_cas:title">Current pharmaceutical design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">971-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity.  It is currently estimated that nearly 15% of the general population has some degree of renal damage, a figure that reaches 50% in at-risk subgroups.  Renin-angiotensin-aldosterone system (RAAS) inhibitors represent the agents of choice to control hypertension and reduce urinary albumin excretion, thereby delaying renal function deterioration.  Greater blockade of the RAAS either by the combined use of multiple drugs or by supramaximal doses of single agents may provide greater renal protection.  Furthermore, it has been proposed especially in the presence of proteinuria.  However, at this time there is insufficient evidence to routinely recommend this therapeutic approach in patients with chronic kidney disease.  The present article examines the currently available evidence and practical implications of pharmacological disruption of RAAS activity for renal protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRq5tMlSZ--yw8IxFYvehhofW6udTcc2ebzj3-0ysuS9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ltFGnsg%253D%253D&md5=707978d75a16cc4300928ea54b0e75b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F138161212799436520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212799436520%26sid%3Dliteratum%253Aachs%26aulast%3DLeoncini%26aufirst%3DG.%26aulast%3DViazzi%26aufirst%3DF.%26aulast%3DPontremoli%26aufirst%3DR.%26atitle%3DRAAS%2520inhibition%2520and%2520renal%2520protection%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D971%26epage%3D980%26doi%3D10.2174%2F138161212799436520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span> <span> </span><span class="NLM_article-title">Eplerenone in patients with systolic heart failure and mild symptoms</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1009492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJMoa1009492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=21073363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=11-21&author=F.+Zannadauthor=J.+J.+V.+McMurrayauthor=H.+Krumauthor=D.+J.+van+Veldhuisenauthor=K.+Swedbergauthor=H.+Shiauthor=J.+Vincentauthor=S.+J.+Pocockauthor=B.+Pitt&title=Eplerenone+in+patients+with+systolic+heart+failure+and+mild+symptoms&doi=10.1056%2FNEJMoa1009492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone in patients with systolic heart failure and mild symptoms</span></div><div class="casAuthors">Zannad, Faiez; McMurray, John J. V.; Krum, Henry; van Veldhuisen, Dirk J.; Swedberg, Karl; Shi, Harry; Vincent, John; Pocock, Stuart J.; Pitt, Bertram</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction.  We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms.  In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Assocn. class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addn. to recommended therapy.  The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.  The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 mo.  The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P < 0.001).  A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P = 0.008); 10.8% and 13.5%, resp., died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P = 0.01).  Hospitalizations for heart failure and for any cause were also reduced with eplerenone.  A serum potassium level exceeding 5.5 mmol per L occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P < 0.001).  Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRI60N9G6VWrVg90H21EOLACvtfcHk0lhfkZRwIinejg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D&md5=70f8085ca6ac39316015b1c349312771</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009492%26sid%3Dliteratum%253Aachs%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DJ.%26aulast%3DPocock%26aufirst%3DS.%2BJ.%26aulast%3DPitt%26aufirst%3DB.%26atitle%3DEplerenone%2520in%2520patients%2520with%2520systolic%2520heart%2520failure%2520and%2520mild%2520symptoms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D11%26epage%3D21%26doi%3D10.1056%2FNEJMoa1009492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alderman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sealey, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laragh, J. H.</span></span> <span> </span><span class="NLM_article-title">Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypentension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1104</span>, <span class="refDoi"> DOI: 10.1056/NEJM199104183241605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJM199104183241605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1759997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADyaK3M7nvFClsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=1991&pages=1098-1104&author=M.+H.+Aldermanauthor=S.+Madhavanauthor=W.+L.+Ooiauthor=H.+Cohenauthor=J.+E.+Sealeyauthor=J.+H.+Laragh&title=Association+of+the+renin-sodium+profile+with+the+risk+of+myocardial+infarction+in+patients+with+hypentension&doi=10.1056%2FNEJM199104183241605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension</span></div><div class="casAuthors">Alderman M H; Madhavan S; Ooi W L; Cohen H; Sealey J E; Laragh J H</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1098-104</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  To test the prognostic value of plasma renin activity prospectively, we determined the pretreatment renin-sodium profile of 1717 subjects with mild-to-moderate hypertension (mean age, 53 years; 36 percent white; 67 percent men) in a systematic work-site treatment program.  METHODS:  Renin profiles, obtained by plotting plasma renin activity against the urinary excretion of sodium, were classified as high (12 percent of the subjects), normal (56 percent), and low (32 percent), and there were expected variations according to age, sex, and race.  Modified stepped-care treatment for hypertension, prescribed without reference to the renin profile, was similar in the three renin groups.  RESULTS:  Mean (+/- SD) blood pressure at entry was 151 +/- 19/100 +/- 10 mm Hg in the subjects with a high renin profile, 151 +/- 19/97 +/- 10 mm Hg in those with a normal profile, and 151 +/- 20/96 +/- 11 mm Hg in those with a low profile.  During 8.3 years of follow-up, there were 27 myocardial infarctions.  As adjusted for age, sex, and race, the incidence of myocardial infarction per 1000 person-years was 14.7 among the subjects with a high renin profile, 5.6 among those with a normal profile, and 2.8 among those with a low profile (rate ratio for high vs. low, 5.3; 95 percent confidence interval, 3.4 to 8.3).  The rate of mortality from all causes was 9.3 in the high-profile group, 5.3 in the normal-profile group, and 3.9 in the low-profile group.  The independent association of a high renin profile with myocardial infarction (but not with stroke or noncardiovascular events) was affirmed by Cox analyses (rate ratio for high vs. normal plus low, 3.2; 95 percent confidence interval, 1.2 to 8.4) after adjustment for race, sex, age at entry, serum cholesterol level, smoking status, electrocardiographic evidence of left ventricular hypertrophy, blood glucose level, body-mass index, history of cardiovascular disease or treatment, blood pressure, and use of beta-blockers.  CONCLUSIONS:  In the study population, whose blood pressure before and during treatment was in a narrow range, and after other cardiovascular risk factors had been considered, the renin profile before treatment remained independently associated with the subsequent risk of myocardial infarction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_J2lWA6pUO1w2ofyr07jXfW6udTcc2ebl4nF3p1JT6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7nvFClsw%253D%253D&md5=23d944a68f431b4cc0e8d838be1e896c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM199104183241605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199104183241605%26sid%3Dliteratum%253Aachs%26aulast%3DAlderman%26aufirst%3DM.%2BH.%26aulast%3DMadhavan%26aufirst%3DS.%26aulast%3DOoi%26aufirst%3DW.%2BL.%26aulast%3DCohen%26aufirst%3DH.%26aulast%3DSealey%26aufirst%3DJ.%2BE.%26aulast%3DLaragh%26aufirst%3DJ.%2BH.%26atitle%3DAssociation%2520of%2520the%2520renin-sodium%2520profile%2520with%2520the%2520risk%2520of%2520myocardial%2520infarction%2520in%2520patients%2520with%2520hypentension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1991%26volume%3D324%26spage%3D1098%26epage%3D1104%26doi%3D10.1056%2FNEJM199104183241605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bomback, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemmer, P. J.</span></span> <span> </span><span class="NLM_article-title">The incidence and implications of aldosterone breakthrough</span>. <i>Nat. Clin. Pract. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1038/ncpneph0575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1038%2Fncpneph0575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=17717561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=486-492&author=A.+S.+Bombackauthor=P.+J.+Klemmer&title=The+incidence+and+implications+of+aldosterone+breakthrough&doi=10.1038%2Fncpneph0575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The incidence and implications of aldosterone breakthrough</span></div><div class="casAuthors">Bomback, Andrew S.; Klemmer, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Nephrology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">486-492</span>CODEN:
                <span class="NLM_cas:coden">NCPNC3</span>;
        ISSN:<span class="NLM_cas:issn">1745-8323</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interruption of the renin-angiotensin-aldosterone system has become a leading therapeutic strategy in the treatment of chronic heart and kidney disease.  Angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers do not, however, uniformly suppress the renin-angiotensin-aldosterone system.  Plasma aldosterone levels are elevated in a subset of patients despite therapy.  This phenomenon, known as 'aldosterone escape' or 'aldosterone breakthrough', has only been directly examd. in small nos. of patients.  The key questions of how often breakthrough occurs and whether breakthrough leads to worse outcomes have yet to be definitively answered.  In this Review, we summarize the reported data on the incidence and clin. implications of aldosterone breakthrough, and highlight areas of uncertainty that have yet to be adequately addressed in the literature.  Although the available evidence is not strong enough to support widespread screening for aldosterone breakthrough, our findings should prompt physicians to consider the phenomenon in select patients as well as guide future research efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFN5ofkTncrVg90H21EOLACvtfcHk0lhfkZRwIinejg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtr7O&md5=f3bf536da1222852edec19ceecc8afaf</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fncpneph0575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncpneph0575%26sid%3Dliteratum%253Aachs%26aulast%3DBomback%26aufirst%3DA.%2BS.%26aulast%3DKlemmer%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520incidence%2520and%2520implications%2520of%2520aldosterone%2520breakthrough%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Nephrol.%26date%3D2007%26volume%3D3%26spage%3D486%26epage%3D492%26doi%3D10.1038%2Fncpneph0575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remme, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaigne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palensky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span> <span> </span><span class="NLM_article-title">The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1056/NEJM199909023411001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJM199909023411001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10471456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=709-717&author=B.+Pittauthor=F.+Zannadauthor=W.+J.+Remmeauthor=R.+Codyauthor=A.+Castaigneauthor=A.+Perezauthor=J.+Palenskyauthor=J.+Wittes&title=The+effect+of+spironolactone+on+morbidity+and+mortality+in+patients+with+severe+heart+failure.+Randomized+aldactone+evaluation+study+investigators&doi=10.1056%2FNEJM199909023411001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of spironolactone on morbidity and mortality in patients with severe heart failure</span></div><div class="casAuthors">Pitt, Bertram; Zannad, Faiez; Remme, Willem J.; Cody, Robert; Castaigne, Alain; Perez, Alfonso; Palensky, Jolie; Wittes, Janet</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-717</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Aldosterone is important in the pathophysiol. of heart failure.  In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin.  A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo.  The primary end point was death from all causes.  The trial was discontinued early, after a mean follow-up period of 24 mo, because an interim anal. detd. that spironolactone was efficacious.  There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001).  This 30 percent redn. in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes.  The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001).  In addn., patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Assocn. functional class (P<0.001).  Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001).  The incidence of serious hyperkalemia was minimal in both groups of patients.  Blockade of aldosterone receptors by spironolactone, in addn. to std. therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOy-U1QzrSbVg90H21EOLACvtfcHk0liglOWOHSiccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D&md5=3e34cf3cd2ac38b96cefdfda593a02f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909023411001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909023411001%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DRemme%26aufirst%3DW.%2BJ.%26aulast%3DCody%26aufirst%3DR.%26aulast%3DCastaigne%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DPalensky%26aufirst%3DJ.%26aulast%3DWittes%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520spironolactone%2520on%2520morbidity%2520and%2520mortality%2520in%2520patients%2520with%2520severe%2520heart%2520failure.%2520Randomized%2520aldactone%2520evaluation%2520study%2520investigators%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D709%26epage%3D717%26doi%3D10.1056%2FNEJM199909023411001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remme, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roniker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatlin, M.</span></span> <span> </span><span class="NLM_article-title">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1309</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa030207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1056%2FNEJMoa030207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=12668699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1309-1321&author=B.+Pittauthor=F.+Zannadauthor=W.+Remmeauthor=J.+Neatonauthor=F.+Martinezauthor=B.+Ronikerauthor=R.+Bittmanauthor=S.+Hurleyauthor=J.+Kleimanauthor=M.+Gatlin&title=Eplerenone%2C+a+selective+aldosterone+blocker%2C+in+patients+with+left+ventricular+dysfunction+after+myocardial+infarction&doi=10.1056%2FNEJMoa030207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span></div><div class="casAuthors">Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie; Ambrosioni, E.; Anderson, J. L.; Apetrei, E.; Aschermann, M.; Banas, J.; Cardoso, S.; Caspi, A.; Chung, N.; Corbalan, R.; Dargie, H. J.; Bietz, R.; Erhardt, L.; Garcia-Castillo, A.; Gheorghiade, M.; Hernandez, E.; Hess, O.; Jamerson, K.; Kjekshus, J.; Klug, E.; Krum, H.; Lee, Y.-T.; Lopez, N.; Lopez-Sendon, J.-L.; Martinez, F.; Murin, J.; Neaton, J.; Nicolau, J.-C.; Ostor, E.; Parkhomenko, A.; Pitt, B.; Ross, H.; Stepinska, J.; Torp-Pedersen, C.; Van Mieghem, W.; van Veldhuisen, D.-J.; White, H.; Wilvox, R. G.; Willenbrock, R.; Yotov, Y.-T.; Zannad, F.; Boissel, J.-P.; Furberg, C.; Julian, D.; Kulbertus, H.; Pocock, S.; Wittes, J.; Battler, A.; Blumenfeld, J.; Brilla, C.; Duprez, D.; Fowler, M.; Gavazzi, A.; Hildebrandt, P.; Komajda, M.; Korewicki, J.; Kosturakis, D.; Marin-Neto, J. A.; Miller, A.; Munoz Aguilera, R.; Oliveri, R.; Remme, W.; White, M.; Widimsky, P.; Bakris, G.; Castaigne, A.; Deedwania, P.; Duprez, D.; Ketelslegers, J. M.; Liu, P.; Mancia, G.; Nicklas, J.; Rouleau, J.-L.; Ruilope, L.; Sasayama, S.; Schiffrin, E.; Spertus, J.; Struthers, A.; Vaughan, D.; Weber, M.; Williams, G.; Abinader, E.; Adams, J.; Adams, P. C.; Adamus, J.; Ahlstrom, P.; Akesson, H. S.; Akhmedzhanov, N.; Alcasena Juango, S.; Ali Khan, S.; Alonso Garcia, A.; Amat, G.; Amerena, J.; Arnosova, K. M.; Andreoli, L.; Angelo-Nielsen, K.; Antonio de Velasco, J.; Apetrei, E.; Aroutiounov, G.; Aschermann, M.; Asklund, M.; Assmann, I.; Aumont, M.-C.; Avtandilov, A.; Azarin, O.; Bada, V.; Bakoumov, P.; Balazovjech, L.; Baldjiev, E.; Baluda, M.; Barrazueta, R.; Barsi, B.; Bashir, Y.; Batin, P. D.; Belenky, D.; Belyi, Y.; Bendermacher, P. E. F.; Berget, K.; Bergmeier, C.; Berning, J.; Berrazueta-Fernandez, J. R.; Block, P.; Boberg, G.; Bocek, P.; Bohlscheid, V.; Bokarev, I.; Bolinska, H.; Boman, K.; Bondarev, S.; Bonzel, T.; Boreux, J.-L.; Borggrefe, M.; Borisov, M.; Boxho, G.; Boyarkin, M.; Brachmann, J.; Brack, M.; Branea, I.; Breivik, K.; Brigden, G. S.; Bronzwaer, P. N. A.; Bruce, D.; Bruckner, I.; Brunvand, H.; Bryukhovetski, A.; Buser, P.; Campbell, T.; Campeanu, A.; Capucci, A.; Carasca, E.; Cardoso, J.; Carrageta, M.; Caspi, A.; Cassim, S.; Caturla, J.; Ceia, F.; Cernosek, B.; Channer, K.; Chati, Z.; Christensen, P. D.; Chung, N. S.; Cinteza, M.; Cleland, J. G. F.; Cocchieri, M.; Commerford, P.; Conti, U.; Corsini, G.; Cortina Liosa, A.; Coupez, J.-M.; Cribier, A.; Csillag, J.; Cyran, J.; Dahlstrom, U.; Dalby, A.; Dalin, L. J.; Dalkowski, M.; Dargie, H. J.; Darius, H.; Datcu, D. M.; David, D.; De Myttenaere, M.; De Teresa, E.; De Velasco, J.; de Vries, A. G.; den Hartog, F. R.; Desjoyaux, E.; Dezerbi, A.; Dhawan, J.; Biaz Molina, B.; Dickstein, K.; Dorobantu, M.; Doschitsin, V.; Doubell, A.; Dovgalevsky, P.; Dragulescu, S. I.; Drapkina, O.; Dubourg, O.; Dunselman, P. H. J. M.; Dyadyk, O. I.; Dykun, Y. V.; Dzyak, G. V.; Egorova, L. P.; Egstrup, K.; Eha, J.; Ehrenbergerova, M.; El Allaf, D.; Elenkova, A.; Ellis, C. J.; Engbers, J. G.; Fainyk, A. F.; Falck, G.; Fanelli, R.; Farre-Mun, J.; Favier, J.; Ferrari, G.; Ferreira, I.; Rischer, H.; Fotyanov, S.; Freericks, M. P.; Froeland, G.; Galve, E.; Garcia, M. M.; Garcia, A. A.; Garnier, L. F.; Gazaryan, G.; Georgescu, C.; Geraedts, J.; Glezer, M. G.; Goloborodko, B. I.; Goloshchekin, B.; Gonsorcik, J.; Gotchev, D.; Gotcheva, N.; Gottwik, M. G.; Grande, P.; Gratsiansky, N.; Grishina, E. I.; Groch, L.; Gruzdev, A.; Guenova, D.; Gundersen, T.; Hagerman, I.; Hambrecht, R.; Hammermann, H.; Hansen, O.; Hansteen, V.; Hart, H.; Hauf, G. F.; Hecker, U.; Hegyi, I.; Herlitz, J.; Hertzberger, D. P.; Herweijer, A. H.; Heyndrickx, G. R.; Hittinger, L.; Hoang, V.; Hobbach, H.-P.; Hofman-Bang, C.; Holwerda, N. J.; Hong, K. P.; Horacek, T.; Hormann, J.; Horowitz, J. D.; Hradec, J.; Hurtig, U.; Ikram, H.; Ioan, A.; Jaarsma, W.; Jadraque, L. M.; Jakobsen, T. J.; Janicki, K. J.; Jankelow, D.; Janosi, A.; Jansky, P.; Janssens, L.; Janzen, I.; Jensen, P.; Jirmar, R.; Jobic, Y.; Jones, A.; Jonsson, J.; Kahles, H.; Kaliska, G.; Kamensky, G.; Kappenberger, L.; Karlsson, J. E.; Karpati, P.; Karpenko, O. I.; Karpov, Y.; Kawecka-Jaszcz, J.; Keeling, P. J.; Keren, G.; Khalife, K.; Khrakovskaya, M.; Khrustalev, O. A.; Klarlund, K. K.; Kleber, E.-X.; Klug, E.; Koenig, W.; Komarek, J.; Kononenko, L. G.; Konz, K.; Komacewicz-Jach, Z.; Kostenko, V.; Kotous, J.; Kovalsky, I.; Kozak, P.; Kreider-Stempfle, H. U.; Kromer, E. P.; Krum, H.; Krzeminska-Pakula, M.; Kuc, K.; Kucera, P.; Kurowski, M.; Lach, L.; Lai, C.; Lane, G.; Lang, E.; Lankes, W.; Lankisch, P.-G.; Laraudogoitia, E.; Larsen, J.; Larsson, L.-E.; Laruelle, C.; Lazar, A.; Lee, Y.-T.; Legkonogov, A. V.; Leitch, J.; Lengfelder, W.; Lescot, C. D.; Lewis, B. S.; Lewis, P.; Libov, I. A.; Liel-Cohen, N.; Lim, H. K.; Lin, C.-S.; Linssen, G. C. M.; Liu, C.-P.; Lok, D. J. A.; Lopatin, Y. M.; Lopez De Sa, E.; Lotan, C.; Lousada, N.; Lucas, C.; Lucatti, A.; Lusov, V.; Mabin, T. A.; Macleod, D. C.; Maeurer, W.; Magnusson, J.-O.; Maisch, B.; Malinski, A.; Maltchougine, M.; Manga, P.; Mantov, S.; Marchi, S.; Marcinowska-Suchowierska, E.; Marenne, F.; Maresca, F. S.; Markov, V.; Marmor, A. T.; Martines, C.; Martinez, A.; Martin-Jadraque, L.; Martins, L. F. R.; Martos Ferres, R.; Mary, D. A. S. G.; Masini, F.; Matta, F.; Maurer, W.; Mazzini, A. C.; McDonald, K. M. A.; Meeder, J. G.; Melandri, F.; Melin, J.; Menezes, C.; Michels, H. R.; Missault, L.; Mitrovic, V.; Mntla, P.; Mobilij, A.; Mogilevsky, A.; Moiseev, V.; Mokan, M.; Moeller, B.; Moreira, I.; Mouhoub, D.; Moura, B.; Muders, E.; Mudra, H.; Munz, J.; Murin, J.; Musial, W. J.; Myburgh, D. P.; Naqvi, N.; Naumann, G.; Nazimov, S. V.; Nadelec, G.; Nedogoda, S. V.; Nielsen, I.; Nielsen, T.; Nierop, P. R.; Nilsson, G.; Notaristefano, A.; Novitsky, I. N.; Nykl, L.; Ofner, P.; Olariu, C.; Olbrich, H. G.; Oldroyd, K. G.; Olinic, N.; Oliveira, J.; Omland, T.; Orus, J.; Owensby, D.; Page, A.; Park, K. S.; Parkhomenko, O. M.; Pasotti, C.; Pasowicz, M.; Pecce, P.; Pell, A. C. H.; Penkov, N. I.; Perez de Juan, M.; Perez, H.; Petersen, M.; Petrov, A. A.; Peuhkurinen, K.; Philonenko, X.; Pieper, M.; Pieske, B.; Pluta, W.; Podzemska, B.; Popeye, R.; Prost, C.; Purcaro, A.; Put, P.; Radchenko, V.; Radoi, M.; Rae, A. P.; Raev, D.; Ramik, C.; Rasmussen, S. L.; Reisin, L.; Renker, B.; Ribeiro, V. G.; Richardt, G.; Rjecansky, I.; Risenfors, M.; Rivis, I. A.; Robson, R. H.; Rocher, R.; Rodriquez Padial, L.; Rose, E. L.; Rosen, S. D.; Rosenfeld, T.; Rowlands, D. B.; Rozkovec, A.; Rudas, L.; Rudenko, L. V.; Ruiz-Rejon, F.; Rutsch, W.; Rybar, R.; Rybka, J.; Saetre, H. A.; Sarosi, I.; Savalle, L. H.; Schmidt, A.; Schuren, K. P.; Schwartz, Y.; Schwinger, R.; Schwob, J. P.; Scott, D.; Sechtem, U.; Sela, O.; Semrad, B.; Senni, M.; Shilkina, N. P.; Shpektor, A.; Silas, J.; Sindone, A.; Sinescu, C. J.; Sipila, R.; Sirek, J.; Skagen, K.; Shura, M.; Slanina, M.; Slowinski, S.; Smid, J.; Smielak-Korombel, W.; Solodky, A.; Spacek, R.; Squire, I.; Steingo, L.; Stepinska, J.; Stogowski, A.; Storzhakov, G.; Striouk, R.; Strunge, P.; Suter, T.; Svitil, P.; Swedberg, K.; Swidzinski, M.; Syvolap, V. D.; Sztajzel, J.; Tahk, S. J.; Tans, A. C.; Tans, J. G. M.; Targonski, R.; Tarjan, J.; Tartagni, F.; Tchartchoglian, R.; Tebloev, K.; Teesalu, R.; Ten Kate, J. B. L.; Terrosu, P.; Thompson, P. L.; Thybo, N. K.; Thygesen, K.; Tilon, P. A.; Timar, S.; Titkov, Y.; Titlbach, O. J.; Torp-Pedersen, C.; Torvik, D. T.; Touboul, P.; Trelawny, J. M.; Trillo Nouche, R.; Trochina, E.; Trojnar, R.; Tzekova, M. L.; Tzivoni, D.; Vahula, V.; Valagussa, F.; Valdes, M.; Van Der Heijden, R.; Van Der Sloot, J. A. P.; Van Hal, J. M. C.; Van Kempen, L. H. J.; Van Mieghem, W.; Van Rugge, F. P.; Van Veldhuisen, D. J.; Van Vlies, B.; Van Wijk, L. M.; Vasyuk, Y.; Vatutin, M.; Vered, Z.; Vergoni, W.; Vertkine, A.; Vigholt, E.; Vishnevskiy, A.; Voegelin, H.-P.; Voipio-Pulkki, L. M.; Von Mengden, H.-J.; Waites, J.; Watson, R. D. S.; Weiss, A. T.; Werner, H. A.; Wesdorp, J. C. L.; White, H.; Wiggers, P.; Wilcox, R. G.; Wilkinson, P.; Willems, A. R.; Willenbrock, R.; Wirth, M.; Wojciechowski, D.; Worth, H.; Wray, R.; Wu, C.-J.; Yakusevich, V. V.; Yang, S.-P.; Yarohno, N.; Zadionchenko, V. S.; Zaleska, T.; Zalewski, M.; Zannad, F.; Zateyshchikov, D.; Zeltin-Abramov, E.; Zeymer, U.; Zimmermann, R.; Albuquerque, D. C.; Alcaino, M.; Allall, O. A.; Beer, N.; Bortman, G.; Botero, R.; Cardoso, J. S.; Carrageta, M.; Carrillo, E.; Carvalho, A. C.; Castano, R.; Ceia, F.; Cesar, L. A. M.; Chevez, E.; Coelho, O. R.; Colombo, H. R.; Corbalan, R.; Doval, H.; Dutra, O.; Franken, R. A.; Gallardo, L.; Garcia, A.; Garcia, J.; Gomez, E. A.; Gomez, E.; Gonzalez, J.; Gonzalez, R. A.; Greque, G. V.; Guzman, L.; Haiek, J. C.; Hernandez, E.; Hominal, M. A.; Isea, J.; Lanas, F.; Leiva, J. L.; Lemus, J.; Llancaqueo, A.; Lopez, N.; Lousada, N.; Maia, L. N.; Maranhao, M. F.; Martinez, J. A.; Martinez, F. A.; Martins, F. A.; Martins, L.; Matadamas, N.; Matiz, H.; Mendoza, I.; Menezes, C.; Moises, O.; Moreira, J. I.; Moura, J. C.; Nicolau, J. C.; Nobrega, J.; Null, D.; Oliveira, M. S.; Palacios, A. O.; Pazin Filho, A.; Perrone, S. V.; Peigas, L. S.; Prieto, J. C.; Junior, A. R.; Rassi, S.; Ribeiro, V. G.; Rico, J. N.; Rivera, J. M.; Robledo, G.; Rodriguez, H.; Rosenthal, J.; Rossi, P. R. F.; Saraiva, J. F.; Soifer, S.; Sosa Liprandi, A.; Torres, H. G.; Uruchurtu, E.; Velasco, R. G.; Velasquez, J. G.; Vita, N.; Waich, S.; Zelaya, F. R.; Abariotis, N.; Abdollah, H.; Abraham, W.; Alaie, D.; Allison, W.; Ameen, A.; Amidi, M.; Anand, I.; Anderson, J. L.; Andreae, G. E.; Aquino, V.; Ballard, W.; Banas, J. S.; Baron, S. B.; Bata, I.; Berk, M. R.; Bhesania, T.; Binkley, P.; Booth, D. C.; Borts, D.; Brookfield, L. A.; Brown, C. S.; Browne, K. F.; Butman, S. M.; Capodilupo, R. C.; Caralis, D. G.; Carr, K. W.; Castan, R.; Chadow, H.; Chalavarya, G. K.; Chua, G. L.; Cinderella, J. A.; Clavette, P.; Clemson, B. S.; Cohen, T. J.; Colfer, H. T.; Corder, C. N.; Courtade, D. J.; Courtney, D. L.; Coutu, B.; Cucher, F. H.; Czarnecki, W.; Danisa, K.; D'Astous, M.; Dauber, I.; Davies, R.; Deedwania, P. C.; Delehanty, J. M.; Denny, D. M.; Denys, B. G.; DeYoung, P. J. P.; Dion, D.; Donohue, T. J.; El Shahawy, M.; Elkayam, U.; Escabi, J.; Essandoh, L. K.; Felicetta, J. V.; Fintel, D.; Fontaine, J. M.; Foster, R. E.; Frank, T. A.; Gin, K.; Goldberg, M. C.; Goldman, S.; Gossard, D.; Gosselin, G.; Gradman, A. H.; Grandmont, D.; Hack, T.; Hagar, J.; Haikal, M.; Hall, S. A.; Halpern, S.; Hanley, H. G.; Hanovich, G. D.; Hargrove, J. L.; Harlamert, E. A.; Hastings, T. E.; Hathaway, W. R.; Haught, W. H.; Hilliard, G. K.; Hodsden, J.; Hui, W.; Hurley, W.; Ibrahim, H. M.; Jafri, S.; Jain, A.; Jennison, S.; Jesse, R. L.; Joseph, J.; Kalman, J.; Karisberg, R. P.; Khant, R.; Koren, M.; Kosinski, E. J.; Kosolcharoen, P.; Kostuk, W. J.; Kouz, S. M.; Lai, C.; Langholz, D. E.; LeJemtel, T. H.; Leader, R.; Leblanc, M.-H.; Lee, H.; Lepage, S.; Lopez, M.; Lu, D. Y.; Lubelsky, B. J.; Luckasen, G. J.; Ma, P.-T.-S.; MacCallum, C. G.; Madu, E. C.; Maisel, A. S.; Mallis, G. I.; Mann, J. T.; Marr, D. R.; McGrew, F. A., III; McKay, R. J.; Mclellan, B.; Meisner, J.; Meyer, T.; Mikati, I.; Miller, L. A.; Miller, L. W.; Moe, G. W.; Mohiuddin, S. M.; Moir, G. D.; Morgan, A. W.; Morris, A.; Murphy, B. J.; Nallasivan, M.; Narula, J.; Nicklas, J. M.; Niederman, A. L.; Nitkin, R.; O'Keefe, J. H.; Oken, K. R.; O'Neill, P. G.; Orchard, R. C.; O'Riordan, W. D.; Paraboschi, C. F.; Patel, R. I.; Pennock, G.; Pesant, Y.; Phaneuf, D.; Phillips, D. F.; Plehn, J.; Promisloff, S.; Rajakumar, A. J.; Ramadurai, R.; Rashkow, A.; Rauh, R. A.; Rebane, T. M.; Riba, A. L.; Richard, C.; Riddle, J. C.; Ringuette, G.; Rivera, E.; Rockson, S.; Rogers, E.; Ross, H.; Roux, R.; Rupka, D.; Saenz, A.; Sampson, J.; Schulman, S. P.; Schuyler, G.; Sequeira, R. F.; Shah, A. R.; Shah, P. K.; Shakar, S. F.; Shalev, Y.; Sheikh, K. H.; Shettigar, U. R.; Siegel, R. M.; Sigal, S. L.; Singh, V. N.; Sotolongo, C. M.; Soucier, R. J.; Stagaman, D. J.; Stephan, W. J.; Stine, M.; Stoever, W. W.; Talano, J. V.; Tan, J. L.; Tanser, P. H.; Taussig, A. S.; Thadani, U.; Timmis, S. B. H.; Timothee, J. R.; Tragoon, S.; Tremblay, B.; Upadhya, K. J.; Vijay, N. K.; Wagoner, L. E.; Walker, J. L.; Wickemeyer, W. J.; Williams, G. A.; Williams, M. B.; Williams, R. E.; Wiseman, A. H.; Wool, K. J.; Yasin, M.; Zabalgoitia, M.; Zarich, S.; Zimmermann, R.; Zucker, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1309-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure.  We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.  Methods: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a max. of 50 mg per day; 3313 patients) or placebo (3319 patients) in addn. to optimal medical therapy.  The study continued until 1012 deaths occurred.  The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia.  Results: During a mean follow-up of 16 mo, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008).  Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P= 0.005).  The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02).  There was also a redn. in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03).  The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001).  Conclusions: The addn. of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXvg9fCdjlrVg90H21EOLACvtfcHk0liglOWOHSiccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D&md5=cee432bc75bcca5f33098fe3bc8575df</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030207%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DRemme%26aufirst%3DW.%26aulast%3DNeaton%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DRoniker%26aufirst%3DB.%26aulast%3DBittman%26aufirst%3DR.%26aulast%3DHurley%26aufirst%3DS.%26aulast%3DKleiman%26aufirst%3DJ.%26aulast%3DGatlin%26aufirst%3DM.%26atitle%3DEplerenone%252C%2520a%2520selective%2520aldosterone%2520blocker%252C%2520in%2520patients%2520with%2520left%2520ventricular%2520dysfunction%2520after%2520myocardial%2520infarction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1309%26epage%3D1321%26doi%3D10.1056%2FNEJMoa030207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, M. A.</span></span> <span> </span><span class="NLM_article-title">Progress towards clinically useful aldosterone synthase inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1401</span>, <span class="refDoi"> DOI: 10.2174/1568026611313120003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.2174%2F1568026611313120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=23688131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1385-1401&author=M.+A.+Cerny&title=Progress+towards+clinically+useful+aldosterone+synthase+inhibitors&doi=10.2174%2F1568026611313120003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Progress Towards Clinically Useful Aldosterone Synthase Inhibitors</span></div><div class="casAuthors">Cerny, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1385-1401</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Owing to the high degree of similarity between aldosterone synthase (CYP11B2) and cortisol synthase (CYP11B1), the design of selective inhibitors of one or the other of these two enzymes was, at one time, thought to be impossible.  Through development of novel enzyme screening assays and significant medicinal chem. efforts, highly potent inhibitors of CYP11B2 have been identified with selectivities approaching 1000-fold between the two enzymes.  Many of these mols. also possess selectivity against other steroidogenic cytochromes P 450 (e.g. CYP17A1 and CYP19A1) as well as hepatic drug metabolizing P450s.  Though not as well developed or explored, inhibitors of CYP11B1, with selectivities approaching 50-fold, have also been identified.  The therapeutic benefits of affecting the renin-angiotensin-aldosterone system have been well established with the therapeutically useful angiotensin-converting enzymes inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists.  Data regarding the addnl. benefits of an aldosterone synthase inhibitor (ASi) are beginning to emerge from animal models and human clin. trials.  Despite great promise and much progress, addnl. challenges still exist in the path towards development of a therapeutically useful ASi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrk4wlx7NurVg90H21EOLACvtfcHk0lhum2cqVn5Jlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O&md5=bce9e566a086d1c2c58df2811ced6230</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568026611313120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313120003%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DM.%2BA.%26atitle%3DProgress%2520towards%2520clinically%2520useful%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1385%26epage%3D1401%26doi%3D10.2174%2F1568026611313120003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5011</span>– <span class="NLM_lpage">5022</span>, <span class="refDoi"> DOI: 10.1021/jm401430e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401430e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5011-5022&author=Q.+Huauthor=L.+Yinauthor=R.+W.+Hartmann&title=Aldosterone+synthase+inhibitors+as+promising+treatments+for+mineralocorticoid+dependent+cardiovascular+and+renal+diseases&doi=10.1021%2Fjm401430e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases</span></div><div class="casAuthors">Hu, Qingzhong; Yin, Lina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5011-5022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Besides the well-known roles of aldosterone as a mineralocorticoid in regulating homeostasis of electrolytes and vol., recent studies revealed that it is also a potent proinflammation factor inducing reactive oxygen species and up-regulating a panel of fibrosis related genes.  Under pathol. circumstances, excessive aldosterone is involved in a lot of chronic diseases, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and diabetic nephropathy.  Therefore, the inhibition of aldosterone synthase (CYP11B2), which is the pivotal enzyme in aldosterone biosynthesis, was proposed as a superior approach.  Expected pharmacodynamic effects have been demonstrated in both animal models and clin. trials after the application of CYP11B2 inhibitors.  The importance of selectivity over other steroidogenic CYP enzymes, in particular 11β-hydroxylase (CYP11B1), was also revealed.  Recently, much more selective CYP11B2 inhibitors have been reported, which could be promising drug candidates for the treatment of aldosterone related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22wShTUgyNrVg90H21EOLACvtfcHk0lhum2cqVn5Jlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D&md5=585f8d88a1df8d22382e6a58ab0283b0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm401430e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401430e%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DAldosterone%2520synthase%2520inhibitors%2520as%2520promising%2520treatments%2520for%2520mineralocorticoid%2520dependent%2520cardiovascular%2520and%2520renal%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5011%26epage%3D5022%26doi%3D10.1021%2Fjm401430e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weldon, S. M.</span>; <span class="NLM_string-name">Brown, N. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of aldosterone synthase</span>. In  <i>Vitamins and Hormones</i>; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">109</span>, pp  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">239</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=211-239&author=S.+M.+Weldon&author=N.+F.+Brown&title=Vitamins+and+Hormones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26atitle%3DInhibitors%2520of%2520aldosterone%2520synthase%26btitle%3DVitamins%2520and%2520Hormones%26pub%3DAcademic%2520Press%26date%3D2019%26volume%3D109%26spage%3D211%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. S.</span></span> <span> </span><span class="NLM_article-title">Evolving research in nongenomic actions of aldosterone</span>. <i>Curr. Opin. Endocrinol. Diabetes Obes.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1097/MED.0b013e328360c200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1097%2FMED.0b013e328360c200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=23519092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=198-203&author=J.+S.+Williams&title=Evolving+research+in+nongenomic+actions+of+aldosterone&doi=10.1097%2FMED.0b013e328360c200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving research in nongenomic actions of aldosterone</span></div><div class="casAuthors">Williams, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Endocrinology, Diabetes and Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">COEDFK</span>;
        ISSN:<span class="NLM_cas:issn">1752-296X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Aldosterone is now recognized as an increasingly important contributor to cardiometabolic pathol. via inflammatory and fibrosis-related pathways in addn. to its classically described role in sodium and vol. regulation.  Consequently, much effort has been directed towards characterizing the mol. pathways involved in aldosterone-mediated fibrosis and inflammation.  What was once viewed as straightforward steroid hormone biol. is now appreciated as a highly complex and tightly regulated series of pathways and interactions.  These recognitions have fuelled a multidisciplinary effort to identify precisely how aldosterone mediates intracellular activation of both genomic (latent) and nongenomic (rapid) mechanisms of influence.  This review will explore recent novel pathways regulating aldosterone action, focusing on the nongenomic pathways.  Recent findings: Several recent discoveries have redefined our understanding of aldosterone interactions at the cellular level.  This includes activation of the mineralocorticoid receptor at the plasma membrane instead of via classical nuclear hormone receptor interaction, and identification of novel cofactor scaffolding proteins that modify aldosterone influence at the cellular level.  In addn., aldosterone activation of secondary messenger system cascades can occur directly and independent of mineralocorticoid receptor interaction.  Summary: Substantial progress in detailing the mol. biol. of aldosterone regulation and action should facilitate study of how it exerts detrimental effects in cardiometabolic diseases.  However, to date, the clin. impact of these discoveries has not been validated.  Translational efforts are now required to det. if novel therapeutic targets can be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAysZZicBVGbVg90H21EOLACvtfcHk0lhum2cqVn5Jlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D&md5=a81a4387404a0cca288612daf8473973</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1097%2FMED.0b013e328360c200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMED.0b013e328360c200%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BS.%26atitle%3DEvolving%2520research%2520in%2520nongenomic%2520actions%2520of%2520aldosterone%26jtitle%3DCurr.%2520Opin.%2520Endocrinol.%2520Diabetes%2520Obes.%26date%3D2013%26volume%3D20%26spage%3D198%26epage%3D203%26doi%3D10.1097%2FMED.0b013e328360c200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mornet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">20961</span>– <span class="NLM_lpage">20967</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=2592361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADyaK3cXitFWktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1989&pages=20961-20967&author=E.+Mornetauthor=J.+Dupontauthor=A.+Vitekauthor=P.+C.+White&title=Characterization+of+two+genes+encoding+human+steroid+11+beta-hydroxylase+%28P-450%2811%29+beta%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of two genes encoding human steroid 11β-hydroxylase (P-45011β)</span></div><div class="casAuthors">Mornet, Etienne; Dupont, Jakob; Vitek, Alena; White, Perrin C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">20961-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Steroid 11β-hydroxylase (P-45011β) is a mitochondrial cytochrome P-450 enzyme necessary for cortisol biosynthesis.  Deficiency of 11β-hydroxylase causes a hypertensive form of congenital adrenal hyperplasia.  A partial cDNA clone encoding this enzyme was previously isolated and the corresponding gene, CYP11B1, mapped to human chromosome 8q.  This gene has now been isolated along with a second linked homologous gene, CYP11B2.  Each gene contains 9 exons.  The 8 introns are identical in location to the introns of the CYP11A gene encoding another mitochondrial P-450 enzyme, cholesterol desmolase, confirming that 11β-hydroxylase and cholesterol desmolase are in the same gene family within the P-450 superfamily.  The nucleotide sequences of CYP11B1 and B2 are 95% identical in coding regions and about 90% identical in introns.  The putative proteins encoded by CYP11B1 and B2 each contain 503 amino acids, including a 24-residue signal peptide, and have sequences that are 93% identical to each other and 75% identical to the predicted sequence of bovine P-45011β.  There are no obviously deleterious mutations in coding sequences of CYP11B2.  However, the 5'-flanking regions of CYP11B1 and B2 have diverged considerably, and B2 transcripts were not detected in human adrenal mRNA or among cDNA clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBAvV2I6oAobVg90H21EOLACvtfcHk0lgVTMXoZ1WW4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitFWktr0%253D&md5=658e13b32eaf0fb2a236d32074454c80</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMornet%26aufirst%3DE.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DVitek%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DP.%2BC.%26atitle%3DCharacterization%2520of%2520two%2520genes%2520encoding%2520human%2520steroid%252011%2520beta-hydroxylase%2520%2528P-450%252811%2529%2520beta%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1989%26volume%3D264%26spage%3D20961%26epage%3D20967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouin, P.-F.</span></span> <span> </span><span class="NLM_article-title">Aldosterone synthase inhibition with LCI699: A proof-of concept study in patients with primary aldosteronism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.110.157271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1161%2FHYPERTENSIONAHA.110.157271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=20837883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSqurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=831-838&author=L.+Amarauthor=M.+Aziziauthor=J.+Menardauthor=S.+Peyrardauthor=C.+Watsonauthor=P.-F.+Plouin&title=Aldosterone+synthase+inhibition+with+LCI699%3A+A+proof-of+concept+study+in+patients+with+primary+aldosteronism&doi=10.1161%2FHYPERTENSIONAHA.110.157271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism</span></div><div class="casAuthors">Amar, Laurence; Azizi, Michel; Menard, Joel; Peyrard, Severine; Watson, Catherine; Plouin, Pierre-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">831-838</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We report the first administration of an orally active aldosterone synthase inhibitor, LCI699, to 14 patients with primary aldosteronism.  After a 2-wk placebo run-in, patients received oral LCI699 (0.5 mg BID) for 2 wk, LCI699 (1.0 mg BID) for 2 wk, and placebo for 1 wk.  We assessed changes in hormone concns., plasma potassium levels, and 24-h ambulatory systolic blood pressure and safety.  The supine plasma aldosterone concn. decreased from 540 pmol/L (95% CI: 394 to 739 pmol/L) to 171 pmol/L (95% CI: 128 to 230 pmol/L) after 0.5 mg of LCI699 (-68%; P < 0.0001) and to 133 pmol/L (95% CI: 100 to 177 pmol/L) after 1.0 mg of LCI699 (-75%; P < 0.0001).  Plasma 11-deoxycorticosterone concns. increased by 710% after 0.5 mg of LCI699 (P < 0.0001) and by 1427% after 1.0 mg of LCI699 (P < 0.0001).  The plasma potassium concn. increased from 3.27 ± 0.31 to 4.03 ± 0.33 mmol/L (P < 0.0001) after only 1 wk on 0.5 mg of LCI699.  Twenty-four-hour ambulatory systolic blood pressure decreased by -4.1 mm Hg (95% CI: -8.1 to -0.1 mm Hg) after 4 wk of treatment (P = 0.046).  Basal plasma cortisol concns. remained unchanged, whereas plasma adrenocorticotropic hormone concns. increased by 35% after 0.5 mg of LCI699 (P = 0.08) and by 113% after 1.0 mg of LCI699 (P < 0.0001), and the plasma cortisol response to an adrenocorticotropic hormone test was blunted.  All of the variables except plasma 11-deoxycorticosterone concn. returned to initial levels after the placebo.  LCI699 was well tolerated.  In conclusion, the administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.  This 4-wk treatment cor. the hypokalemia and mildly decreased blood pressure.  The effects on the glucocorticoid axis were consistent with a latent inhibition of cortisol synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZwuj3BojUqrVg90H21EOLACvtfcHk0lgVTMXoZ1WW4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSqurfK&md5=ae64ff66f93f94628a52570bf0e74a8a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.110.157271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.110.157271%26sid%3Dliteratum%253Aachs%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DMenard%26aufirst%3DJ.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DPlouin%26aufirst%3DP.-F.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520with%2520LCI699%253A%2520A%2520proof-of%2520concept%2520study%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DHypertension%26date%3D2010%26volume%3D56%26spage%3D831%26epage%3D838%26doi%3D10.1161%2FHYPERTENSIONAHA.110.157271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowita, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménard, J.</span></span> <span> </span><span class="NLM_article-title">Effects of a novel aldosterone synthease inhibitor of treatment of primary hypertension: Results of a randomized, double-blind, placeo- and active-control phase 2 trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1945</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.029892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1161%2FCIRCULATIONAHA.111.029892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=21986283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ku7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=1945-1955&author=D.+A.+Calhounauthor=W.+B.+Whiteauthor=H.+Krumauthor=W.+Guoauthor=G.+Bermannauthor=A.+Trapaniauthor=M.+P.+Lefkowitaauthor=J.+M%C3%A9nard&title=Effects+of+a+novel+aldosterone+synthease+inhibitor+of+treatment+of+primary+hypertension%3A+Results+of+a+randomized%2C+double-blind%2C+placeo-+and+active-control+phase+2+trial&doi=10.1161%2FCIRCULATIONAHA.111.029892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial</span></div><div class="casAuthors">Calhoun, David A.; White, William B.; Krum, Henry; Guo, Weinong; Bermann, Georgina; Trapani, Angelo; Lefkowitz, Martin P.; Menard, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1945-1955</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: LCI699, a novel inhibitor of aldosterone synthase, reduces serum aldosterone, and may have benefit in the treatment of hypertension.  METHODS AND RESULTS: We performed the first double-blind, randomized trial with LCI699 in patients with primary hypertension.  We randomized 524 patients to LCI699 0.25 mg once daily (n=92), 0.5 mg once daily (n=88), 1.0 mg once daily (n=86), and 0.5 mg twice daily (n=97); eplerenone 50 mg twice daily (n=84); or placebo (n=77) for 8 wk.  Adrenocorticotropic hormone (250 μg IV) stimulation testing was performed in a subset of patients to quantify the selectivity of LCI699 for aldosterone synthase compared with 11-β-hydroxylase.  Redns. in clinic diastolic blood pressure were significant for LCI699 1.0 mg (-7.1 mm Hg; P=0.0012) and eplerenone 50 mg twice daily (-7.9 mm Hg; P<0.0001) compared with placebo (-2.6 mm Hg) but not other doses of LCI699.  Significant redns. in clinic systolic blood pressure were obsd. with all doses of LCI699 (P<0.005 or better) and eplerenone (P<0.0001).  All doses of LCI699 significantly reduced 24-h ambulatory blood pressure compared with placebo (P<0.01).  Adrenocorticotropic hormone stimulation of cortisol was suppressed in ≈20% of subjects receiving LCI699 at a total daily dose of 1.0 mg.  Safety and tolerability were similar among LCI699, placebo, and eplerenone.  CONCLUSIONS: Aldosterone synthase inhibition with LCI699 significantly lowered clinic and ambulatory blood pressure.  A minority of subjects developed blunted adrenocorticotropic hormone-stimulated release of cortisol.  These results support addnl. research to evaluate use of aldosterone synthase inhibition in primary hypertension and/or patients characterized by aldosterone excess.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGByhACTf6bVg90H21EOLACvtfcHk0lgVTMXoZ1WW4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ku7nP&md5=17a0d159894d6735707197bc6e7bf625</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.029892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.029892%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26aulast%3DWhite%26aufirst%3DW.%2BB.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DBermann%26aufirst%3DG.%26aulast%3DTrapani%26aufirst%3DA.%26aulast%3DLefkowita%26aufirst%3DM.%2BP.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520a%2520novel%2520aldosterone%2520synthease%2520inhibitor%2520of%2520treatment%2520of%2520primary%2520hypertension%253A%2520Results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placeo-%2520and%2520active-control%2520phase%25202%2520trial%26jtitle%3DCirculation%26date%3D2011%26volume%3D124%26spage%3D1945%26epage%3D1955%26doi%3D10.1161%2FCIRCULATIONAHA.111.029892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delporte, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudrt, M. C. D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferber, P.</span></span> <span> </span><span class="NLM_article-title">Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.116.07716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1161%2FHYPERTENSIONAHA.116.07716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=27872236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=189-196&author=K.+Bogmanauthor=D.+Schwabauthor=M.-L.+Delporteauthor=G.+Palermoauthor=K.+Amreinauthor=S.+Mohrauthor=M.+C.+D.+V.+Mudrtauthor=M.+J.+Brownauthor=P.+Ferber&title=Preclinical+and+early+clinical+profile+of+a+highly+selective+and+potent+oral+inhibitor+of+aldosterone+synthase+%28CYP11B2%29&doi=10.1161%2FHYPERTENSIONAHA.116.07716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)</span></div><div class="casAuthors">Bogman, Katrijn; Schwab, Dietmar; Delporte, Marie-Laure; Palermo, Giuseppe; Amrein, Kurt; Mohr, Susanne; De Vera Mudry, Maria Cristina; Brown, Morris J.; Ferber, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-196</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Primary hyperaldosteronism is a common cause of resistant hypertension.  Aldosterone is produced in the adrenal by aldosterone synthase (AS, encoded by the gene CYP11B2).  AS shares 93% homol. to 11β-hydroxylase (encoded by the gene CYP11B1), responsible for cortisol prodn.  This homol. has hitherto impeded the development of a drug, which selectively suppresses aldosterone but not cortisol prodn., as a new treatment for primary hyperaldosteronism.  We now report the development of RO6836191 as a potent (Ki 13 nmol/L) competitive inhibitor of AS, with in vitro selectivity >100-fold over 11β-hydroxylase.  In cynomolgus monkeys challenged with synthetic adrenocorticotropic hormone, single doses of RO6836191 inhibited aldosterone synthesis without affecting the adrenocorticotropic hormone-induced rise in cortisol.  In repeat-dose toxicity studies in monkeys, RO6836191 reproduced the adrenal changes of the AS mouse: expansion of the zona glomerulosa; increased expression of AS (or disrupted green fluorescent protein gene in the AS mouse); hypertrophy, proliferation, and apoptosis of zona glomerulosa cells.  These changes in the monkey were partially reversible and partially preventable by electrolyte supplementation and treatment with an angiotensin-converting enzyme inhibitor.  In healthy subjects, single doses of RO6836191, across a 360-fold dose range, reduced plasma and urine aldosterone levels with max. suppression at a dose of 10 mg, but unchanged cortisol, on adrenocorticotropic hormone challenge, up to 360 mg, and increase in the precursors 11-deoxycorticosterone and 11-deoxycortisol only at or >90 mg.  In conclusion, RO6836191 demonstrates that it is possible to suppress aldosterone prodn. completely in humans without affecting cortisol prodn.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT01995383.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYz7MQIXbBrVg90H21EOLACvtfcHk0liR_0sFcV9YYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegtrrL&md5=e1f0817077a1495be20e1137bdd8318f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.116.07716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.116.07716%26sid%3Dliteratum%253Aachs%26aulast%3DBogman%26aufirst%3DK.%26aulast%3DSchwab%26aufirst%3DD.%26aulast%3DDelporte%26aufirst%3DM.-L.%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DAmrein%26aufirst%3DK.%26aulast%3DMohr%26aufirst%3DS.%26aulast%3DMudrt%26aufirst%3DM.%2BC.%2BD.%2BV.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%26aulast%3DFerber%26aufirst%3DP.%26atitle%3DPreclinical%2520and%2520early%2520clinical%2520profile%2520of%2520a%2520highly%2520selective%2520and%2520potent%2520oral%2520inhibitor%2520of%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DHypertension%26date%3D2017%26volume%3D69%26spage%3D189%26epage%3D196%26doi%3D10.1161%2FHYPERTENSIONAHA.116.07716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demers, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melby, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santen, R. J.</span></span> <span> </span><span class="NLM_article-title">The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=2156889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A280%3ADyaK3c3gtlWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1990&pages=1162-1166&author=L.+M.+Demersauthor=J.+C.+Melbyauthor=T.+E.+Wilsonauthor=A.+Liptonauthor=H.+A.+Harveyauthor=R.+J.+Santen&title=The+effects+of+CGS+16949A%2C+an+aromatase+inhibitor+on+adrenal+mineralocorticoid+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis</span></div><div class="casAuthors">Demers L M; Melby J C; Wilson T E; Lipton A; Harvey H A; Santen R J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical endocrinology and metabolism</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1162-6</span>
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">The family of cytochrome P450 enzymes that mediates steroid hydroxylations are distinct but structurally related proteins.  Inhibitors of these steroidogenic steps generally exhibit only relative and dose-related specificity.  We evaluated an imidazole, cytochrome P450-related inhibitor, CGS 16949A, in postmenopausal patients with metastatic breast cancer.  While a relatively specific aromatase inhibitor at daily dosages of 1-2 mg, CGS 16949A significantly blunted cortisol responses to ACTH at a dose of 16 mg daily.  To further evaluate other inhibitory effects of this drug, we determined blood levels of aldosterone (ALDO) and 18-hydroxycorticosterone and their respective urinary metabolites, tetrahydroaldosterone and tetrahydro-18-hydroxy-11-dehydrocorticosterone in 16 postmenopausal women receiving CGS 16949A.  At a dose of 16 mg/day, CGS 16949A produced significant (P less than 0.001) suppression of both basal and ACTH-stimulated ALDO production.  This was accompanied by a significant rise in the blood 18-hydroxycorticosterone/ALDO ratio (11.4 +/- 0.19; normal, less than 2; P less than 0.001), consistent with a corticosterone methyloxidase type II inhibition.  A similar significant elevation (7.5 +/- 1.2; normal, less than 5; P less than 0.001) in the urinary tetrahydro-18-hydroxy-11-dehydrocorticosterone/tetrahydroaldosterone ratio was also observed.  These results suggest that CGS 16949A is a potent inhibitor of the corticosterone methyloxidase type II enzyme at a dose of 16 mg daily.  At doses of 1-2 mg daily, CGS 16949A blocks aromatase without altering basal aldosterone production and, thus, exhibits dose-related specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9Ux-hB5ma9UNoizSOkG_FfW6udTcc2eZOXaK1pNazwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c3gtlWnug%253D%253D&md5=b2ce73daab3c1a84b2133f3d60ec152f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDemers%26aufirst%3DL.%2BM.%26aulast%3DMelby%26aufirst%3DJ.%2BC.%26aulast%3DWilson%26aufirst%3DT.%2BE.%26aulast%3DLipton%26aufirst%3DA.%26aulast%3DHarvey%26aufirst%3DH.%2BA.%26aulast%3DSanten%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520effects%2520of%2520CGS%252016949A%252C%2520an%2520aromatase%2520inhibitor%2520on%2520adrenal%2520mineralocorticoid%2520biosynthesis%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1990%26volume%3D70%26spage%3D1162%26epage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monovich, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papillon, J. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigel, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaSala, D.</span></span> <span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.1021/ml400324c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400324c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1203-1207&author=E.+L.+Meredithauthor=G.+Ksanderauthor=L.+G.+Monovichauthor=J.+P.+N.+Papillonauthor=Q.+Liuauthor=K.+Mirandaauthor=P.+Morrisauthor=C.+Raoauthor=R.+Burgisauthor=M.+Capparelliauthor=Q.-Y.+Huauthor=A.+Singhauthor=D.+F.+Rigelauthor=A.+Y.+Jengauthor=M.+Beilauthor=F.+Fuauthor=C.-W.+Huauthor=D.+LaSala&title=Discovery+and+in+vivo+evaluation+of+potent+dual+CYP11B2+%28aldosterone+synthase%29+and+CYP11B1+inhibitors&doi=10.1021%2Fml400324c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors</span></div><div class="casAuthors">Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; LaSala, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1203-1207</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathol. such as hypertension and heart failure.  Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target.  A series of imidazole derived inhibitors, including clin. candidate I, have been identified through design and structure-activity relationship studies both in vitro and in vivo.  Compd. I was also found to be a potent inhibitor of 11β-hydroxylase (CYP11B1), which is responsible for cortisol prodn.  Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZqZXmMc5qE7Vg90H21EOLACvtfcHk0ljZDo5w14jCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP&md5=3f2301a71dfd1bf91a99ac68f5ca91ff</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml400324c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400324c%26sid%3Dliteratum%253Aachs%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DKsander%26aufirst%3DG.%26aulast%3DMonovich%26aufirst%3DL.%2BG.%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMiranda%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DBurgis%26aufirst%3DR.%26aulast%3DCapparelli%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLaSala%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520potent%2520dual%2520CYP11B2%2520%2528aldosterone%2520synthase%2529%2520and%2520CYP11B1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1203%26epage%3D1207%26doi%3D10.1021%2Fml400324c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roumen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmen, J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beugels, I. P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Custers, E. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Gooyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieterse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilbers, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, J. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vekemans, J. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottenheijm, H. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, J. J. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1712</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1021/jm901356d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901356d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1712-1725&author=L.+Roumenauthor=J.+W.+Peetersauthor=J.+M.+A.+Emmenauthor=I.+P.+E.+Beugelsauthor=E.+M.+G.+Custersauthor=M.+de%0AGooyerauthor=R.+Plateauthor=K.+Pieterseauthor=P.+A.+J.+Hilbersauthor=J.+F.+M.+Smitsauthor=J.+A.+J.+Vekemansauthor=D.+Leysenauthor=H.+C.+J.+Ottenheijmauthor=H.+M.+Janssenauthor=J.+J.+R.+Hermans&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+1-benzyl-1H-imidazoles+as+selective+inhibitors+of+aldosterone+synthase+%28CYP11B2%29&doi=10.1021%2Fjm901356d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Molecular Modeling of 1-Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)</span></div><div class="casAuthors">Roumen, Luc; Peeters, Joris W.; Emmen, Judith M. A.; Beugels, Ilona P. E.; Custers, Erica M. G.; de Gooyer, Marcel; Plate, Ralf; Pieterse, Koen; Hilbers, Peter A. J.; Smits, Jos F. M.; Vekemans, Jef A. J.; Leysen, Dirk; Ottenheijm, Harry C. J.; Janssen, Henk M.; Hermans, J. J. Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1712-1725</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reducing aldosterone action is beneficial in various major diseases such as heart failure.  Currently, this is achieved with mineralocorticoid receptor antagonists, however, aldosterone synthase (CYP11B2) inhibitors may offer a promising alternative.  In this study, three-dimensional modeling of CYP11B2 was used to model the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole (I) as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles.  Their syntheses, in vitro inhibitor potencies, and in silico docking are described.  Some promising CYP11B2 inhibitors were identified, with the novel lead MOERAS115 (II) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (vs. CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC50 for CYP11B2 6.0 nM, selectivity 19.8).  Mol. docking of the inhibitors in the models enabled the generation of posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz3kri2YpzBLVg90H21EOLACvtfcHk0ljZDo5w14jCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D&md5=95b05f5ad57464a12715c4cf15502b83</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm901356d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901356d%26sid%3Dliteratum%253Aachs%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DPeeters%26aufirst%3DJ.%2BW.%26aulast%3DEmmen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DBeugels%26aufirst%3DI.%2BP.%2BE.%26aulast%3DCusters%26aufirst%3DE.%2BM.%2BG.%26aulast%3Dde%2BGooyer%26aufirst%3DM.%26aulast%3DPlate%26aufirst%3DR.%26aulast%3DPieterse%26aufirst%3DK.%26aulast%3DHilbers%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DSmits%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DVekemans%26aufirst%3DJ.%2BA.%2BJ.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DOttenheijm%26aufirst%3DH.%2BC.%2BJ.%26aulast%3DJanssen%26aufirst%3DH.%2BM.%26aulast%3DHermans%26aufirst%3DJ.%2BJ.%2BR.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%25201-benzyl-1H-imidazoles%2520as%2520selective%2520inhibitors%2520of%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1712%26epage%3D1725%26doi%3D10.1021%2Fjm901356d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto-Bazurco
Mendieta, M. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagusch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller-Vieira, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauterbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5009</span>– <span class="NLM_lpage">5018</span>, <span class="refDoi"> DOI: 10.1021/jm800355c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800355c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2huro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5009-5018&author=M.+A.+E.+Pinto-Bazurco%0AMendietaauthor=M.+Negriauthor=C.+Jaguschauthor=U.+Mueller-Vieiraauthor=T.+Lauterbachauthor=R.+W.+Hartmann&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+abiraterone+analogues%3A+novel+CYP17+inhibitors+for+the+treatment+of+prostate+cancer&doi=10.1021%2Fjm800355c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer</span></div><div class="casAuthors">Pinto-Bazurco Mendieta, Mariano A. E.; Negri, Matthias; Jagusch, Carsten; Mueller-Vieira, Ursula; Lauterbach, Thomas; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5009-5018</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clin. trials as a potential drug for the treatment of androgen-dependent prostate cancer.  Since steroidal compds. often show side effects attributable to their structure, we have tried to replace the sterane scaffold by nonsteroidal core structures.  The design and synthesis of 20 new abiraterone mimetics are described.  Their activities have been tested with recombinant human CYP17 expressed in E. coli.  Promising compds. were further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4.  Compds. I and II showed comparable activity to abiraterone (IC50 values of 144 and 64 nM vs 72 nM) and similar or even better selectivity against the other CYP enzymes.  Selected compds. were also docked into our homol. model, and the same binding modes as for abiraterone were found.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUdezwVmhvrVg90H21EOLACvtfcHk0ljZDo5w14jCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2huro%253D&md5=c4db0a4f38ff6ac36ff05fb0c8cdc2fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm800355c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800355c%26sid%3Dliteratum%253Aachs%26aulast%3DPinto-Bazurco%2BMendieta%26aufirst%3DM.%2BA.%2BE.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DJagusch%26aufirst%3DC.%26aulast%3DMueller-Vieira%26aufirst%3DU.%26aulast%3DLauterbach%26aufirst%3DT.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520abiraterone%2520analogues%253A%2520novel%2520CYP17%2520inhibitors%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5009%26epage%3D5018%26doi%3D10.1021%2Fjm800355c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brixius-Anderko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. E.</span></span> <span> </span><span class="NLM_article-title">Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.006214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1074%2Fjbc.RA118.006214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=30425102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=453-460&author=S.+Brixius-Anderkoauthor=E.+E.+Scott&title=Structure+of+human+cortisol-producing+cytochrome+P450+11B1+bound+to+the+breast+cancer+drug+fadrozole+provides+insights+for+drug+design&doi=10.1074%2Fjbc.RA118.006214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design</span></div><div class="casAuthors">Brixius-Anderko, Simone; Scott, Emily E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">453-460</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Human cytochrome P 450 11B1 (CYP11B1) is responsible for the final step generating the steroid hormone cortisol, which controls stress and immune responses and glucose homeostasis.  CYP11B1 is a promising drug target to manage Cushing's disease, a disorder arising from excessive cortisol prodn.  However, the design of selective inhibitors has been hampered because structural information for CYP11B1 is unavailable and the enzyme has high amino acid sequence identity (93%) to a closely related enzyme, the aldosterone-producing CYP11B2.  Here the authors report the x-ray crystal structure of human CYP11B1 (at 2.1 Å resoln.) in complex with fadrozole, a racemic compd. normally used to treat breast cancer by inhibiting estrogen-producing CYP19A1.  Comparison of fadrozole-bound CYP11B1 with fadrozole-bound CYP11B2 revealed that despite conservation of the active-site residues, the overall structures and active sites had structural rearrangements consistent with distinct protein functions and inhibition.  Whereas fadrozole binds to both CYP11B enzymes by coordinating the heme iron, CYP11B2 binds to the R enantiomer of fadrozole, and CYP11B1 binds to the S enantiomer, each with distinct orientations and interactions.  These results provide insights into the cross-reactivity of drugs across multiple steroidogenic cytochrome P 450 enzymes, provide a structural basis for understanding human steroidogenesis, and pave the way for the design of more selective inhibitors of each human CYP11B enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTP9ulILGhLVg90H21EOLACvtfcHk0liBXSu1ghMzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjurg%253D&md5=d8b75ec9b273e63a2ff26bfbcf4b60ef</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.006214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.006214%26sid%3Dliteratum%253Aachs%26aulast%3DBrixius-Anderko%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DE.%2BE.%26atitle%3DStructure%2520of%2520human%2520cortisol-producing%2520cytochrome%2520P450%252011B1%2520bound%2520to%2520the%2520breast%2520cancer%2520drug%2520fadrozole%2520provides%2520insights%2520for%2520drug%2520design%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D453%26epage%3D460%26doi%3D10.1074%2Fjbc.RA118.006214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">Compounds <b>1</b>–<b>4</b> were also reported as CYP11B2 inhibitor by another research group.</p></div><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vock, C. A.</span></span> <span> </span><span class="NLM_article-title">N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.bmcl.2010.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=21129965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=186-190&author=C.+Zimmerauthor=M.+Hafnerauthor=M.+Zenderauthor=D.+Ammannauthor=R.+W.+Hartmannauthor=C.+A.+Vock&title=N-%28Pyridin-3-yl%29benzamides+as+selective+inhibitors+of+human+aldosterone+synthase+%28CYP11B2%29&doi=10.1016%2Fj.bmcl.2010.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)</span></div><div class="casAuthors">Zimmer, Christina; Hafner, Marieke; Zender, Michael; Ammann, Dominic; Hartmann, Rolf W.; Vock, Carsten A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-190</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 23 N-(pyridin-3-yl)benzamides was synthesized and evaluated for their potential to inhibit human steroid-11β-hydroxylase (CYP11B1) and human aldosterone synthase (CYP11B2).  The most potent and selective CYP11B2 inhibitors (IC50 values 53-166 nM) were further evaluated for their potential to inhibit human CYP17 and CYP19, and no inhibition was obsd.  Clear evidence was shown for N-(pyridin-3-yl)benzamides to be a highly selective class of CYP11B2 inhibitors in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2o811K_snXbVg90H21EOLACvtfcHk0liBXSu1ghMzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsLfP&md5=7df67fe9c17bf80a16b0d4983650f49d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DZender%26aufirst%3DM.%26aulast%3DAmmann%26aufirst%3DD.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DVock%26aufirst%3DC.%2BA.%26atitle%3DN-%2528Pyridin-3-yl%2529benzamides%2520as%2520selective%2520inhibitors%2520of%2520human%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D186%26epage%3D190%26doi%3D10.1016%2Fj.bmcl.2010.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornsperger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Märki, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riboulet, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayway, A. V.</span></span> <span> </span><span class="NLM_article-title">Discovery 4-aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: <i>in vivo</i> evaluation in rodents and cynomolgus monkeys</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8054</span>– <span class="NLM_lpage">8065</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00851</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00851" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGltb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8054-8065&author=R.+E.+Martinauthor=J.+D.+Aebiauthor=B.+Hornspergerauthor=H.-J.+Krebsauthor=B.+Kuhnauthor=A.+Kuglstatterauthor=A.+M.+Alkerauthor=H.-P.+M%C3%A4rkiauthor=S.+M%C3%BCllerauthor=D.+Burgerauthor=G.+Ottavianiauthor=W.+Ribouletauthor=P.+Verryauthor=X.+Tanauthor=K.+Amreinauthor=A.+V.+Mayway&title=Discovery+4-aryl-5%2C6%2C7%2C8-tetrahydroisoquinolines+as+potent%2C+selective%2C+and+orally+active+aldosterone+synthase+%28CYP11B2%29+inhibitors%3A+in+vivo+evaluation+in+rodents+and+cynomolgus+monkeys&doi=10.1021%2Facs.jmedchem.5b00851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys</span></div><div class="casAuthors">Martin, Rainer E.; Aebi, Johannes D.; Hornsperger, Benoit; Krebs, Hans-Jakob; Kuhn, Bernd; Kuglstatter, Andreas; Alker, Andre M.; Marki, Hans Peter; Muller, Stephan; Burger, Dominique; Ottaviani, Giorgio; Riboulet, William; Verry, Philippe; Tan, Xuefei; Amrein, Kurt; Mayweg, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8054-8065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inappropriately high levels of aldosterone are assocd. with many serious medical conditions, including renal and cardiac failure.  A focused screen hit has been optimized into a potent and selective aldosterone synthase (CYP11B2) inhibitor with in vitro activity against rat, mouse, human, and cynomolgus monkey enzymes, showing a selectivity factor of 160 against cytochrome CYP11B1 in the last species.  The novel tetrahydroisoquinoline compd. (I) selectively reduced aldosterone plasma levels in vivo in a dose-dependent manner in db/db mice and cynomolgus monkeys.  The selectivity against CYP11B1 as predicted by cellular inhibition data and free plasma fraction translated well to Synacthen challenged cynomolgus monkeys up to a dose of 0.1 mg kg-1.  This compd., displaying good in vivo potency and selectivity in mice and monkeys, is ideally suited to perform mechanistic studies in relevant rodent models and to provide the information necessary for translation to non-human primates and ultimately to man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXeatPr5nOtrVg90H21EOLACvtfcHk0liBXSu1ghMzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGltb7K&md5=ce9a9f7af76a7d63429d3ec282068395</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00851%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DHornsperger%26aufirst%3DB.%26aulast%3DKrebs%26aufirst%3DH.-J.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DAlker%26aufirst%3DA.%2BM.%26aulast%3DM%25C3%25A4rki%26aufirst%3DH.-P.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DD.%26aulast%3DOttaviani%26aufirst%3DG.%26aulast%3DRiboulet%26aufirst%3DW.%26aulast%3DVerry%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DAmrein%26aufirst%3DK.%26aulast%3DMayway%26aufirst%3DA.%2BV.%26atitle%3DDiscovery%25204-aryl-5%252C6%252C7%252C8-tetrahydroisoquinolines%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%2520inhibitors%253A%2520in%2520vivo%2520evaluation%2520in%2520rodents%2520and%2520cynomolgus%2520monkeys%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8054%26epage%3D8065%26doi%3D10.1021%2Facs.jmedchem.5b00851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csengery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmenk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K.</span></span> <span> </span><span class="NLM_article-title">Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: utility of money as a surrogate for human</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2015.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.jsbmb.2015.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=26303746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVagtL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2015&pages=197-205&author=M.+A.+Cernyauthor=A.+Csengeryauthor=J.+Schmenkauthor=K.+Frederick&title=Development+of+CYP11B1+and+CYP11B2+assays+utilizing+homogenates+of+adrenal+glands%3A+utility+of+money+as+a+surrogate+for+human&doi=10.1016%2Fj.jsbmb.2015.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human</span></div><div class="casAuthors">Cerny, Matthew A.; Csengery, Alexander; Schmenk, Jennifer; Frederick, Kosea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">197-205</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Elevated levels of aldosterone are assocd. with arterial hypertension, congestive heart failure, chronic kidney disease, and obesity.  Aldosterone is produced predominantly in the zona glomerulosa of the cortex of the adrenal gland by the enzyme aldosterone synthase (CYP11B2).  Treatment of the above indications by decreasing prodn. of aldosterone is thought to be of therapeutic benefit by lessening the deleterious effects of aldosterone mediated through both the mineralocorticoid receptor and also through so called non-genomic pathways.  However, inhibition of the highly similar enzyme, CYP11B1, which is responsible for the prodn. of cortisol, must be avoided in the development of clin. useful aldosterone synthase inhibitors due to the resulting impairment of the cortisol-induced stress response.  In efforts to assess the interactions of compds. with the CYP11B enzymes, a variety of cell-based inhibitor screening assays for both CYP11B1 and CYP11B2 have been reported.  Herein we report details of assays employing both cynomolgus monkey adrenal homogenate (CAH) and human adrenal homogenate (HAH) as sources of CYP11B1 and CYP11B2 enzymes.  Utilizing both CAH and HAH, we have characterized the kinetics of the CYP11B1-mediated conversion of 11-deoxycortisol to cortisol and the CYP11B2-mediated oxidn. of corticosterone to aldosterone.  Inhibition assays for both CYP11B1 and CYP11B2 were subsequently developed.  Based on a comparison of human and monkey amino acid sequences, kinetics data, and inhibition values derived from the HAH and CAH assays, evidence is provided in support of using cynomolgus monkey tissue-derived cell homogenates as suitable surrogates for the human enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpcI8q0Ww1R7Vg90H21EOLACvtfcHk0lgSGKT3A1Qo9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVagtL%252FJ&md5=8b2c5d217c353e0e7ec0e5cef071ef5f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2015.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DM.%2BA.%26aulast%3DCsengery%26aufirst%3DA.%26aulast%3DSchmenk%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520CYP11B1%2520and%2520CYP11B2%2520assays%2520utilizing%2520homogenates%2520of%2520adrenal%2520glands%253A%2520utility%2520of%2520money%2520as%2520a%2520surrogate%2520for%2520human%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D154%26spage%3D197%26epage%3D205%26doi%3D10.1016%2Fj.jsbmb.2015.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weldon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueneva-Boucheva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. F.</span></span> <span> </span><span class="NLM_article-title">Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.236463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1124%2Fjpet.116.236463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=27481775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2jtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2016&pages=142-150&author=S.+M.+Weldonauthor=M.+A.+Cernyauthor=K.+Gueneva-Bouchevaauthor=D.+Coganauthor=X.+Guoauthor=N.+Mossauthor=J.-H.+Parmentierauthor=J.+R.+Richmanauthor=G.+A.+Reinhartauthor=N.+F.+Brown&title=Selectivity+of+BI+689648%2C+a+novel%2C+highly+selective+aldosterone+synthase+inhibitor%3A+comparison+with+FAD286+and+LCI699+in+nonhuman+primates&doi=10.1124%2Fjpet.116.236463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates</span></div><div class="casAuthors">Weldon, Steven M.; Cerny, Matthew A.; Gueneva-Boucheva, Kristina; Cogan, Derek; Guo, Xin; Moss, Neil; Parmentier, Jean-Hugues; Richman, Jeremy R.; Reinhart, Glenn A.; Brown, Nicholas F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-150</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The mineralocorticoid aldosterone is an important regulator of blood pressure, vol., and electrolyte balance.  However, excess aldosterone can be deleterious as a driver of vascular remodeling and tissue fibrosis assocd. with cardiometabolic diseases.  Aldosterone synthase (AS) inhibitors (ASI) attenuate the prodn. of aldosterone directly and have been proposed as an alternative to mineralocorticoid receptor antagonists for blocking the pathol. effects of excess aldosterone.  Discovery of selective ASIs has been challenging because of the high sequence identity (93%) AS shares with cortisol synthase (CS), and the low identity of rodent AS compared with human (63%).  Using cynomolgus (cyno) monkey-based models, we identified BI 689648 [6-(5-methoxymethyl-pyridin-3-yl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid amide], a novel, highly selective ASI that exhibits an in vitro IC50 of 2 nMagainst AS and 300 nm against CS (150-fold selectivity) compared with the recently described ASIs FAD286 [4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile] (3 nM AS; 90 nM CS; 40-fold) and LCI699 (4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile) (10 nM AS; 80 nM CS; 8-fold).  After oral administration in cyno monkeys, BI 689648 (5 mg/kg) exhibits a peak plasma concn. of ∼500 nM.  For in vivo profiling we used an ACTH-challenge model in which BI 689648 was.20-fold more selective compared with FAD286 and LCI699.  Because both FAD286 and LCI699 failed to provide adequate selectivity for CS when tested in patients, the desire for more selective mols. to test the ASI hypothesis remains high.  Therefore, highly selective aldosterone synthase inhibitors such as BI 689648 represent an important step forward toward developing ASIs with greater potential for clin. success in cardiometabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5pUr1dc_oLVg90H21EOLACvtfcHk0lgSGKT3A1Qo9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2jtLrK&md5=584b931b62922f854df7b68b288d5d19</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236463%26sid%3Dliteratum%253Aachs%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DCerny%26aufirst%3DM.%2BA.%26aulast%3DGueneva-Boucheva%26aufirst%3DK.%26aulast%3DCogan%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DParmentier%26aufirst%3DJ.-H.%26aulast%3DRichman%26aufirst%3DJ.%2BR.%26aulast%3DReinhart%26aufirst%3DG.%2BA.%26aulast%3DBrown%26aufirst%3DN.%2BF.%26atitle%3DSelectivity%2520of%2520BI%2520689648%252C%2520a%2520novel%252C%2520highly%2520selective%2520aldosterone%2520synthase%2520inhibitor%253A%2520comparison%2520with%2520FAD286%2520and%2520LCI699%2520in%2520nonhuman%2520primates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D359%26spage%3D142%26epage%3D150%26doi%3D10.1124%2Fjpet.116.236463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stribling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenot, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinsanya, K. O.</span></span> <span> </span><span class="NLM_article-title">Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmocodynamics of aldosterone synthase inhibitors</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2014.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.vascn.2014.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=25304940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=137-146&author=T.-Q.+Caiauthor=S.+Striblingauthor=X.+Tongauthor=L.+Xuauthor=T.+Wisniewskiauthor=J.+A.+Fontenotauthor=M.+Struthersauthor=K.+O.+Akinsanya&title=Rhesus+monkey+model+for+concurrent+analyses+of+in+vivo+selectivity%2C+pharmacokinetics+and+pharmocodynamics+of+aldosterone+synthase+inhibitors&doi=10.1016%2Fj.vascn.2014.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors</span></div><div class="casAuthors">Cai, Tian-Quan; Stribling, Sloan; Tong, Xinchun; Xu, Ling; Wisniewski, Thomas; Fontenot, Jane A.; Struthers, Mary; Akinsanya, Karen O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vivo profiles of aldosterone synthase inhibitors (ASIs) have been investigated utilizing various rodent models.  Due to lack of CYP17 activity, rodents produce corticosterone rather than cortisol as that of humans, which raised concern to their effectiveness in translational pharmacol. characterization of ASI.  A rhesus monkey model that combines a low sodium diet with ACTH (ACTH) treatment was developed.  Plasma concns. of steroid metabolites assocd. with reactions catalyzed by CYP11B2 and CYP11B1 were measured concurrently by a UPLC/MS method.  Plasma concn. of aldosterone in regular diet fed rhesus monkeys was low at 109 pg/mL.  Aldosterone concns. were increased to 252 pg/mL when animals were maintained on a low sodium diet for 3 wk, and to 300 pg/mL with ACTH treatment at 0.3 mg/kg.  The combination of low sodium diet with ACTH treatment further increased plasma concn. of aldosterone to 730 pg/mL and other steroid metabolites at various levels.  I.v. administration of ASI, fadrozole (0.001-1 mg/kg) or LCI699 (0.003-3 mg/kg), led to dose-dependent redns. in aldosterone and 18-hydroxycorticosterone, increases in 11-deoxycorticosterone and 11-deoxycortisol, and bell-shaped changes in cortisol and corticosterone.  In vivo selectivity of CYP11B2/CYP11B1 for fadrazole was 26-fold and LCI-699 was 27-fold, which was consistent with relative selectivity using in vitro values from recombinant cells transfected with rhesus monkey CYP11B2 and CYP11B1.  This model enables concurrent characterization of pharmacokinetics, pharmacodynamics and selectivity of CYP11B2 over CYP11B1 inhibition in the same animal.  It may be used as a translational model for pharmacol. characterization of ASI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgHmCwgc290bVg90H21EOLACvtfcHk0lgSGKT3A1Qo9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K&md5=912a384735308d52a410cc2397ff9e83</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2014.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2014.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DStribling%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DFontenot%26aufirst%3DJ.%2BA.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DAkinsanya%26aufirst%3DK.%2BO.%26atitle%3DRhesus%2520monkey%2520model%2520for%2520concurrent%2520analyses%2520of%2520in%2520vivo%2520selectivity%252C%2520pharmacokinetics%2520and%2520pharmocodynamics%2520of%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2015%26volume%3D71%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.vascn.2014.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papillon, J. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beil, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung-Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaSala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigel, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vest, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9382</span>– <span class="NLM_lpage">9394</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01545</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01545" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyisbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9382-9394&author=J.+P.+N.+Papillonauthor=C.+Louauthor=A.+K.+Singhauthor=C.+M.+Adamsauthor=G.+M.+Ksanderauthor=M.+E.+Beilauthor=W.+Chenauthor=J.+Leung-Chuauthor=F.+Fuauthor=L.+Ganauthor=C.-W.+Huauthor=A.+Y.+Jengauthor=D.+LaSalaauthor=G.+Liangauthor=D.+F.+Rigelauthor=K.+S.+Russellauthor=J.+A.+Vestauthor=C.+Watson&title=Discovery+of+N-%5B5-%286-chloro-3-cyano-1-methyl-1H-indol-2-yl%29-pyridin-3-ylmethyl%5D-ethanesulfonamide%2C+a+cortisol-sparing+CYP11B2+inhibitor+that+lowers+aldosterone+in+human+subjects&doi=10.1021%2Facs.jmedchem.5b01545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects</span></div><div class="casAuthors">Papillon, Julien P. N.; Lou, Changgang; Singh, Alok K.; Adams, Christopher M.; Ksander, Gary M.; Beil, Michael E.; Chen, Wei; Leung-Chu, Jennifer; Fu, Fumin; Gan, Lu; Hu, Chii-Whei; Jeng, Arco Y.; LaSala, Daniel; Liang, Guiqing; Rigel, Dean F.; Russell, Kerry S.; Vest, John A.; Watson, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9382-9394</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human clin. studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure.  However, LCI699's low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion.  This property of LCI699 prompted its development in Cushing's disease, but limited more extensive clin. studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors.  This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclin. species and human subjects of the selective CYP11B2 inhibitor 8(I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFKKZ5bXRjrLVg90H21EOLACvtfcHk0lg8GyWnKvXEGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyisbbO&md5=be9aeef496bdfe7a2e9ca0e70eff1b56</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01545%26sid%3Dliteratum%253Aachs%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DLou%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DBeil%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLeung-Chu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DRussell%26aufirst%3DK.%2BS.%26aulast%3DVest%26aufirst%3DJ.%2BA.%26aulast%3DWatson%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520N-%255B5-%25286-chloro-3-cyano-1-methyl-1H-indol-2-yl%2529-pyridin-3-ylmethyl%255D-ethanesulfonamide%252C%2520a%2520cortisol-sparing%2520CYP11B2%2520inhibitor%2520that%2520lowers%2520aldosterone%2520in%2520human%2520subjects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9382%26epage%3D9394%26doi%3D10.1021%2Facs.jmedchem.5b01545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaw, A.</span>; <span class="NLM_string-name">Cowan, R. A.</span>; <span class="NLM_string-name">O’Reilley, D. S. J.</span>; <span class="NLM_string-name">Stewart, M. J.</span>; <span class="NLM_string-name">Shepherd, J.</span></span> <span> </span><span class="NLM_article-title">Endocrinology</span>. In  <i>Clinical Biochemistry</i>; <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">Churchill Livingston</span>: <span class="NLM_publisher-loc">Edinburgh</span>, <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=86-91&author=A.+Gaw&author=R.+A.+Cowan&author=D.+S.+J.+O%E2%80%99Reilley&author=M.+J.+Stewart&author=J.+Shepherd&title=Clinical+Biochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGaw%26aufirst%3DA.%26atitle%3DEndocrinology%26btitle%3DClinical%2520Biochemistry%26pub%3DChurchill%2520Livingston%26date%3D1999%26spage%3D86%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haggard, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmaus, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow
Setzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, K. P.</span></span> <span> </span><span class="NLM_article-title">High-throughput H295R steroidogenesis assay: utility as an alternative and a statistical approach to characterize effects on steroidogenesis</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1093%2Ftoxsci%2Fkfx274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=29216406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=509-534&author=D.+E.+Haggardauthor=A.+L.+Karmausauthor=M.+T.+Martinauthor=R.+S.+Judsonauthor=R.+Woodrow%0ASetzerauthor=K.+P.+Friedman&title=High-throughput+H295R+steroidogenesis+assay%3A+utility+as+an+alternative+and+a+statistical+approach+to+characterize+effects+on+steroidogenesis&doi=10.1093%2Ftoxsci%2Fkfx274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput H295R steroidogenesis assay: utility as an alternative and a statistical approach to characterize effects on steroidogenesis</span></div><div class="casAuthors">Haggard, Derik E.; Karmaus, Agnes L.; Martin, Matthew T.; Judson, Richard S.; Setzer, R. Woodrow; Friedman, Katie Paul</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">509-534</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The U.S. Environmental Protection Agency Endocrine Disruptor Screening Program and the Organization for Economic Co-operation and Development (OECD) have used the human adrenocarcinoma (H295R) cell-based assay to predict chem. perturbation of androgen and estrogen prodn.  Recently, a high-throughput H295R (HT-H295R) assay was developed as part of the ToxCast program that includes measurement of 11 hormones, including progestagens, corticosteroids, androgens, and estrogens.  To date, 2012 chems. have been screened at 1 concn.; of these, 656 chems. have been screened in concn.-response.  The objectives of this work were to: (1) develop an integrated anal. of chem.-mediated effects on steroidogenesis in the HT-H295R assay and (2) evaluate whether the HT-H295R assay predicts estrogen and androgen prodn. specifically via comparison with the OECD-validated H295R assay.  To support application of HT-H295R assay data to wt.-of-evidence and prioritization tasks, a single numeric value based on Mahalanobis distances was computed for 654 chems. to indicate the magnitude of effects on the synthesis of 11 hormones.  The max. mean Mahalanobis distance (maxmMd) values were high for strong modulators (prochloraz, mifepristone) and lower for moderate modulators (atrazine, molinate).  Twenty-five of 28 ref. chems. used for OECD validation were screened in the HT-H295R assay, and produced qual. similar results, with accuracies of 0.90/0.75 and 0.81/0.91 for increased/decreased testosterone and estradiol prodn., resp.  The HT-H295R assay provides robust information regarding estrogen and androgen prodn., as well as addnl. hormones.  The maxmMd from this integrated anal. may provide a data-driven approach to prioritizing lists of chems. for putative effects on steroidogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFY1QUcArL6bVg90H21EOLACvtfcHk0lg8GyWnKvXEGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjurfF&md5=33d40dab23c67650ce8db22bb45cff0e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx274%26sid%3Dliteratum%253Aachs%26aulast%3DHaggard%26aufirst%3DD.%2BE.%26aulast%3DKarmaus%26aufirst%3DA.%2BL.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DWoodrow%2BSetzer%26aufirst%3DR.%26aulast%3DFriedman%26aufirst%3DK.%2BP.%26atitle%3DHigh-throughput%2520H295R%2520steroidogenesis%2520assay%253A%2520utility%2520as%2520an%2520alternative%2520and%2520a%2520statistical%2520approach%2520to%2520characterize%2520effects%2520on%2520steroidogenesis%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26spage%3D509%26epage%3D534%26doi%3D10.1093%2Ftoxsci%2Fkfx274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J.</span>; <span class="NLM_string-name">Amrein, K.</span>; <span class="NLM_string-name">Chen, W.</span>; <span class="NLM_string-name">Hornsperger, B.</span>; <span class="NLM_string-name">Kuhn, B.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Märki, H.-P.</span>; <span class="NLM_string-name">Mayweg, A. V.</span>; <span class="NLM_string-name">Mohr, P.</span>; <span class="NLM_string-name">Tan, X.</span>; <span class="NLM_string-name">Wang, Z.</span>; <span class="NLM_string-name">Zhou, M.</span></span> <span> </span><span class="NLM_article-title">New Bicyclic Dihydroisoquinoline-1-one Derivatives</span>. <span class="NLM_patent">WO2013/079452 A1</span>, June 6, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Aebi&author=K.+Amrein&author=W.+Chen&author=B.+Hornsperger&author=B.+Kuhn&author=Y.+Liu&author=H.-P.+M%C3%A4rki&author=A.+V.+Mayweg&author=P.+Mohr&author=X.+Tan&author=Z.+Wang&author=M.+Zhou&title=New+Bicyclic+Dihydroisoquinoline-1-one+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAebi%26aufirst%3DJ.%26atitle%3DNew%2520Bicyclic%2520Dihydroisoquinoline-1-one%2520Derivatives%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assmus, F.</span></span> <span> </span><span class="NLM_article-title">Carrier mediated distribution system (CAMDIS): a new approach for the measurement of octanol/water distribution coefficients</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=10.1016%2Fj.ejps.2014.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=25513709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2015&pages=68-77&author=B.+Wagnerauthor=H.+Fischerauthor=M.+Kansyauthor=A.+Seeligauthor=F.+Assmus&title=Carrier+mediated+distribution+system+%28CAMDIS%29%3A+a+new+approach+for+the+measurement+of+octanol%2Fwater+distribution+coefficients&doi=10.1016%2Fj.ejps.2014.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Carrier Mediated Distribution System (CAMDIS): A new approach for the measurement of octanol/water distribution coefficients</span></div><div class="casAuthors">Wagner, Bjoern; Fischer, Holger; Kansy, Manfred; Seelig, Anna; Assmus, Frauke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-77</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we present a miniaturized assay, referred to as Carrier-Mediated Distribution System (CAMDIS) for fast and reliable measurement of octanol/water distribution coeffs., log Doct.  By introducing a filter support for octanol, phase sepn. from water is facilitated and the tendency of emulsion formation (emulsification) at the interface is reduced.  A guideline for the best practice of CAMDIS is given, describing a strategy to manage drug adsorption at the filter-supported octanol/buffer interface.  We validated the assay on a set of 52 structurally diverse drugs with known shake flask logDoct values.  Excellent agreement with literature data (r2 = 0.996, std. error of est., SEE = 0.111), high reproducibility (std. deviation, SD < 0.1 log Doct units), minimal sample consumption (10 μL of 100 μM DMSO stock soln.) and a broad anal. range (log Doct range = -0.5 to 4.2) make CAMDIS a valuable tool for the high-throughput assessment of log Doct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsNSPSNv4bP7Vg90H21EOLACvtfcHk0lg8GyWnKvXEGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVChtQ%253D%253D&md5=e0631985c73afe8838fce2eb24ccf686</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DSeelig%26aufirst%3DA.%26aulast%3DAssmus%26aufirst%3DF.%26atitle%3DCarrier%2520mediated%2520distribution%2520system%2520%2528CAMDIS%2529%253A%2520a%2520new%2520approach%2520for%2520the%2520measurement%2520of%2520octanol%252Fwater%2520distribution%2520coefficients%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D68%26spage%3D68%26epage%3D77%26doi%3D10.1016%2Fj.ejps.2014.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVQ','PDB','4DVQ'); return false;">PDB: 4DVQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8','PDB','6XZ8'); return false;">PDB: 6XZ8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ9','PDB','6XZ9'); return false;">PDB: 6XZ9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i91"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00233">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88834"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00233?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00233</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Structures of selected reference inhibitors; experimental procedures for the syntheses of key intermediates; <sup>1</sup>H NMR, <sup>13</sup>C NMR, and LC-MS spectra of compounds <b>52</b> and <b>62</b>; relative configuration assignment of compounds <b>29–38</b>; analytical method for the measurement of steroid concentrations in cynomolgus monkey plasma; selectivity assessment of steroid production in potassium-induced Hek293 cells (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>1</b>–<b>62</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_001.pdf">jm0c00233_si_001.pdf (767.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00233/suppl_file/jm0c00233_si_002.csv">jm0c00233_si_002.csv (3.99 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB codes for <b>45</b> and <b>58</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ8">6XZ8</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XZ9">6XZ9</a>, respectively. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00233&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-13%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00233%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00233" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799183e6e96198b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
